

AWARD NUMBER: W81XWH-14-1-0087

TITLE: Treatment-Induced Autophagy Associated with Tumor Dormancy and Relapse

PRINCIPAL INVESTIGATOR: Dr. Masoud Manjili

CONTRACTING ORGANIZATION: Virginia Commonwealth University  
Richmond, Va 23284-9040

REPORT DATE: July 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE July 2015		2. REPORT TYPE Annual		3. DATES COVERED 1 July 2014 - 30 June 2015	
4. TITLE AND SUBTITLE  Treatment-Induced Autophagy Associated with Tumor Dormancy and Relapse				5a. CONTRACT NUMBER W81XWH-14-1-0087	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Dr. Masoud Manjili and Dr. David Gewirtz  E-Mail: <a href="mailto:mmanjili@vcu.edu">mmanjili@vcu.edu</a> , <a href="mailto:gewirtz@vcu.edu">gewirtz@vcu.edu</a>				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  Virginia Commonwealth University 800 East Leigh Street, Suite 3200 P.O. Box 980568 Richmond, VA 23298-0568				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT  Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Studies relating to the role autophagy in susceptibility to adriamycin (ADR) in mouse mammary carcinoma (MMC) cells generated somewhat contradictory outcomes. Whereas pharmacological inhibition of autophagy using chloroquine (CQ) did not affect cytotoxicity of ADR, knock down of the autophagy gene, ATG5, resulted in the inhibition of ADR-induced apoptosis. These data suggest that the autophagy induced by ADR that is ATG5-regulated may have cytotoxic characteristics. Using ionizing radiation as a positive control for cytoprotective autophagy in MMC, we also found that ADR induces autophagy but fails to drive autophagy to completion. However, ADR-induced tumor dormancy was prolonged by CQ, both in vitro and in vivo. ADR was also found to induce immunogenic apoptosis, as characterized by membrane translocation of calreticulin (CRT), irrespective of the blockade of autophagy by CQ. As ADR did not induce autophagy in human SKBR3 tumor cell line, we plan to evaluate the capacity of ADR to promote autophagy in p53 wild-type MCF7 cells and p53 mutant MDA-MB-453 human breast tumor cells. We will also determine whether autophagy may be differentially regulated by select autophagy genes such that e.g. ATG5 is involved in cytotoxic autophagy whereas ATG7 or ATG12 are involved in nonprotective autophagy induced by ADR.					
15. SUBJECT TERMS Autophagy, tumor dormancy, tumor relapse, chemotherapy, immunotherapy					
16. SECURITY CLASSIFICATION OF: U			17. LIMITATION OF ABSTRACT  UU	18. NUMBER OF PAGES  65	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT  U	b. ABSTRACT  U	c. THIS PAGE  U			19b. TELEPHONE NUMBER (include area code)

## Table of Contents

	<u>Page</u>
<b>1. Introduction.....</b>	<b>1</b>
<b>2. Keywords.....</b>	<b>1</b>
<b>3. Accomplishments.....</b>	<b>1</b>
<b>4. Impact.....</b>	<b>8</b>
<b>5. Changes/Problems.....</b>	<b>8</b>
<b>6. Products.....</b>	<b>8</b>
<b>7. Participants &amp; Other Collaborating Organizations.....</b>	<b>9</b>
<b>8. Special Reporting Requirements.....</b>	<b>10</b>
<b>9. Appendices.....</b>	<b>11</b>

1. **INTRODUCTION:**

The objective of the proposal is to understand the role of autophagy in chemotherapy induced tumor dormancy and recurrence.

2. **KEYWORDS:**

Autophagy, tumor dormancy, tumor relapse, chemotherapy, immunotherapy

3. **ACCOMPLISHMENTS:**

**What were the major goals of the project?**

- 1) Understand the role of autophagy in chemotherapy-induced tumor dormancy (Aim 1)
- 2) Understand the role of tumor IFN-gamma Rα in determining tumor recurrence under immune pressure (Aim 2)

**What was accomplished under these goals?**

Major objectives include: 1) understanding the mechanism of tumor dormancy, and 2) understanding different types of tumor dormancy in order to prevent tumor relapse by prolonging tumor dormancy. In order to achieve the first objective we explore the role of autophagy in chemotherapy-induced tumor dormancy. To achieve the second objective we determine the relationship(s) between immunogenic versus non-immunogenic tumor dormancy and autophagy.

**Major accomplishments:**

***ADR chemotherapy induces autophagy in MMC tumor cells which does not appear to be cytoprotective***

In order to determine whether ADR (Adriamycin; doxorubicin) induces autophagy and in turn establishes tumor dormancy, MMC (mouse mammary cancer) cells were treated with ADR in the presence or absence of CQ (chloroquine), a pharmacological agent used to block the final stages of autophagy, specifically the fusion of the autophagosome with the lysosome that is necessary for digestion of the cargo in the autophagosome (frequently termed “autophagic flux”). CQ blocked this autophagic flux as evidenced by the enhanced accumulation of acidic vesicle (red signals) (Fig. 1A, ADR vs. ADR+CQ). We further monitored degradation of the p62/SQSTM1 protein as a marker of autophagic flux, and LC3B expression as a marker of autophagosome formation (since LC3 is a component of the autophagosome). As shown in Fig. 1B, ADR did not induce degradation of p62/SQSTM1 although it elevated LC3B, suggesting that ADR induces autophagy but fails to drive autophagy to completion. Furthermore, CQ did not affect toxicity of ADR, as the number of viable cells was essentially identical under these experimental conditions (ADR + CQ and ADR alone) (Fig. 1C). These findings are consistent with preliminary findings that Dr. Gewirtz’s group reported previously in the human MCF-7 breast tumor cell line (Goehe et al, 2012). These observations also provide support for a premise Dr. Gewirtz’s group proposed in a recent paper published in *Molecular Pharmacology* (Chakradeo et al, 2015), that stress-induced autophagy can be *nonprotective* as well as protective. Specifically, whereas interference with protective autophagy generally promotes apoptosis and enhances sensitivity to the autophagy-inducing stress, interference with nonprotective autophagy fails to result in either of these outcomes (Gewirtz, 2014; Sharma et al, 2014b).


Since it is generally insufficient to develop conclusions relating to autophagy function based on the use of pharmacological inhibitors alone, in order to further explore the role of autophagy in MMC tumor cells exposed to Adriamycin, we developed stable MMC lines where either the autophagy regulatory gene, ATG5, was knocked down (ATG5(-)) or the scrambled control (shC) was utilized (Fig. 2A). As shown in Fig. 2B, MMC cells in which autophagy had been compromised using ATG5(-) showed *reduced* sensitivity to ADR compared to the autophagy competent MMC (shC MMC) cells ( $p=0.00007$ ). This

suggests that the autophagy induced by ADR is unlikely to be protective but may instead have a cytotoxic function (Gewirtz, 2014; Sharma et al, 2014b). Parallel experiments were performed using CQ to block the late stage of autophagy; again, as was the case with genetic silencing of autophagy, there was no enhancement of the sensitivity of MMC cells exposed to ADR with CQ (Fig. 2C); however, unlike the experiments involving genetic silencing, sensitivity to ADR was not reduced. While these studies are consistent in demonstrating that autophagy induced by ADR is not protective, the differing outcomes when blocking autophagy pharmacologically and genetically suggest that the autophagy induced by ADR that is ATG5-regulated may have cytotoxic characteristics. Dr. Gewirtz's group previously reported on cytotoxic autophagy induced by vitamin D + radiation in breast tumor cells (Bristol et al, 2013). To further explore the possibility that the autophagy induced by ADR is cytotoxic in function, we plan to silence or knock down ATG7 and/or ATG12 in order to determine whether different genes may regulate different types of autophagy such that ATG5 might be involved in cytotoxic autophagy whereas ATG7 or ATG12 might be involved in nonprotective autophagy induced by ADR.


We did not detect induction of autophagy by ADR in SKBR3 human tumor cell line (data not shown). This is an unexpected finding but could possibly relate to the fact that the MMC cells are likely to be wild type in p53 while the SKBR3 cells are mutant in p53. Therefore, we plan to evaluate the capacity of ADR to promote autophagy in other breast tumor cell lines, including p53 wild-type MCF7 cells and p53 mutant MDA-MB-453 human breast tumor cells.

#### *Use of ionizing radiation as a positive control for cytoprotective autophagy in MMC cells.*

Given that autophagy induced by chemotherapy or radiation is generally cytoprotective, the finding that this was not the case for ADR was unexpected. In order to confirm that the experimental model was behaving appropriately, we performed similar studies to determine whether radiation would promote autophagy in the MMC cells and to identify the nature of this autophagy. Figure 3 shows acridine orange staining indicative of autophagic vacuole formation induced by both ADR and radiation.



**Fig. 1. CQ blocks ADR-induced autophagy.** MMC tumor cells received three daily doses of ADR alone (1  $\mu$ M ADR for 2 hrs) (ADR) or in the presence of CQ (10  $\mu$ M 3 hrs before ADR and 2hrs during ADR treatment) (ADR+CQ), washed after each daily treatment and analyzed by acridine orange one day after the last treatment. Untreated MMC (Medium) or MMC treated with CQ (CQ) served as controls (A; quantified in lower figure). Levels of p62/SQSTM1 and LC3 after treatment with ADR  $\pm$  CQ indicative of autophagy induction in the absence of autophagic flux (B) A fraction of the cell population was also analyzed for apoptosis by flow cytometry. Frequency of Annexin V-/PI- viable cells was determined (C). CQ exposure did not sensitize the cells to ADR.



**Fig. 2. ATG5 and CQ regulates different types of autophagy.** MMC cells were stably transfected with lentivirus expressing shRNA against ATG5 (ATG5(-) MMC). Parallel experiments were done with scrambled RNA (shC MMC). Cell lysates were collected and used for immunoblotting for ATG5 (A). shATG5 MMC or ATGscr MMC control were treated with a single dose of ADR alone (1  $\mu$ M ADR for 2 hrs) (B), MMC tumor cells were also treated with ADR alone (1  $\mu$ M ADR for 2 hrs) (ADR) or in the presence of CQ (10  $\mu$ M 3 hrs before ADR and 2hrs during ADR treatment) (ADR+CQ) (C). Tumor cells were analyzed by Annexin v/PI staining prior to treatment (Day 0) and three days after the treatment (Day 4). Experiments were performed in triplicates.




Figure 3. Mouse mammary carcinoma (MMC) cells were treated with Ionizing radiation (6 Gy) or Adriamycin (ADR) (1 $\mu$ M) and stained with Acridine orange (1 $\mu$ g/ml) 24 hr post treatment.

Figure 4 shows that radiation promotes the degradation of p62, indicative of the completion of autophagy, in contrast to the apparent inability of ADR to promote autophagic flux. This capacity is attenuated or eliminated in the cells where autophagy has been silenced (shATG5). Finally, Figure 5 shows that the autophagy induced by radiation is cytoprotective, since silencing of ATG5 clearly enhances sensitivity to radiation. Taken together, these experiments demonstrate distinct differences in the nature of autophagy induced by ADR (non-protective or cytotoxic) and radiation (protective) in the MMC breast tumor cells. These findings will provide a foundation for comparing the influence of different forms of autophagy on activating an immune response to therapy in tumor-bearing animals.

### Time response MMC vs ATG5 (IR 6Gy)




Figure 4. ATG5 knockdown MMC and sh control MMCs were treated with IR (6G) and cells lysates were collected at 6, 18, 24 hrs post treatment. Immunoblotting for p62 and LC3.B was done using mouse specific antibody.




Figure 5. ATG5 knockdown MMC and shcontrol MMCs cells were plated and treated with IR (6G). Cells were allowed to form colonies for 7 days and stained with crystal violet. Colony forming ability of ATG5 knockdown MMC cells was greatly decreased compared to sh Control cells


### Combinatorial therapy prolongs tumor dormancy

Dr. Manjili's group has previously established a model of tumor dormancy *in vivo* using MMC cells (Kmieciak et al., 2013; Kmieciak et al., 2011; Kmieciak et al., 2007). To initiate efforts to determine the contribution(s) of autophagy to tumor dormancy, dormancy was established *in vitro* (Fig. 6) by treatment with ADR. Dormant tumor cells that were established 3 weeks after the completion of ADR therapy began to resume proliferation after 6 weeks (Fig. 6A, ADR group Week 3 vs. Week 6). Co-treatment with the pharmacological autophagy inhibitor, i.e. the CQ + ADR condition, resulted in a prolongation of the period of tumor dormancy at week 6 (Fig. 6A, ADR+CQ group Weeks 3 vs. Week 6). Similar observations were made *in vivo* such that tumor-bearing animals that were treated with ADR+CQ survived longer (one month) compared with the ADR alone treatment group, where animals became morbid and had to be sacrificed by 3 weeks after tumor challenge (Fig. 6B).

We plan to perform long-term follow up studies in order to determine whether treatment with ADR alone will allow the tumors to resume normal proliferation, consistent with disease relapse in patients, while the ADR+CQ treatment group may remain dormant. We will perform parallel studies using ATG5<sup>-/-</sup>, ATG7<sup>-/-</sup> and/or ATG12<sup>-/-</sup> MMC tumor cells where we might also expect that ADR treatment will result in sustained growth arrest/dormancy.


#### ***ADR chemotherapy induces immunogenic apoptosis***

It has been reported that calreticulin (CRT) is a marker of autophagy that contributes to activation of an immune response (Sukkurwala et al., 2014). We show that ADR induces membrane translocation of calreticulin (CRT) on necrotic cells and late apoptotic cells (Fig. 7). Unexpectedly, blockade of autophagy in the MMC cells by CQ did not affect ADR-induced CRT expression. We postulate that this may reflect the fact that the ADR induced autophagy is not cytoprotective in this experimental model. Since it can be shown that autophagy induced by ionizing radiation *is cytoprotective*, we will perform parallel studies in irradiated cells where we might expect that a blockade to autophagy will alter CRT expression. It is further possible that CRT expression is not a particularly relevant autophagy signaling molecular and consequently we will also examine additional markers of immunogenic tumor cell death (Kepp et al., 2011) including ATP and HMGB1 for both ADR and radiation with and without CQ. Similar experiments will be performed using MMC cells that are genetically silenced for ATG5, 7, and 12 both *in vitro* as well as *in vivo* using flow cytometry and IHC analysis of tumor cells. Functional assays will be performed *in vivo* to determine whether immunogenic tumor dormancy will be sustained by the immune response without tumor relapse while the capacity of MMC cells exposed to ADR (and radiation as a putative positive control) with and without autophagy inhibition to induce an immune response *in vitro* will be determined using a model where the tumor cells are exposed either directly to interferon gamma or to activated T cells (Kmieciak et al., 2011, Kmieciak et al., 2007).



**Fig. 6. Use of CQ prolongs ADR-induced tumor dormancy in MMC.** A) MMC tumor cells were treated with 3 daily doses of ADR (1uM for 2 hrs) in the absence or presence of CQ (10nM for 5 hrs; 2hrs before ADR + 3hrs during ADR). At weeks 1, 3, and 6 post-treatments, adherent tumor cells were counted by trypan blue exclusion. Experiments were performed in duplicates. B) FVBN202 mice were inoculated with MMC tumor cells and split into 4 groups which included no treatment, CQ treatment (daily injection of 60mg/kg i.p. for the duration of the study), ADR (i.v. injection of 20mg/Kg twice weekly for two weeks), or ADR+CQ.. Injection of CQ and/or ADR began one week after tumor challenge.





**Fig. 7. ADR induces immunogenic apoptosis in MMC.** MMC tumor cells were treated with a single dose of ADR alone (1  $\mu$ M ADR for 2 hrs) (ADR) or in the presence of CQ (10  $\mu$ M 3 hrs before ADR and 2hrs during ADR treatment) (ADR+CQ). Tumor cells were analyzed by Annexin v/PI staining prior to treatment (Media) and three days after the treatment (ADR and ADR+CQ). Experiments were performed in triplicates.

Data presented in Fig. 1A, C; Fig. 2B, C; Fig. 6, Fig. 7 were generated in the laboratory of the initiating PI. Data presented in Fig. 1B, Fig. 2A, Fig. 3, Fig. 4, Fig. 5 were generated in the laboratory of the collaborating PI.

## REFERENCES

- Bristol ML, Emery SM, Maycotte P, Thorburn A, Chakradeo S, Gewirtz DA. Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy? *J Pharmacol Exp Ther*. 2013;344(3):544-52.
- Chakradeo S, Sharma K, Alhaddad A, Bakhshwin D, Le N, Harada H, Nakajima W, Yeudall WA, Torti SV, Torti FM, Gewirtz DA. Yet another function of p53: the switch that determines whether radiation-induced autophagy will be cytoprotective or nonprotective. Implications for autophagy inhibition as a therapeutic strategy. *Mol Pharm*, In Press.
- Gewirtz D.A. Cytoprotective and nonprotective autophagy in cancer therapy. *Autophagy*. 2013; 9(9):1263-5
- Gewirtz DA. The Four Faces of Autophagy: Implications for Cancer Therapy. *Cancer Res*. 2014;74(3):647-51.
- Goehe RW, Di X, Sharma K, Bristol ML, Henderson SC, Valerie K, Rodier F, Davalos AR, Gewirtz DA. The autophagy-senescence connection in chemotherapy: must tumor cells (self) eat before they sleep? *J Pharmacol Exp Ther*. 2012;343(3):763-78.

- Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, Sukkurwala AQ, Menger L, Zitvogel L, Kroemer G. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. *Cancer Metastasis Rev.* 2011 Mar;30(1):61-9.
- Kmieciak M, Payne KK, Wang XY, Manjili MH. IFN- $\gamma$  R $\alpha$  is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse. *PLoS ONE* 8(12): e82544. doi:10.1371/journal.pone.0082544, 2013. PMID: PMC3131490.
- Kmieciak M, Worschech A, Nikizad H, Gowda M, Habibi M, Depcrynski A, Wang E, Godder K, Holt S, Marincola FM, Manjili MH. CD4+ T cells inhibit neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer. *Breast Cancer Res Treat.* 126(2):385-94, 2011 PMID: 20480224
- Kmieciak M, Knutson KL, Dumur C, Manjili MH. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. *Eur J Immunol.* 37:675-85, 2007 PMID: 17304628
- Sharma K, Goehre R, Beckta JM, Valerie K, Gewirtz DA. Autophagy and Radiosensitization in Cancer EXCLI Journal 2014;13:178-191
- Sharma K, Le N, Alotaibi M, Gewirtz DA. Cytotoxic Autophagy in Cancer Therapy. *International Journal of Molecular Sciences.* 2014b;15(6):10034-51.
- Sukkurwala AQ, Martins I, Wang Y, Schlemmer F, Ruckentstahl C, Durchschlag M, Michaud M, Senovilla L, Sistigu A, Ma Y, Vacchelli E, Sulpice E, Gidrol X, Zitvogel L, Madeo F, Galluzzi L, Kepp O, Kroemer G. Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. *Cell Death Differ.* 2014 Jan;21(1):59-68.

**What opportunities for training and professional development has the project provided?**

Nothing to Report

**How were the results disseminated to communities of interest?**

- 1) Concepts that are proposed in this project were used to formulate two undergraduate lectures on tumor dormancy and autophagy. As guest speakers, the initiating PI and collaborating PI each presented 1/5 hours lecture to over 200 undergraduate students in BIOL450 (Biology of Cancer). Among 15 guest lecturers, the initiating PI and collaborating PI were rated by the students as best basic science lecturers.
- 2) A PhD student, Hussein Aqbi, an undergraduate student, Maureen Ansah, and a high school student, Siri Tupurani, rotated in Dr. Manjili laboratory in the area of treatment-induced tumor dormancy and autophagy.
- 3) An undergraduate student, Swara Farniss, was trained in Dr. Gewirtz's laboratory in the area of chemotherapy and radiation-induced autophagy.

**What do you plan to do during the next reporting period to accomplish the goals?**

We will perform *in vivo* studies in FVBN202 and FVB mice models of tumor dormancy using MMC with or without CQ as well as using genetically silenced ATG tumor cells. These studies will determine the role of autophagy blockade in tumor dormancy. We will examine additional markers of immunogenic tumor cell death including ATP and HMGB1 using MMC cells genetically silenced for ATG5, 7, and 12, *in vitro*, as well as *in vivo* using flow cytometry and IHC analysis of tumor cells. Functional assays will be performed to determine whether immunogenic tumor dormancy might be sustained by the immune

response without tumor relapse. We did not detect induction of autophagy by ADR in SKBR3 human tumor cell line (data not shown). Therefore, we will test other breast tumor cell lines, including MCF7 and MDA-MB-231. We will also use ionizing radiation as a control for the induction of autophagy in tumor cell lines.

#### **4. IMPACT:**

**What was the impact on the development of the principal discipline(s) of the project?**

Dr. Manjili provided expert commentary in a Twitter Chat hosted by the National Cancer Institute in April 2015 following the national airing of the PBS documentary cancer: the Emperor of All Maladies. The subject was “immunotherapy of cancer”.

**What was the impact on other disciplines?**

Nothing to Report

**What was the impact on technology transfer?**

Nothing to Report

**What was the impact on society beyond science and technology?**

Nothing to Report

#### **5. CHANGES/PROBLEMS:**

**Changes in approach and reasons for change**

Nothing to Report

**Actual or anticipated problems or delays and actions or plans to resolve them**

Nothing to Report

**Changes that had a significant impact on expenditures**

Nothing to Report

**Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

Nothing to Report

#### **6. PRODUCTS:**

- **Publications, conference papers, and presentations**

Goodson III WH, Lowe L, Carpenter DO, Gilbertson M, Ali AM, López de Ceráin Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglione C, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown D, Ratovitski E, Ryan E, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami G, Rice G, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lysterly HK, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Kotubash I, Miousse IR, Scovassi I, Klaunig JE, Vondráček J, Raju J, Roman J, Wise Sr. JP,

Whitfield JR, Woodrick J, Christopher J, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzio LS, Lin LT, Li L, Gulliver L, McCawley LJ, Knudsen LE, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, **Manjili MH**, Lleonart M, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson P, Dent P, Heneberg P, Darbre P, Leung PS, Nangia-Makker P, Cheng Q, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber R, Nahta R, Castellino RC, Palorini R, Hamid RA, Langie SAS, Eltom S, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris S, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarneri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z. Assessing the Carcinogenic Potential of Low Dose Exposures to Chemical Mixtures in the Environment: The Challenge Ahead. *Carcinogenesis* (in press)

Chakradeo S, Sharma K, Alhaddad A, Bakhshwin D, Le N, Harada H, Nakajima W, Yeudall WA, Torti SV, Torti FM, **Gewirtz DA**. Yet another function of p53: the switch that determines whether radiation-induced autophagy will be cytoprotective or nonprotective. Implications for autophagy inhibition as a therapeutic strategy. *Mol Pharm*, In Press.

#### **Other publications, conference papers, and presentations.**

Dr. Manjili gave a seminar presentation at the Molecular Biology & Genetics (MBG) Seminar Series, VCU School of Medicine, Richmond VA. Title: Immunotherapy of cancer dormancy (December 2014).  
Dr. Gewirtz presented seminars relating to the work on autophagy at MD Anderson, the University of Pennsylvania and Johns Hopkins.

- **Website(s) or other Internet site(s)**

Nothing to Report

- **Technologies or techniques**

Nothing to Report

- **Inventions, patent applications, and/or licenses**

Nothing to Report

- **Other Products**

Nothing to Report

## **7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**

### **What individuals have worked on the project?**

Name:	Rebecca Keim
Project Role:	Research fellow
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	6

Contribution to Project:	Ms. Keim has performed in vitro studies of chemotherapy-induced tumor dormancy as well as generating anti-CD4 Ab for in vivo T cell depletion studies in FVB mice.
Funding Support:	DoD
Name:	Kyle Payne
Project Role:	Graduate Student
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	6
Contribution to Project:	Mr. Payne has performed in vivo studies of chemotherapy-induced tumor dormancy, and in vitro studies of tumor dormancy.
Funding Support:	AAI and DoD
Name:	Supriya Joshi
Project Role:	Graduate Student
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	9
Contribution to Project:	Ms. Joshi has performed in vitro studies of chemotherapy-induced tumor dormancy.
Funding Support:	First year of graduate students are supported by the school of Medicine. She will be supported by this grant this year.
Name:	Theresa Thekkudan
Project Role:	Postdoctoral fellow
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	12
Contribution to Project:	Dr. Thekkudan performed in vitro studies of radiation and ADR induced autophagy in MMC cells with regard to assays for autophagy and sensitivity to treatment with autophagy inhibition. She also developed the stable cell lines where ATG5 was silenced.
Funding Support:	DoD

**Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

Nothing to Report

**What other organizations were involved as partners?**

Nothing to Report

## **8. SPECIAL REPORTING REQUIREMENTS:**

**COLLABORATIVE AWARDS:** The partnering PI, Dr. David Gewirtz, will be submitting a duplicative progress report

**9. APPENDICES:** Documents Attached

Journal : CARCIN

Article Doi : 10.1093/carcin/bgv039

Article Title : Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead

OXFORD  
UNIVERSITY PRESS

## INSTRUCTIONS

- 1. Author groups:** Please check that all names have been spelled correctly and appear in the correct order. Please also check that all initials are present. Please check that the author surnames (family name) have been correctly identified by a pink background. If this is incorrect, please identify the full surname of the relevant authors. Occasionally, the distinction between surnames and forenames can be ambiguous, and this is to ensure that the authors' full surnames and forenames are tagged correctly, for accurate indexing online. Please also check all author affiliations.
- 2. Figures:** If applicable figures have been placed as close as possible to their first citation. Please check that they are complete and that the correct figure legend is present. Figures in the proof are low resolution versions that will be replaced with high resolution versions when the journal is printed.
- 3. Colour reproduction:** Please note that if you opt out of paying for colour online and in print, any figures changed to black and white should be checked carefully in your figures legends for any reference to colour. Please check the black and white versions (these may be available at the end of the paper) and contact us if you have any concerns. Please re-word the legend/text to avoid using reference to colour. Alternatively, please let us know if you wish to pay for print colour reproduction or to have both versions in black and white. Please note that there is a £350/\$600 charge for each figure reproduced in colour in print.
- 4. Missing elements:** Please check that the text is complete and that all figures, tables and their legends are included.
- 5. Funding:** Please provide a Funding statement, detailing any funding received. Remember that any funding used while completing this work should be highlighted in a separate Funding section. Please ensure that you use the full official name of the funding body, and if your paper has received funding from any institution, such as NIH, please inform us of the grant number to go into the funding section. We use the institution names to tag NIH-funded articles so they are deposited at PMC. If we already have this information, we will have tagged it and it will appear as coloured text in the funding paragraph. Please check the information is correct. [red text to be used for suppliers who are tagging the funding]
- 6. Conflict of interest:** All authors must make a formal statement indicating any potential conflict of interest that might constitute an embarrassment to any of the authors if it were not to be declared and were to emerge after publication. Such conflicts might include, but are not limited to, shareholding in or receipt of a grant or consultancy fee from a company whose product features in the submitted manuscript or which manufactures a competing product. The following statement has been added to your proof: 'Conflict of Interest: none declared'. If this is incorrect please supply the necessary text to identify the conflict of interest.
- 7. Abbreviations:** some commonly used abbreviations have been automatically expanded for clarity to readers. By using the tracked changes proof for reference, please check the expanded abbreviations have been made correctly and mark up any corrections (if required) here or by email, listing the line and page numbers your correction refers to.

# MAKING CORRECTIONS TO YOUR PROOF


These instructions show you how to mark changes or add notes to the document using the Adobe Acrobat Professional version 7(or onwards) or Adobe Reader X (or onwards). To check what version you are using go to **Help** then **About**. The latest version of Adobe Reader is available for free from [get.adobe.com/reader](http://get.adobe.com/reader).

## Displaying the toolbars

### Adobe Professional X, XI and Reader X, XI


Select **Comment, Annotations and Drawing Markups**.

If this option is not available, please let me know so that I can enable it for you.




### Acrobat Professional 7, 8 and 9

Select **Tools, Commenting, Show Commenting Toolbar**.



## Using Text Edits

This is the quickest, simplest and easiest method both to make corrections, and for your corrections to be transferred and checked.



1. Click **Text Edits**
2. Select the text to be annotated or place your cursor at the insertion point.
3. Click the **Text Edits** drop down arrow and select the required action.


*You can also right click on selected text for a range of commenting options.*

## SAVING COMMENTS

In order to save your comments and notes, you need to save the file (**File, Save**) when you close the document. A full list of the comments and edits you have made can be viewed by clicking on the Comments tab in the bottom-left-hand corner of the PDF.


## Pop up Notes

With *Text Edits* and other markup, it is possible to add notes. In some cases (e.g. inserting or replacing text), a pop-up note is displayed automatically.



To **display** the pop-up note for other markup, right click on the annotation on the document and selecting **Open Pop-Up Note**.

To **move** a note, click and drag on the title area.



To **resize** of the note, click and drag on the bottom right corner.



To **close** the note, click on the cross in the top right hand corner.

To **delete** an edit, right click on it and select **Delete**. The edit and associated note will be removed.



## AUTHOR QUERY FORM

Journal : CARCIN

Article Doi : 10.1093/carcin/bgv039

Article Title : Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead

First Author : William H.Goodson III

Corr. Author : William H.Goodson III

### AUTHOR QUERIES - TO BE ANSWERED BY THE CORRESPONDING AUTHOR

The following queries have arisen during the typesetting of your manuscript. Please answer these queries by marking the required corrections at the appropriate point in the text. Failure to do so could result in delayed publication.

AQ1	Please provide city and state in affiliation 17. Please provide postal/zip code in affiliations 1, 2, 4, 10, 11–14, 16, and 17. Please provide department/unit name (if any) in California Pacific Medical Center Research Institute, 1, 3–6, 10, and 14–17.
AQ2	Please check if the affiliation and corresponding author details are correct.
AQ3	Please check if the change made to the sentence “Low-dose exposures to ...” is correct and convey the intended meaning.
AQ4	Please check the accuracy of reference citations. Also, please check that the text is complete and that all figures, tables and their legends are included.
AQ5	Figure has been placed as close as possible to its first citation. Please check that it has no missing sections and that the correct figure legend is present. Alternatively, figure can be published in black and white online and in print for no charge.
AQ6	Please review the typeset tables carefully against copies of the originals to verify accuracy of editing and typesetting.
AQ7	The references and their respective citations have been renumbered to maintain the sequential order of citations. Please check that each citation points to the correct reference.
AQ8	Per journal style, papers in preparation, submitted for publication and unpublished report should not be in the reference list. Hence, we have moved the original references 73, 75, and 393 to the text. Please check.
AQ9	Please check if the typeset of head levels is correct.
AQ10	Please note that Refs. 23 and 85, 95 and 344, 121 and 136, 332 and 502, 334 and 503, 335 and 504, 338 and 405, 345 and 487, 357 and 489, and 358 and 514 are identical. Therefore, duplicate references have been deleted and the subsequent references have been renumbered both in list and text. Please check.
AQ11	Please provide the author names and publisher location for refs. 105, 115 and 161.
AQ12	Please provide the chapter/book title, author names and publisher details for the ref. 141.
AQ13	Please check the editors name in reference 207.
AQ14	Please provide the publisher name and location details for refs. 218, 235 and 430.
AQ15	Please provide the volume number and page range for refs. 250, 368, 379, 457, 509, and 65.
AQ16	Please provide the volume number for ref. 301.
AQ17	Please provide the page range for the ref. 313.
AQ18	Please provide editor names (if any) in ref. 314.
AQ19	Please provide the editor names and publisher location for refs. 445, 446 and 463.
AQ20	Please provide the publisher location for refs. 407, 450–452.
AQ21	Please check editor name in ref. 472. Also, provide the publisher location for the same.

AQ22	Please provide the author names and check if the editor names are correct for ref. 483. Also, provide the publisher name and location for the same.
AQ23	Please provide the conference location and author names for ref. 487.
AQ24	Please provide author names and editor names for ref. 493.



## REVIEW

# Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead

William H. Goodson III<sup>\*</sup>, Leroy Lowe<sup>1,2</sup>, David O. Carpenter<sup>3</sup>, Michael Gilbertson<sup>4</sup>, William H. Bisson<sup>5</sup>, Amancio Carnero<sup>6</sup>, Wilhelm Engström<sup>7</sup>, Dean W. Felsher<sup>8</sup>, Zhiwei Hu<sup>9</sup>, Sabine A.S. Langie<sup>10</sup>, H. Kim Lyster<sup>11</sup>, Rita Nahta<sup>12</sup>, Josiah Ochieng<sup>13</sup>, Hyun Ho Park<sup>14</sup>, R. Brooks Robey<sup>15,16</sup>, Patricia Thompson<sup>17</sup> and for The Halifax Project Environmental Mixtures Taskforce<sup>†</sup>

California Pacific Medical Center Research Institute, 2100 Webster Street #401, San Francisco, CA 94115, USA, <sup>1</sup>Getting to Know Cancer, 36 Arthur Street, Truro, Nova Scotia, Canada, <sup>2</sup>Lancaster Environment Centre, Lancaster University, Bailrigg, Lancaster, UK, <sup>3</sup>Institute for Health and the Environment, University at Albany, 5 University Pl., Rensselaer, NY 12144, USA, <sup>4</sup>Getting to Know Cancer, Guelph, Canada, <sup>5</sup>Environmental and Molecular Toxicology, Environmental Health Sciences Center, Oregon State University, Corvallis, OR 97331, USA, <sup>6</sup>Instituto de Biomedicina de Sevilla, Consejo Superior de Investigaciones Científicas, Hospital Universitario Virgen del Rocío, Univ. de Sevilla, Avda Manuel Siurot sn, 41013 Sevilla, Spain, <sup>7</sup>Department of Biosciences and Veterinary Public Health, Faculty of Veterinary Medicine, Swedish University of Agricultural Sciences, PO Box 7028, 75007 Uppsala, Sweden, <sup>8</sup>Division of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA, <sup>9</sup>Department of Surgery, The Ohio State University College of Medicine, The James Comprehensive Cancer Center, Columbus, OH 43210, USA, <sup>10</sup>Environmental Risk and Health Unit, Flemish Institute for Technological Research, Mol, Belgium, <sup>11</sup>Department of Pathology, Duke University Medical Center, USA, <sup>12</sup>Departments of Pharmacology and Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA, <sup>13</sup>Department of Biochemistry and Cancer Biology, Meharry Medical College, Nashville, TN, USA, <sup>14</sup>School of Biotechnology, Yeungnam University, South Korea, <sup>15</sup>White River Junction Veterans Affairs Medical Center, White River Junction, VT 05009, USA, <sup>16</sup>Geisel School of Medicine at Dartmouth, Hanover, NH, USA and <sup>17</sup>The University of Arizona Cancer Center, USA

<sup>\*</sup>To whom correspondence should be addressed. William H. Goodson III, California Pacific Medical Center Research Institute, 2100 Webster Street #401, San Francisco, CA 94115, USA Tel: +415 923 3925; Fax: +415 776 1977; Email: [whg3md@att.net](mailto:whg3md@att.net)

Correspondence may also be addressed to Leroy Lowe. Tel: +902 893 5362; Fax: +902 893 5610; Email: [leroy.lowe@gettingtoknowcancer.org](mailto:leroy.lowe@gettingtoknowcancer.org)

<sup>†</sup>See appendix for the details on The Halifax Project Environmental Mixtures Taskforce

Part of the special issue on 'Assessing the Carcinogenic Potential of Low-Dose Exposures to Chemical Mixtures in the Environment: The Challenge Ahead'

## Abstract

Lifestyle factors are responsible for a considerable portion of cancer incidence worldwide, but credible estimates from the World Health Organization and the International Agency for Research on Cancer (IARC) suggest that the fraction of cancers attributable to toxic environmental exposures is between 7% and 19%. To explore the hypothesis that low-dose exposures to mixtures of chemicals in the environment may be combining to contribute to environmental carcinogenesis, we reviewed

Received: August 7, 2014; Revised: January 23, 2015; Accepted: January 31, 2015

© The Author 2015. Published by Oxford University Press.  
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

11 hallmark phenotypes of cancer, multiple priority target sites for disruption in each area and prototypical chemical disruptors for all targets; this included dose-response characterizations, evidence of low-dose effects and cross-hallmark effects for all targets and chemicals. In total, 85 examples of chemicals were reviewed for actions on key pathways/mechanisms related to carcinogenesis. Only 15% (13/85) were found to have evidence of a dose-response threshold, whereas 59% (50/85) exerted low-dose effects. No dose-response information was found for the remaining 26% (22/85). Our analysis suggests that the cumulative effects of individual (non-carcinogenic) chemicals acting on different pathways, and a variety of related systems, organs, tissues and cells could plausibly conspire to produce carcinogenic synergies. Additional basic research on carcinogenesis and research focused on low-dose effects of chemical mixtures needs to be rigorously pursued before the merits of this hypothesis can be further advanced. However, the structure of the World Health Organization International Programme on Chemical Safety 'Mode of Action' framework should be revisited as it has inherent weaknesses that are not fully aligned with our current understanding of cancer biology.

### Abbreviations

AhR	aryl hydrocarbon receptor
BPA	bisphenol A
EPA	environmental protection agency
HTS	high-throughput screening
IARC	International Agency for Research on Cancer
IL	interleukin
LDE	low-dose effect
LOAEL	lowest-observed-adverse-effect level
LOEL	lowest observed effect level
miRNA	microRNAs
4-NP	nonylphenol
NF- $\kappa$ B	nuclear factor- $\kappa$ B
PBDE	polybrominated diphenyl ethers
PPAR	peroxisome proliferator-activated receptor
ROS	reactive oxygen species

### Introduction

Cancer is a burden on humanity and among the leading causes of morbidity and mortality worldwide, with ~14 million new cases and 8.2 million cancer-related deaths in 2012 (1). In general, both genetic and environmental factors play a role in an individual's cancer susceptibility (2,3), so there has been a long-standing emphasis on avoidable 'lifestyle' factors (i.e. those that can be modified to reduce the incidence of the disease) and a parallel focus on exogenous chemical exposures (e.g. agricultural, occupational and so on) (4). But advances in our understanding of the complexity of cancer biology have resulted in serious critiques of current risk assessment practices related to exogenous exposures (5) along with calls for an expanded focus on research that will allow us to evaluate the (potentially carcinogenic) effects of *in-utero* exposures and low-level exposures to combinations of chemicals that occur throughout our lifetime (6,7).

The 2008–09 President's Cancer Panel Annual Report in the USA (8) opined that the 'true burden of environmentally induced cancer has been grossly underestimated' (7), whereas Parkin *et al.* (9) estimates in a British study that the fraction of cancer that can now be attributed to both lifestyle and environmental factors is only 43% (i.e. the underlying cause of 57% of all cancers is still unexplained). However, an expanded focus on research that will allow us to evaluate the (potentially carcinogenic) contribution of low-level exposures to combinations of chemicals that occur *in utero* and throughout our lifetime is not a trivial undertaking.

First of all, the number of chemicals to which we are exposed is substantial, and many have not been adequately tested.

Christiani (6) cited increased and persistently high incidence rates of various cancers and called on the National Institutes of Health to expand their investigation of environmental causes of cancer noting that 'Massive gaps exist in toxicologic data, even in the case of widely used synthetic chemicals. Only about 50% of chemicals classified by the Environmental Protection Agency as "high production volume" have undergone even minimal testing for carcinogenicity'. But even though the incidence of cancer attributable to environmental exposures has not been definitively established (3,6), it remains an important focus of our prevention efforts [with credible estimates from the World Health Organization [WHO] and the IARC suggesting that the fraction of cancers attributable to toxic environmental exposures is between 7% and 19%] (10,11).

The possibility that unanticipated low-dose effects (LDE) are also a factor in environmental carcinogenesis further complicates matters. Vandenberg *et al.* (12) recently reviewed the accumulating evidence that points to LDE that occur at levels that are well below those used for traditional toxicological studies. This review identified several hundred examples of non-monotonic dose-response relationships (i.e. examples where the relationship between dose and effect is complex and the slope of the curve changes sign—from positive to negative or *vice versa*—somewhere within the range of doses examined). Drawing on the known actions of natural hormones and selected environmental chemicals examined in cell cultures, animals and epidemiology, the authors emphasized that when non-monotonic dose-response curves occur, the effects of low doses cannot be predicted by the effects observed at high doses. However, endocrine disruption research to this point has been aimed primarily at chemicals that disrupt developmental processes through a relatively small subset of hormones (e.g. estrogen, androgen, thyroid and so on), and thus, many commonly encountered chemicals have not been tested at all for these effects (at environmentally relevant dose levels) and, to date, mechanisms that relate to carcinogenesis have typically not been the focus of these studies.

Generally for chemical risk assessments, toxicity studies are conducted with individual chemicals in animal models based on regulatory test guidelines [e.g. Organization for Economic Co-operation and Development (OECD) test guidelines (13)] with a key objective of providing a dose-response assessment that estimates a point of departure [traditionally the no-observed-adverse-effect level or the lowest-observed-adverse-effect level (LOAEL)], which is then used to extrapolate the quantity of substance above which adverse effects can be expected in humans. The no-observed-adverse-effect level, combined with uncertainty factors (which acknowledge gaps in the available data), is then used to establish safety criteria

for human exposure. However, in order to be able to detect adverse effects utilizing classical toxicological endpoints, dose selection has historically involved the use of high dose levels and appropriate dose level spacing to obtain the LOAEL or no-observed-adverse-effect level thresholds. Techniques such as linear extrapolation or benchmark dose modeling (14) are then employed to predict safety margins for low-dose exposures. This approach to risk assessment depends on the use of appropriate and sensitive endpoints, and on valid assumptions for extrapolation estimates (e.g. dose-response linearity) and calculations, and on the existence of thresholds of effects (15–17). So when the potential for non-linear dose-response relationships is combined with the possibility of synergism between and amongst low doses of mixtures of individual chemicals in the environment, it appears plausible that chemicals that are not individually carcinogenic may be capable of producing carcinogenic synergies that would be missed using current risk assessment practices.

The complex nature of the biology of cancer adds another layer of complexity for risk assessment. In a landmark paper in 1979, Ames (18) noted that damage to DNA appeared to be a major cause of most cancers and suggested that natural chemicals in the human diet and the tens of thousands of man-made chemicals that had been introduced into the environment in the preceding decades be tested for their ability to damage DNA. In doing so, he sketched out the difficulty of dealing with complex chemical mixtures and he proposed the use of rapid mutagenicity assays to identify environmental mutagens and carcinogens. The strategy was sound at the time, but it led to a scientific and regulatory emphasis on ‘mutagens as carcinogens’, whereas the issue of complex environmental mixtures, or carcinogens that are not mutagens, was never vigorously pursued. Instead, what followed was an international quest to find individual chemicals and a few well-defined mixtures (e.g. diesel exhaust) that could be shown to be ‘complete’ carcinogens (i.e. substances that could cause cancer on their own).

However, advances in cancer biology have revealed the limitations of this approach. Armitage and Doll first laid out a multistage theory of carcinogenesis in 1954 (19), and by 1990, initiation and promotion were well established as discrete steps in the evolution towards malignancy, along with the influence of ‘free radicals’, proto-oncogenes, oncogenes, epigenetic mechanisms and other synergistic or antagonistic factors (20). In 2000, Hanahan et al. (21) gave structure to this rapidly growing field of research with the proposal that ‘the vast catalog of cancer cell genotypes [could be organized into] a manifestation of six essential alterations in cell physiology that collectively dictate malignant growth’. They called these alterations the Hallmarks of Cancer, defined as ‘... acquired capabilities’ common to most cancers that ‘... incipient cancer cells ... [must acquire to] enable them to become tumorigenic and ultimately malignant.’ The hallmarks delineated at the time were as follows:

- *Self-sufficiency in growth signals* (later renamed proliferative signaling)—cancer cells grow at a seemingly unlimited rate.
- *Insensitivity to antigrowth signals* (evading growth suppressors)—cancer cells are not subject to antigrowth signals or withdrawal of normal growth signals.
- *Evading apoptosis* (resisting cell death)—cancer cells avoid the usual process whereby abnormal or redundant cells trigger internal self-destroying (as opposed to cell death) mechanisms.
- *Limitless replicative potential* (enabling replicative immortality)—cancer cells do not senesce (or age) and die after a limited number of cell divisions.
- *Sustained angiogenesis* (inducing angiogenesis)—cancer cells elicit new blood vessels to sustain growth.
- *Tissue invasion and metastasis* (activating invasion and metastasis)—in situ or non-invasive cancers, e.g. ductal carcinoma in situ in the breast or carcinoma in situ in colon polyps, grow into pre-existing spaces but invasive tumors must create a space to expand into normal tissue.

From this perspective risk assessments based on limited ‘mode of action’ information, assumptions of linear dose-response relationships and a focus on individual chemicals (as complete carcinogens) appeared to be inadequate to estimate human cancer risks. So in 2005, a scientist at the United States Environmental Protection Agency (EPA) called for a shift in risk assessment practices that would move the field towards the development of biomarkers directly related to the pathways found within the Hallmarks of Cancer framework (22).

The Hallmarks of Cancer framework was subsequently revisited by Hanahan et al. (21) and expanded to encompass additional areas suggested by subsequent cancer research (23). This expansion included the following:

Two enabling characteristics:


- *Genome instability and mutation*, which allows changes in one cell to pass to daughter cells through mutation or epigenetic changes in the parent cell DNA.
- *Tumor-promoting inflammation*, which helps cancer cells grow via the same growth signals normal cells provide to each other during wound healing and embryonic growth; inflammation further contributes to the survival of malignant cells, angiogenesis, metastasis and the subversion of adaptive immunity (24).

Two ‘emerging’ hallmarks:

- *Avoiding immune destruction* whereby tumor cells avoid immune surveillance that would otherwise mark them for destruction.
- *Dysregulated metabolism*, one of the most recognizable features of cancer; its exclusion from the original list of hallmarks (21) probably represented a significant oversight, as it constitutes one of the earliest described hallmarks of cancer (25,26). It is needed to support the increased anabolic and catabolic demands of rapid proliferation and is likely an enabler of cancer development and its other associated hallmarks.

Unfortunately, risk assessment practices that are currently used to assess the carcinogenic potential of chemicals have changed very little (despite the vast literature that now underpins the main tenets of the Hallmarks of Cancer framework). For example, a chemical that disrupts DNA repair capacity might prove to be non-carcinogenic at any level of exposure (when tested on its own), but that very same chemical may have the potential to be an important contributor to carcinogenesis (e.g. in the presence of mutagens that cause DNA damage). Similarly, a chemical that has immuno-suppressive qualities may not be carcinogenic on its own, but if it acts to suppress the immune response, it may contribute to carcinogenesis (by dismantling an important layer of defense) in the presence of other disruptive chemicals. Considering the multistep nature of cancer and the acquired capabilities implied by each of these hallmarks, it is therefore a very small step to envision how a series of complementary exposures acting in concert might prove to be far more carcinogenic than predictions related to any single exposure might suggest (see Figure 1). Interacting contributors need not act simultaneously or continuously, they might act sequentially or discontinuously. So a sustained focus on the carcinogenicity of individual chemicals may miss the sorts of synergies that might reasonably be anticipated to occur when combinations of disruptive chemicals (i.e. those that can act in concert on





**Figure 1.** Disruptive potential of environmental exposures to mixtures of chemicals. Note that some of the acquired hallmark phenotypes are known to be involved in many stages of disease development, but the precise sequencing of the acquisition of these hallmarks and the degree of involvement that each has in carcinogenesis are factors that have not yet been fully elucidated/defined. This depiction is therefore only intended to illustrate the ways in which exogenous actions might contribute to the enablement of these phenotypes.

the key mechanisms/pathways related to these hallmarks) are encountered.

To address the biological complexity issue associated with chronic diseases, the EPA and other agencies have begun to pursue risk assessment models that incorporate biological information. This is the basis of the Adverse Outcome Pathway concept, a construct that is gaining momentum because it ties existing knowledge of disease pathology (i.e. concerning the linkage between a direct molecular initiating event and an adverse outcome at a biological level of organization) to risk assessment (27,28). This line of thinking inspired a recent initiative by the EPA, where the agency tested a proposal for characterizing the carcinogenic potential of chemicals in humans, using *in-vitro* high-throughput screening (HTS) assays. The selected HTS assays specifically matched key targets and pathways within the Hallmarks of Cancer framework. The authors tested 292 chemicals in 672 assays and were successfully able to correlate the most disruptive chemicals (i.e. those that were most active across the various hallmarks) with known levels of carcinogenicity. Chemicals were classified as 'possible'/'probable'/'likely' carcinogens or designated as 'not likely' or with 'evidence of non-carcinogenicity' and then compared with *in-vivo* rodent carcinogenicity data in the Toxicity Reference Database to evaluate their predictions. The model proved to be a good predictive tool, but it was developed only as a means to help the EPA prioritize many untested individual chemicals for their carcinogenic potential (i.e. in order to establish priorities for individual chemical testing (29)).

What is still needed, is an approach employing the Hallmarks of Cancer framework that can be used to identify priority mixtures (i.e. those with substantive carcinogenic potential). Without a way to anticipate the carcinogenicity of complex mixtures, an important gap in capability exists and it creates a significant weakness in current risk assessment practices. Countries around the globe have made a significant investment in the regulatory infrastructure and risk

assessment practices that protect us from unwanted exposures to harmful chemicals and carcinogens, so we wanted to review the biology of cancer to map out the challenges associated with the development of an approach that would help us assess the carcinogenic potential of low-dose exposures to chemical mixtures in the environment. Such an approach was seen as a reasonable step to provide impetus for progress in this area of research and ultimately to inform risk assessment practices worldwide.

## Materials and methods

In 2012, the non-profit organization 'Getting to Know Cancer' instigated an initiative called 'The Halifax Project' to develop such an approach using the 'Hallmarks of Cancer' framework as a starting point. The aim of the project was to produce a series of overarching reviews of the cancer hallmarks that would collectively assess biologically disruptive chemicals (i.e. chemicals that are known to have the ability to act in an adverse manner on important cancer-related mechanisms, but not deemed to be carcinogenic to humans) that might be acting in concert with other seemingly innocuous chemicals and contributing to various aspects of carcinogenesis (i.e. at levels of exposure that have been deemed to be safe via the traditional risk assessment process). The reviews were to be written by 12 writing teams.

The writing teams were recruited by Getting to Know Cancer circulating an email in July 2012 to a large number of cancer researchers, asking about their interest in the project. Respondents were asked to submit personal details through a dedicated webpage that provided additional project information. A total of 703 scientists responded to the email, and from that group, 11 team leaders were selected to lead reviews of each hallmark (10 Hallmarks plus an 11th team to consider the tumor microenvironment as a whole) and one leader for the cross-validation team (see below). Writing group leaders were asked to form individual teams drawn from the pool of researchers who expressed interest in the project and from their own circles of collaborators. Leaders were encouraged to engage junior researchers as well. Team leaders received project participation guidelines and ongoing communication from the project leaders, L.Lowe and M.Gilbertson. Each team

included: a lead author with a published expertise in the hallmark area; domain experts who assisted in the production of the descriptive review of the biology; environmental health specialists (e.g. specialists in toxicology, endocrine disruption, or other related disciplines) and support researchers.

Each writing team was charged to describe the hallmark, its systemic and cellular dysfunctions and its relationships to other hallmarks. A priority list of relevant (i.e. prototypical) target sites for disruption was to be developed by the team and a list of corresponding chemicals in the environment that have been shown to have the potential to act on those targets was requested, along with a discussion of related issues and future research needed (in the context of project goals).

### Selection of target sites for disruption

A 'target' was broadly defined as a procarcinogenic disruption at the system level (e.g. the hypothalamic-pituitary-gonadal axis), organ level, tissue level or cellular level. It was assumed from the outset that a project intended to develop an approach for the assessment of the carcinogenic potential of low-dose exposures to chemical mixtures in the environment would encounter a practical upper limit to the number of potential targets that any given team could realistically review. Therefore, each team was asked to identify up to 10 relevant targets for their domain (bearing in mind that each target would also serve as a starting point for the identification of a disruptive environmental chemical that had already shown a demonstrated ability to act on that target). In theory, it was understood that this could lead to as many as 110 targets for the entire project, and since the teams were also asked to select one disruptive chemical for each target, a maximum of 110 chemicals.

In this phase, teams were asked to focus on specific gene changes common to many cancers as identified by The Cancer Genome Project (30) in order to estimate how the function of specific genes might be altered, not by specific gene mutations, but rather either by direct action or by epigenetic changes that might lead to the same functional ends. Most of these pathways and processes are found within both the hallmarks of cancer and the genomic frameworks, so teams were asked to evaluate both models and consider non-mutagenic/epigenetic pathways of interference as well (given that epigenetic changes such as DNA methylation and histone acetylation are relevant for cancer and often inducible by chemicals and may be transmitted to daughter cells).

### Selection of disruptive chemicals

Teams were then asked to identify 'prototypical' chemicals in the environment that had demonstrated an ability to act on the selected targets. During workshops in Halifax, the teams settled on the following criteria to guide their choices:

- Chemicals should be ubiquitous in the environment because we wanted the broadest possible relevance for the general population.
- Chemicals should selectively disrupt individual targets such as specific receptors, specific pathways or specific mechanisms. Hypothetically speaking, a chemical could affect more than one pathway, receptor and so on; indeed, we expected that most chemicals would likely exert a multitude of actions. However, we used the term 'selectively disruptive' to encourage teams to avoid choosing mutagens that are randomly destructive in their action (i.e. unpredictable and capable of producing varying types of damage across a wide range of pathways).
- Chemicals should not be 'lifestyle' related, such as those encountered from tobacco, poor diet choices (e.g. red meats, French fries, lack of fruit and vegetables and so on), alcohol consumption, obesity, infections (e.g. human papillomavirus) and so on.
- Chemicals should not be known as 'carcinogenic to humans' (i.e. not IARC Group 1, carcinogens).

The choice to focus on environmental pollutants in this project was intentionally restrictive. Countries around the globe have made significant investments in regulatory infrastructure and risk assessment

practices to protect us from unwanted exposures to harmful chemicals and carcinogens. Therefore, we focused on chemicals that are commonly encountered in the environment. Primarily, we wanted to generate insights that would be valuable for cancer researchers who are specifically interested in environmental chemical exposures to chemical mixtures and/or those who are focused on risk assessment practices in general.

### Dose-response characterizations and LDE

Given that much of the evidence in the toxicological literature that documents the disruptive actions of various chemicals has been produced under a wide range of differing experimental circumstances, we wanted to assess the quality and relevance of data that were gathered for exposures discussed in this review. Specifically, for each chemical selected and each mechanism identified, teams were additionally tasked to identify any dose-response characterization results and/or relevant low-dose research evidence that might exist. The term 'low dose' was defined using the European Food Safety Authority definition (i.e. responses that occur at doses well below the traditional lowest dose of 1 mg/kg that is used in toxicology tests) and the definition for 'LDE' was based on the EPA definition (31)—as follows:

Any biological changes occurring

- (a) in the range of typical human exposures or
- (b) at doses lower than those typically used in standard testing protocols, i.e. doses below those tested in traditional toxicology assessments (32), or
- (c) at a dose below the lowest dose for a specific chemical that has been measured in the past, i.e. any dose below the lowest observed effect level (LOEL) or LOAEL (33)
- (d) occurring at a dose administered to an animal that produces blood concentrations of that chemical in the range of what has been measured in the general human population (i.e. not exposed occupationally, and often referred to as an environmentally relevant dose because it creates an internal dose relevant to concentrations of the chemical measured in humans) (34,35).

Each team was then asked to categorize each chemical by using one of five possible categories (to determine the relevance and relative strength of the underlying evidence for each of the chemicals being considered). The categories were as follows: (i) LDE (i.e. levels that are deemed relevant given the background levels of exposure that exist in the environment); (ii) linear dose-response with LDE; (iii) non-linear dose-response with LDE; (iv) threshold (i.e. this action on this mechanism/pathway does not occur at low-dose levels) and (v) unknown. Additional details of the descriptions for each of these categories are shown in Table 1.

### Cross-hallmark relationships

In recognition of the network of signaling pathways involved and the degree of overlap/interconnection between the acquired capabilities described in each hallmark area, the project included a cross-validation step to create a more complete mapping of the actions that might be anticipated as the result of an action on the target sites identified or by the disruptive effects of the chemicals selected. Given the diversity of the targets involved in the 11 hallmark areas, it was anticipated that inhibiting or stimulating a target relevant to one hallmark may have an impact on other targets that are relevant, especially if both are linked via signaling pathways.

Accordingly, the cross-validation team conducted additional background peer-reviewed literature review of submitted targets and chemicals from each writing team, searching for evidence to identify cross-hallmark activity. Each potential target-hallmark or approach-hallmark interaction was assessed to determine whether the inhibition or activation of each target and the corresponding biological activity of each chemical might reasonably be expected to have either a procarcinogenic or anticarcinogenic effect on key pathways/processes in the various hallmark areas.

The cross-validation team also sought out controversial interactions (i.e. mixed indications of hallmark-like effects) and

AQ14 Table 1. Dose-response characterization

Review team	Chemical name	Disruptive action on key mechanism/pathway	Low-dose effect (LDE, LLDE, NLDE, threshold, unknown)
Angiogenesis	Diniconazole	Vascular cell adhesion molecule and cytokine signaling	Threshold (H-PC) (36)
	Ziram	Vascular cell adhesion molecule and cytokine signaling	Threshold (H-PC) (36,37)
	Chlorothalonil	Thrombomodulin, vascular proliferation and cytokine signaling	Unknown (H-PC) (36), NLDE (A-in vivo) (38)
	Biphenyl	Angiogenic cytokine signaling	Unknown (H-PC) (36)
	Tributyltin chloride	Vascular cell proliferation and adhesion molecule signaling	Unknown (H-PC) (36)
	Methylene bis(thiocyanate)	Plasminogen activating system and cytokine signaling	Unknown (H-PC) (36)
	HPTE	Vascular cell adhesion molecule and cytokine signaling	Unknown (H-PC) (36), threshold (A-I <sup>a</sup> ) (39), LDE (A-I <sup>a</sup> ) (40)
	PFOS	Angiogenic cytokine signaling	Threshold (H-PC) (36), LDE (H-CL) (41)
	Bisphenol AF	Matrix metalloproteinase expression and estrogen receptor signaling	Unknown (H-PC) (36)
	C.I. solvent yellow 14	AhR and hypoxic signaling	Unknown (H-PC) (36)
Deregulated metabolism	Cypermethrin	AR and ER expression, reduction of ATP and mitochondrial enzymes, mitochondrial membrane potential	LLDE (A-I) (42), NLDE (A-I) (42), NLDE (H-CL) (36,43,44)
	Acrolein	p53 activation, DNA repair inhibition, PERK phosphorylation, mitochondrial dysfunction, cell survival	LLDE (A-I, A-CL, H-PC, H-CL) (45-50), NLDE (49), threshold (46)
	Rotenone	Cell cycle, DNA damage response, proliferation, differentiation, mitochondria	LLDE (H-CL) (51-53), NLDE (H-CL) (51,53), unknown (H-CL, H-PC) (36)
	Copper	p53 activation, p21 up-regulation, cell viability	LLDE (H-CL) (54-56)
	Nickel	Neutrophil apoptosis, E-cadherin regulation, matrix metalloproteinase (MMP) production	LLDE (H-CL) (57), NLDE (H-CL) (58), Threshold (H-CL) (58)
	Cadmium	p53-dependent apoptosis, cell proliferation	LLDE (H-CL) (59), threshold (H-CL) (60)
	Diazinon	AChE activity, neuronal cytotoxicity	Unknown (A-PC) (61), LLDE (H-CL) (62), threshold (H-CL) (36)
	Iron	KRAS mutations	LLDE (A-I) (63)
	Malathion	Lymphocyte Mutations, Cytotoxicity	Unknown (H-PC, H-E) (36,64)
	BPA	MMP-2 and MMP-9 expression, increased migration, invasion, EMT, oxidative stress, ER signaling	LDE (H-CL) (65,66), threshold (H-CL, H-PC) (36)
Tissue invasion and metastasis	Hexachlorobenzene	Activation of c-Src, HER1, STAT5b and ERK1/2 signaling	LLDE (H-CL, A-I) (67)
	Sulfur dioxide	MMP-9 expression	Unknown (A-PC) (68)
	Phthalates	MMP-2 and MMP-9 expression	LDE (H-CL) (66), Unknown (H-CL, H-PC) (36)
	Iron	ROI generation, NF- $\kappa$ B activation, uPA expression	Unknown (H-CL) (69)
	Biorhythms/melatonin	GSK3 $\beta$ activation, EMT regulation	Unknown (H-CL, H-E) (70,71)
	BPA	Inhibition of GJIC, activation of mTOR pathway, down-regulation of p53, p21 and BAX, binding to ER- $\alpha$ , weakly binds to TH receptor and AR, activation of ERK1/2 and p38	NLDE(H-CL, A-CL) (72-74)
	Dibutyl phthalate	Activation of PPAR- $\alpha$ , inhibition of GJIC, expression of cyclin D and cdk-4, activation of AhR/HDAC6/c-Myc pathway	Threshold (H-CL, H-PC) (36)
	Chlorothalonil	Up-regulation of ErbB-2 tyrosine kinase and MAP kinase, aromatase inhibitor	NLDE (H-CL) (75), unknown (H-CL, H-PC) (36)
	Lindane	Induction of MAPK/ERK pathways	Threshold-based (i.e. non-linear) (A-I) (76), unknown (H-PC) (36), threshold (H-CL) (36)
	Dichlorvos	Expression of p16, Bcl-2 and c-myc	Threshold-based (i.e. non-linear) (A-I) (77), threshold (H-CL) (36)
Resistance to cell death	MXC	Binding to ER- $\alpha$ receptor, up-regulation of cyclin D1, down-regulation of p21	LLDE (H-CL, A-CL) (75,79), unknown (H-PC) (36), threshold (H-CL) (36)
	Oxyfluorfen	Expression of Cyp2b10 and Cyp4a10 transcripts (markers of PPAR- $\alpha$ activation)	Threshold (A-I) (80), unknown (H-CL, H-PC) (36)
	DEHP	Activation of PPAR- $\alpha$ , inhibition of GJIC	Threshold-based (i.e. non-linear) (A-I) (81)
	Linuron	Hypersecretion of LH, inhibition of GJIC	Unknown (H-CL) (82)



Table 1. Continued

Review team	Chemical name	Disruptive action on key mechanism/pathway	Low-dose effect (LDE, LLDE, NLDE, threshold, unknown)
Replicative immortality	Nickel-derived compounds, (e.g. nickel chloride)	Epigenetic silencing of p16	LLDE (H-CL, A-PC) (83)
	Diethylstilbestrol	Allelic loss and point mutation in ETRG-1 gene	LLDE (A-I) (84)
	Reserpine	Epigenetic modifications	Unknown (A-PC) (85), threshold (H-CL) (36)
	Phenobarbital	Reduces expression of the CDKN1A product p21, CAR activation	LLDE (A-I) (86,87)
	Acetaminophen	Cellular energy loss, mitochondrial damage, telomerase activation	LDE (H-CL, A-I, A-CL) (88-92)
	Cotinine	Telomerase activation	LLDE (H-PC) (93)
	Nitric oxide	p53 inactivation	LLDE (H-PC, H-CL, A-CL, A-I) (94)
	Na-selenite	p53 promoter methylation	LLDE (A-CL, A-I) (95,96)
	Lead	p53 inactivation	LLDE (H-PC, H-CL, A-CL, A-I) (94)
	BPA	Estrogen receptor activation, cell cycle/senescence	LLDE (A-I, H-CL, H-E) (12,97), NLDE (A-I) (98,99), threshold (H-CL) (36)
Sustained proliferative signaling	Cyprodinil	Increased proliferation signaling, AhR activation	Unknown (H-PC, H-CL) (36,100,101), threshold (H-CL) (36)
	Imazalil	AR signaling	NLDE (A-I) (102,103), threshold (H-CL, H-PC) (36)
	Maneb	Nitric oxide signaling	Unknown (A-CL, H-CL, H-PC) (36,104,105)
	Methoxychlor	ER signaling	Threshold (H-CL) (36), LDE (A-I) (106,107), NLDE (A-I) (108)
	PFOs	Nuclear hormone receptors	Threshold (H-CL) (36), LLDE (A-I) (109,110)
	Phthalates	CAR, ER signaling	Unknown (H-CL) (36), LDE (A-I) (111-113)
	Phosalone	Increased proliferation, PXR signaling	Unknown (H-PC, H-CL) (36,114,115)
	PBDEs	ER signaling	Unknown (H-PC, H-CL) (36,114,115)
	Prochloraz	ER signaling	LDE (A-I) (116,117)
	Trenbolone acetate	Insulin-like growth hormone-1 and AR signaling	LDE (A-I) (118,119)
Tumor-promoting inflammation	BPA	Immune cell proliferation, proinflammatory cytokine induction	Unknown, LDE (A-I, H-CL, H-E) (120,121)
	Phthalates	Immunomodulation of macrophages, lymphocytes, eosinophils and neutrophils	Threshold (H-PC) (36), LDE (A-I, H-CL, H-E) (122-126)
	PBDEs	Induction of pro-inflammatory cytokines (IL-6, IL8 and CRP), inhibition of anti-inflammatory cytokines (IL-10)	Unknown (H-PC, H-CL, H-E) (36,127)
	Atrazine	Immunomodulation of T cell and B cells, proinflammatory cytokines	Threshold (H-PC, H-CL) (128-131)
	Vinclozolin	Proinflammatory cytokine induction, NF-κB activation	Unknown (H-PC, A-I) (36,132,133)
	4-NP	Proinflammatory cytokine induction, NF-κB activation, iNOS induction	Unknown (H-PC, A-I) (36,134-136)
	Pyridaben	Chemokine signaling, TGF-β, FAK, HIF-1α, IL-1α pathways	Unknown (H-CL, H-PC, A-CL) (36,139,140), threshold (A-I) (141)
	Triclosan	Chemokine signaling, TGF-β, FAK, IL-1α pathways	Threshold (H-CL, H-PC, A-I) (36,142-144), LDE (A-I, H-CL) (145,146)
	Pyraclostrobin	Chemokine signaling, TGF-β, IL-1α pathways	Unknown (H-CL, H-PC) (36)
	Fluoxastrobin	Chemokine signaling, EGR, HIF-1α, IL-1α pathways	Unknown (H-CL, H-PC) (36)
Immune system evasion	BPA	Chemokine signaling, TGF-β pathway	Threshold (H-PC) (36), LDE (A-I) (12), NLDE (H-CL) (147), NLDE (A-CL) (148-151), NLDE (A-I) (152-155)
	Maneb	P13K/Akt signaling, chemokine signaling, TGF-β, FAK, IGF-1, IL-6, IL-1α pathways	Unknown (H-CL, H-PC) (36,139,156-158), LDE (A-I) (159), threshold (A-I) (139,160), threshold (A-CL, A-I) (161)

Table 1. Continued

Review team	Chemical name	Disruptive action on key mechanism/pathway	Low-dose effect (LDE, LLDE, NLDE, threshold, unknown)
Evasion of antitumor signaling	DDT	Induces MDM2, cyclin D1, E2F1 expression, disrupts gap junctions	NLDE (A-I, H-CL, A-CL) (162-164)
	Chlorpyrifos	Increases proliferation	LDE (H-CL, H-PC) (165,166)
	Folpet	Disrupts G <sub>1</sub> -S checkpoint kinases, down-regulates p53, promotes proliferation	LDE(A-C) (167)
Tumor microenvironment	Atrazine	Induces estrogen production and proliferation	LDE(H-CL, A-I) (168-170)
	BPA	Reduced p53, reduced connexin 43 expression, increased proliferation	NLDE (H-CL, A-I) (171-174)
	Nickel	ROS and cellular stress	NLDE (A-I) (175)
Genome instability	BPA	IL-6 expression, improper DC maturation and polarization, ROS production	LLDE (A-I) (176), NLDE (A-I) (176)
	Butyltins (such as tributyltin)	NK cell inhibition	LDE (A-I) (177)
	MeHg	Chronic oxidative stress	LDE (H-PC, H-CL) (178,179)
	Paraquat	Chronic ROS production, cellular stress	Unknown (A-I) (180)
	Lead	Dysfunctional DNA repair, defect in telomere maintenance	Unknown (A-CL) (181-183), threshold (H-CL, H-E) (184,185)
	Acrylamide	Inactivation of DNA repair proteins/enzymes	Unknown (A-CL, A-I, H-CL) (186,187)
	Quinones	Affect free cysteine residues in catalytic center of DNA methyltransferases (DNMT)	Unknown (A-CL) (188)
	Nickel	Affect enzymes that modulate post-translational histone modification	LDE (H-E) (189,190), LDE (A-CL, H-CL) (191)
	BPA	Epigenetic changes via interactions with miRNA	Threshold (H-PC) (192)
	Alloy particles (tungsten/nickel/cobalt)	Disruption of DNA damage/redox signaling involving Nrf, NF- $\kappa$ B, Egr, and so on	LDE (A-I) (193)
	Titanium dioxide NPs	Decreased NADH levels and impaired mitochondrial membrane potential and mitochondrial respiration, ROS generation	Unknown (A-PC) (194)
	Benomyl	Spindle defects leading to formation of micronuclei	Threshold (H-CL) (195), Threshold (A-CL) (196)
	Carbon nanotubes	Spindle defects leading to formation of micronuclei	LLDE (A-CL) (197,198), unknown (A-I) (198)

Each chemical in the table was categorized by using one of five possible categories (to determine the relevance and relative strength of the underlying evidence for each of the chemicals being considered)—as follows: (1) LDE (low-dose effect)—the ability of this chemical to exert this particular effect is not well characterized at a range of dose levels, but the evidence suggests that this chemical can exert this effect at low-dose levels (i.e. levels that are deemed relevant given the background levels of exposure that exist in the environment and as further defined below); (2) LLDE (linear dose-response with low-dose effects)—the ability of this chemical to exert this particular effect is well characterized at a range of dose levels and the evidence suggests that a linear dose-response relationship exists with effects at low-dose levels being evident (i.e. levels that are lower than the LOEL/LOAEL or threshold and deemed relevant given the background levels of exposure that exist in the environment). Note: a linear dose-response model implies no threshold. Effects at low doses are the same as at higher doses even if at a lesser extent. The effect is directly proportional to the dose; (3) NLDE (non-linear dose-response with low-dose effects)—the ability of this chemical to exert this particular effect is well characterized at a range of dose levels and the evidence suggests that a non-linear dose-response relationship exists with exaggerated effects at low-dose levels being evident (i.e. levels that are lower than the LOEL/LOAEL or threshold and deemed relevant given the background levels of exposure that exist in the environment). Note: a non-linear dose-response with low-dose effect implies that the effect does not vary according to the dose of the agent. The effect at low doses may be the same as at the higher doses or different. The non-linear dose-response may have or not have a threshold. It is represented by a sigmoid curve. The non-linear dose-response at low doses may be a non-monotonic dose-response; (4) Threshold—the ability of this chemical to exert this particular effect is well characterized at a range of dose levels, and a threshold has been established for this chemical that suggests that this action on this mechanism/pathway does not occur at low-dose levels (i.e. levels that are lower than the LOEL/LOAEL or threshold and deemed relevant given the background levels of exposure that exist in the environment); (5) Unknown—although the ability of this chemical to exert this particular effect has been shown at higher dose levels, this effect is not well characterized at a range of dose levels, so a LOEL/LOAEL or a threshold has not been determined for this chemical and there is no evidence showing that this chemical exerts this action at low-dose levels (i.e. levels that are lower than the LOEL/LOAEL or threshold and deemed relevant given the background levels of exposure that exist in the environment). A-I, *in-vivo* animal models; A-CL, animal cell lines; A-PC, animal primary cells; H-PC, human primary cells; H-CL, human cell lines; H-E, human epidemiological studies. With respect to the human primary cell (H-PC) data from ToxCast (36): unknown signifies that the compound was tested against a range of doses and showed statistically significant activity against the specified targets at the lowest test concentrations ( $\sim 0.01 \mu\text{M}$ ), therefore, a threshold could not be established. Threshold in this data set signifies that there was no activity against the targets at one or more of the lowest concentrations tested.

\*Extrapolated from *in-vivo* data on the parent compound, MXC.

instances where no known relationship existed. It was our belief that target sites or chemicals that demonstrated a substantial number of 'anticarcinogenic' effects in other hallmark areas would be less suitable to serve as instigating constituents in the design of carcinogenic mixtures (where procarcinogenic synergy was being sought).

It is important to note that the cross-validation team was not given any restrictions for literature selection for this effort, and contributing authors were neither restricted to results from low-dose testing, nor to cancer-related research. This approach was taken because it was realized at the outset that this sort of breadth and homogeneity (of low-dose evidence) does not yet exist in the literature. As a result, the types and sources of data gathered in this effort varied considerably, resulting in an admixture of reviews and original studies. Moreover, many studies that were cited in this effort only considered a chemical's ability to instigate or promote an action that mimics a hallmark phenotype in a manner directionally consistent with changes that have been associated with cancer. So, although we have referred to these actions as procarcinogenic and anticarcinogenic, as these changes are frequently neither fixed nor specific for cancer, the specificity of these changes and implications for carcinogenesis cannot and should not be immediately inferred from this data set. Short-term toxicity and toxic responses—particularly in data from *in-vitro* HTS platforms—must be distinguished from truly 'carcinogenic' long-term changes. In other words, the tabularized results from this particular aspect of the project were only compiled to serve as a starting point for future research. Where cross-hallmark effects were reported (at any dose level and in any tissue type), we wanted samples of that evidence to share with researchers who might be trying to anticipate the types of effects that might be encountered in future research on mixtures of chemicals (in a wide range of possible research contexts).

## Results

The results are presented roughly sequenced in a manner that captures the acquired capabilities found in many/most cancers. The section begins with two enabling characteristics found in most cancers, *Genetic instability* and *Tumor-promoting inflammation*, followed by *Sustained proliferative signaling* and *Insensitivity to antigrowth signals*, the two related hallmarks that ensure that proliferation is unabated in immortalized cells. These sections are followed by *Resistance to cell death* and *Replicative immortality*, two critical layers of defense that are believed to be bypassed in all cancers and then by *Dysregulated metabolism*. Sections on *Angiogenesis* and *Tissue invasion and metastasis* follow and speak to the progression of the disease, and finally, the *Tumor micro-environment* and *Avoiding immune destruction* sections offer summaries related to the very last lines of defense that are defeated in most cancers. Additionally, dose-response characterizations and evidence of LDE are then presented for all of these areas and the results from the cross-validation activity are summarized and reviewed.

### Genetic instability

The phenotypic variations underlying cancer result from interactions among many different environmental and genetic factors, occurring over long time periods (199). One of the most important effects of these interactions is genome instability—loosely defined as an increased likelihood of the occurrence of potentially mutagenic and carcinogenic changes in the genome. The term is used to describe both the presence of markers of genetic change (such as DNA damage and aneuploidy) and intrinsic factors that permit or induce such change (such as specific gene polymorphisms, defective DNA repair or changes in epigenetic regulation).

DNA damage—which can be caused by exposure to external chemicals or radiation, or by endogenous agents such as reactive oxygen or faulty replication—is an event that can initiate the multistep process of carcinogenesis (200). Protection is afforded

at different levels; removal of damaging agents before they reach the DNA, by antioxidant defenses and the phase I/phase II xenobiotic metabolizing enzymes; a second line of defense, DNA repair, operating on the damage that occurs despite the primary protection; and as a last resort, apoptosis (programmed cell death), disposing of heavily damaged cells.

A clear sign of genome instability is aneuploidy—a deviation from the normal number of chromosomes (201). Aneuploidy is a very common feature of human cancers. Another hallmark of cancer is loss of the normal mechanism of telomere shortening, which allows abnormal cells to escape senescence, by avoiding the body's 'editing' processes that normally eliminate aging cells with their accumulated genome aberrations (202,203).

The genes of most significance for cancer are the (proto)-oncogenes which, if defective, or abnormally expressed, lead to uncontrolled cell proliferation; tumor suppressor genes, the normal products of which tend to switch off replication to allow repair, and promote cell death if damage is excessive; and genes such as those involved in DNA repair that can—if faulty—lead to a 'mutator phenotype'. Mutated proto-oncogenes and tumor suppressor genes are found in most if not all cancers and play key roles in cancer etiology (204–207). Rare mutations in DNA repair genes greatly increase the risk of cancer (208,209). However, the evidence for links between common variants of repair genes and cancer is generally inconclusive (210).

The term 'epigenetics' refers to covalent modifications of the DNA (methylation of cytosine in 'CpG islands' within regulatory regions of genes) or of the histones. These modifications can control gene expression and the pattern of modifications is altered in many cancers (211,212). For instance, hypomethylation of proto-oncogenes can lead to overexpression, which is undesirable. MicroRNAs (miRNAs) are responsible for specific down-regulation of gene expression at a post-transcriptional level, by preventing translation from messenger RNAs. miRNAs participate in DNA damage responses and some miRNAs are deregulated in many cancers (213–215).

Mutations in germ and stem cells are potentially more serious than those in other cells as they are passed to the cells' progeny within the developing embryo or regenerating tissue (216,217). There is a presumed survival benefit when stem cells tend to show a particularly stringent maintenance of genome integrity through cell cycle regulation and enhanced responses to DNA damage (218).

The selected 'chemical disruptors' that induce genome instability include chemicals that not only directly damage DNA or cause mutations, but act indirectly, via pathways such as DNA damage signaling, DNA repair, epigenetic regulation or mitochondrial function. They include the following:

Metals such as lead, nickel, cobalt and mercury (common water pollutants) are known to disrupt DNA repair (181,219), whereas nickel also affects epigenetic histone modification (189,191) and lead causes defective telomere maintenance (184,220). Alloy particles, containing tungsten, nickel and cobalt, can be inhaled and disrupt redox signaling (193,221). Titanium dioxide nanoparticles are also common in many consumer products and foods and have been reported to disrupt mitochondrial function and increase oxidative stress, as well as inhibit DNA repair and disrupt mitosis (194,222,223).

Acrylamide occurs in many fried and baked food products, and (apart from the well-known DNA adduct formation) can inactivate many critical proteins by binding sulphydryl groups (186).

Bisphenol A (BPA) is a plasticizer used for manufacturing polycarbonate plastics and epoxy resins, and it can leach

from plastics into food and water. It is implicated in disruption of DNA methylation, histone acetylation and disturbance of miRNA binding (192,224,225), redox signaling (226) and induction of micronuclei through spindle defects in mitosis (227).

The fungicide benomyl is metabolized to carbendazim; both are classified as possible human carcinogens at present. The route of exposure is most likely ingestion via residues in crops. Benomyl disrupts the microtubules involved in the function of the spindle apparatus during cell division, leading to production of micronuclei (Frame, S.R. et al., unpublished report, Schneider, P.W. et al., unpublished report, (228)).

Halobenzoquinones are disinfection by-products in chlorinated drinking water (229). Quinones are electrophilic compounds, known to react with proteins and DNA to form adducts. These electrophilic chemicals can interact with functional thiol groups via Michaelis-Menton type addition, causing modification of enzymes involved in methylation and demethylation (188). This mechanism might be shared by other xenobiotics that increase reactive oxygen species (ROS).

Human exposure to nano-sized materials used in cosmetics, biomedical compounds, textiles, food, plastics and paints has increased not only in a conscious way but also passively by the leakage of nanomaterials from different objects. Nanoparticles can induce genome instability via mitochondrial-related apoptosis (230), decreased DNA repair (222,230,231), hypoacetylation of histones (232), disruption of DNA methylation (231), up-regulation of miRNA (233), reducing telomerase activity (220) and—more specifically for carbon nanotubes—interacting with components of the mitotic spindle during cell division, or with proteins directly or indirectly involved in chromosome segregation (197,234). Nano-sized materials can also produce inflammation and alteration of the antioxidant defenses that can lead to genome instability.

### Tumor-promoting inflammation

One of the earliest hypothesized causes of tumors subsequently supported experimentally was the irritation hypothesis proposed by Virchow. Although it was recognized initially that injury alone was insufficient for carcinogenesis, it was also recognized that 'irritation may have an accessory or predisposing influence in tumor formation, and that it may be enough finally to upset the balance of a group of cells which for some other reason were already hovering on the brink of abnormal growth' (235). Indeed, it is now recognized that inflammatory responses, similar to those associated with wound healing or infection, support the development of invasive carcinomas by altering the microenvironment in favor of proliferation, cell survival, angiogenesis and tumor cell dissemination while also disrupting antitumor immune surveillance mechanisms. In other words, inflammation plays a critical role in tumorigenesis (23,24).

Inflammation is an immediate and necessary host defense mechanism in response to infection or tissue injury by noxious stimuli. In tumor-associated inflammation, both the epithelium and the immune cells express receptors that signal the activation and production of a wide array of biologically active proteins most analogous to an unhealed wound. The sustained or uncontrolled release of potent and reactive molecules such as prostaglandins, cytokines, ROS and chemokines from both the tumor cell and the microenvironment constituents leads to progressive genomic instability, alterations in the integrity and function of the microenvironment including alterations in the vasculature (e.g. vascular hyperpermeability, neovascularization and angiogenesis), as well as alterations in local immune dynamics. The cellular and molecular mechanisms include a

diverse array of immune- and tumor-cell-derived effector molecules such as the proinflammatory reactive oxygen and nitrogen species, a number of cytokines, chemokines as well as cyclooxygenase-2 and its product, prostaglandin  $E_2$ .

In general, there is a paucity of experimentation, and when present, inconsistent findings for the role of environmental chemicals as proinflammatory molecules and more so for a pro-inflammatory action as a co-factors in carcinogenesis. However, some recent studies provide a credible mechanistic basis, particularly early life exposures that might act by disrupting the immune cell balance toward inflammation, and that manifest in adulthood. One example is BPA, one of the most abundant and best studied environmental endocrine disruptors, and its controversial role as an immune disruptor. Specifically, studies in male rats found that early life BPA exposure leads to the development of prostate intraepithelial neoplasia (a prostate cancer precursor lesion) through a pathological process that includes BPA-dependent epigenetic reprogramming of genes involved in the development of lateral prostate inflammation in adulthood (236,237).

This work in prostate is complemented by a much more extensive study of BPA effects on immune cell components, particularly the T-cell compartment, demonstrating that BPA acts as an immune disruptor by promoting 'immune' cell proliferation though the exact nature of the effect on specific cells of the immune system is poorly delineated. Most interesting is the work by Yan et al. (122), who reported findings suggesting that the timing of BPA exposure during development (prenatally, early life or adult) alters the effect of BPA on regulatory T cells. BPA actions also map over to the effects on the immune system including the promiscuity of BPA for a number of nuclear receptors relevant to immune cells such as the estrogen receptor and the aryl hydrocarbon receptor (AhR). As well, bulky BPA analogs may act as antagonists of members of the peroxisome proliferator-activated receptor (PPAR) family, an important family of nuclear receptors with potent anti-inflammatory function (238,239). Effects on the PPAR nuclear receptors may also explain inflammation-associated phenotypes observed with exposures to certain phthalates and nonylphenol (4-NP).

A second example is the reported immunotoxic effects of atrazine (6-chloro-*N*-ethyl-*N*-(1-methylethyl)-1,3,5-triazine-2,4-diamine) (240), a chemical that is the most commonly detected triazine herbicide in USA soil and water. Atrazine is banned by the European Union and drinking water exposures are supposed to be limited in the USA to <3 µg/l (although exposures exceed this limit regularly), but the use of this chemical is high and increasing in Asia and other countries. Thus, atrazine is an important pesticide to which humans are exposed. Atrazine exhibits weak mutagenicity and low oncogenic properties, but research by a number of authors is emerging that suggests that immune system disruption might be a concern (132,240,241).

Although the majority of work on atrazine has been focused on its endocrine disrupting properties, there is also evidence to support immunotoxicity including effects on T-lymphocytes composition with oral dosing (242,243), modulation of nitric oxide production (244) and potential generation of ROS (245,246). The local production of reactive nitrogen species and ROS by mast cells and macrophages are among the better studied immune modulatory molecules for which recent evidence supports important roles both in the tumor microenvironment and in the tumor progression (247–249). Notably, these reactive species trigger oxidative/nitrosative modifications, which can initiate redox signaling that tightly modulates the inflammatory



response in a manner that is highly relevant for carcinogenesis (250,251).

We also looked at polybrominated diphenyl ethers (PBDEs) and their effects on inflammatory cytokines. Peltier et al. (128) recently found that placental explants treated with a mixture of the congeners BDE-47, -99 and -100 and then exposed to *Escherichia coli* were 'reprogrammed' toward a proinflammatory response (increased IL-1 $\beta$  and tumor necrosis factor  $\alpha$ ) and away from the expected anti-inflammatory response (decreased IL-10) compared with untreated placenta. Although these studies are preliminary, chronic PBDE exposure may lower the threshold for bacteria to stimulate a proinflammatory response, which has potential relevance given the established link between bacteria and certain cancers (e.g. *Helicobacter pylori* and gastric cancer), where tumor development is dependent on inflammation.

Vinclozolin was also of particular interest as an environmental chemical because transient early life exposures *in utero* have been linked to both adult-onset disease and transgenerational disease that involves inflammation (134,135). For example, transient vinclozolin exposure *in utero* has been shown to promote inflammation in the prostate (prostatitis) of postpubertal rats coupled with a down-regulation of the androgen receptor and increase in nuclear factor- $\kappa$ B (NF- $\kappa$ B). The late or delayed effect of exposure is hypothesized to reflect a mechanism whereby vinclozolin exposure during a critical development window imprints an irreversible alteration in DNA methyltransferase activity, leading to reprogramming of the androgen receptor (AR) gene(s), which manifests as inflammation in early adult life with adverse effects on spermatid number.

Similarly, 4-NP has been shown to increase progenitor white adipose levels, body weight and overall body size in rodents exposed prenatally. Like vinclozolin, 4-NP effects on adipogenesis in the perinatal period confer transgenerational inheritance of the obesogenic effects observable in F2 offspring, consistent with genome reprogramming through an epigenetic process (252) and others have reported immune and inflammation-related effects (137,138) making it relevant to carcinogenesis a deserving further investigation.

### Sustained proliferative signaling

Sustained proliferative potential is an essential component of cancerous growth. Progressive conversion of normal cells into cancer cells requires a series of genetic alterations, where each alteration confers one or more types of growth advantage. One such alteration that affords the transformed cell a distinct growth advantage over its normal counterparts is the acquired capacity of the cancer cell to proliferate in a sustained manner, so as to crowd out and outnumber the normal cell population (23). One of the fundamental differences between a normal and a transformed cell is that normal cells halt proliferation when subjected to growth inhibitory signals or in the absence of growth stimulatory signals (253). But tumor cells act to sustain proliferative signaling in several different ways. They can activate specific genes to produce relevant growth factors, which in turn bind to signaling receptors giving rise to an autocrine loop (254). Growth factors produced by tumor cells can also stimulate the proliferation of stromal cells that in turn produce growth factors to sustain tumor cell proliferation (255). Sustained proliferation can additionally be maintained at the receptor level by truncation of signaling receptor proteins whereby the ligand-activated switch is missing (256). Alternatively, the number of high-affinity receptor proteins may be increased to levels that will sustain proliferative signaling in otherwise normal growth factor levels. Finally, sustained proliferative signaling may well

be the result of perpetual activation of the intracellular signaling chain independent of growth factors or receptors (e.g. mutated ras (257) or truncated src (258) are intermediaries of a normal proliferation signaling chain responsible for sustained proliferation).

We hypothesized that disruptive environmental chemicals acting in a procarcinogenic manner by inducing what is referred to as 'sustained cell proliferation' likely exert their action by interfering with some basic control mechanisms (23,253). For instance, they could achieve this by positively regulating targets within and outside the cell known to promote cell proliferation or negatively regulating targets within and outside the cell known to halt cell proliferation. In this way, such chemicals could confer proliferative advantage to a distinct cell population and contribute to that population's capability to successfully breach innate anticancer defense mechanisms and to become progressively autonomous.

Specifically, we identified a total of 15 ubiquitous chemical disruptors capable of producing sustained cell proliferation. The majority of these chemicals interacted with multiple targets, and we have tabled this information in our review. In summary, we identified several commonly used insecticides and fungicides capable of causing sustained proliferation. These included cyprodinil, etoxazole, imazalil, lactofen, maneb, methoxychlor (MXC), phosalone, prochloraz and pyridaben, all of which targeted estrogen receptor  $\alpha$  and frequently other steroid hormone receptors such as androgen receptor (102,259–275). Most of these chemicals also targeted growth factors and their receptors (260,264,267,276–280) and induced cytokines and cytokine receptors (identified by ToxCast high-throughput assay). Top disrupting chemical fungicides and insecticides were cyprodinil and MXC, which each interacted with a total of six individual targets that further included the AhR (100), B-lymphocyte markers (ToxCast 2009 high-throughput assay, both chemicals), AP-1 proteins/transcription/translation regulators, downstream signaling molecules and cell cycle regulators (281,282). Other strong performers for sustained proliferation were BPA (activated all targets activated by the insecticides and fungicides above except growth factors and their receptors, B lymphocyte markers and PPAR, but included cell cycle regulators alongside AP-1 proteins/transcription/translation regulators and downstream signaling) (272,281,283–285) (also identified in ToxCast high-throughput assay, 2009), polyfluorinated octinoid sulfate and polybrominated diphenylethers (flame retardants) that either activated AhR (286,287) or up to five other targets that included steroid receptors, growth factors, cytokines and cell cycle regulators (109) (ToxCast high-throughput assay 2009). Three other contenders were phthalates (plasticizers that acted via three targets that included AhR, steroid hormone receptors and PPAR) (265,288–292), trenbolone acetate (a synthetic anabolic steroid that unsurprisingly acted through steroid hormone receptors) (120,293–297) and finally, edible oil adulterants (food contaminants produced during food processing that acted via downstream signaling) (298,299).

We have shown estrogen and androgen receptors to be important targets in relation to sustained proliferative signaling (300), and note that environmental estrogens and androgens are frequently recognized as prototypical disruptor(s) of this hallmark. Although this is a small sample, there are a great number of chemicals in the environment (both naturally occurring and man-made) are estrogenic, interact with estrogen receptor and produce estrogen metabolites (just as naturally derived ovarian estrogen does during metabolic breakdown). Catechol estrogens (hydroxyl derivatives of estrogens), which are formed during

estradiol metabolism, are also potentially important mediators of endogenous estradiol levels, and therefore of sustained proliferative signaling and oncogenesis (301).

### Insensitivity to antigrowth signals

Cell cycle arrest is important for maintaining genomic integrity and for preventing genetic errors from being propagated. The normal cell cycle contains multiple checkpoints to safeguard against DNA-damaging agents. Specific proteins at these checkpoints are activated in response to harmful stimuli, ensuring that cellular proliferation, growth and/or division of cells with damaged DNA are blocked.

There are multiple key mediators of growth inhibition that may become compromised during carcinogenesis. Some, such as p53 and RB1, cause cells to arrest at the G<sub>1</sub>-S phase transition when they are activated by DNA damage. Mutations in the p53 gene occur in ~50% of all cancers, although certain tumor types, such as lung and colon, show a higher than average incidence (302). Some, such as p53, RB1 and checkpoint kinases, cause cells to arrest at the G<sub>1</sub>-S phase transition when they are activated by DNA damage. Similarly, pRb hyperphosphorylation (303), direct mutations (304), loss of heterozygosity (305) and disruption of the INK4-pRb pathway (INK4-CDK4/6-pRb-E2Fs) (306) are common events in the development of most types of cancer. Cancer cells may also evade the growth inhibitory signals of transforming growth factor- $\beta$  (TGF- $\beta$ ) (307) and modulate the action of downstream effectors as well as crosstalk with other pathways.

Cells also receive growth inhibitory signals through intercellular communication via gap junctions. Gap junctions disperse and dilute growth-inhibiting signals, thereby suppressing cell proliferation. In contrast, loss of gap junctions increases intracellular signaling, leading to enhanced proliferation and tumor formation. The molecular components of gap junctions are the connexin proteins (308). Connexins are recognized as tumor suppressors and have been documented to reduce tumor cell growth. Numerous environmental stimuli have been reported to directly affect gap junction intercellular communication. Adherens junction machinery mediates contact inhibition of growth, and loss of contact inhibition is a mediator of tumor cell growth.

Chemicals that may contribute to insensitivity to antigrowth signals through multiple targets of this hallmark are BPA, a common constituent of everyday plastics, and pesticides such as DDT, folpet and atrazine. BPA promotes proliferation by disrupting the growth inhibitory signals of p53 and gap junction communication (171,309). DDT has also been shown to enhance proliferation by increasing the expression of Ccnd1 (cyclin D1)/E2f, inducing phosphorylation of pRb, increasing the expression of p53-degrading protein Mdm2 (a negative regulator of p53) (162) and disrupting gap-junctional intercellular communication (163,164). Folpet down-regulates the functions of p53 and ATM/ATR checkpoint kinases (167) and promotes proliferation. Atrazine shows genotoxic effects at subacute dose on Wistar rats, and the genotoxicity was also associated with increased transcription of connexin accompanied with increased oxidative stress (310).

### Resistance to cell death

Cell death is an actively controlled and genetically regulated program of cell suicide that is essential for maintaining tissue homeostasis and for eliminating cells in the body that are irreparably damaged. Cell death programs include: apoptosis, necrosis, autophagy, senescence and mitotic catastrophe (21). Defects in these pathways are associated with initiation and

progression of tumorigenesis. Normally, cells accumulate from an imbalance of cell proliferation and cell death, permissive cell survival amidst antigrowth signals such as hypoxia and contact inhibition, resistance to the killing mechanisms of immune cell attack and anoikis resistance (311). Increased resistance to apoptotic cell death involves inhibition of both intrinsic and extrinsic apoptotic pathways.

The link between malignancy and apoptosis is exemplified by the ability of oncogenes, such as MYC and RAS, and tumor suppressor genes, such as TP53 and RB, to engage both apoptosis and the aberrant alterations of apoptosis regulatory proteins such as BCL-2 and c-FLIP in various solid tumors (312). This variety of signals driving tumor evolution provides the selective pressure to alter apoptotic programs during tumor development. Some chemical carcinogens and sources of radiation cause DNA damage and increase genetic and/or epigenetic alterations of oncogenes and tumor suppressor genes leading to loss of cellular homeostasis (313). Other signals include growth/survival factor depletion, hypoxia, oxidative stress, DNA damage, cell cycle checkpoint defects, telomere malfunction and oncogenic mutations, and exposure to chemotherapeutic agents and heavy metals (314,315).

Cancer cells resist apoptotic cell death by up-regulation of antiapoptotic molecules and the down-regulation, inactivation or alteration of pro-apoptotic molecules. Activation of p53 usually induces expression of pro-apoptotic proteins (Noxa and PUMA) and facilitates apoptotic cell death (316). Antiapoptotic Bcl-2 family proteins suppress pro-apoptotic Bax/Bak [which would otherwise inhibit mitochondrial outer membrane permeabilization]. Mitochondrial outer membrane permeabilization releases cytochrome c and triggers apoptosis through an intrinsic pathway (317). Thus, regulation of apoptosis can be achieved by inhibiting the antiapoptotic Bcl-2 family proteins and Bcl-X<sub>L</sub> proteins as this restores a cell's ability to undergo apoptosis. During the process of, mitochondrial outer membrane permeabilization, mitochondrial proteins (Smac/DIABLO and Omi/HtrA2), which inhibit the X-linked inhibitor of the apoptosis protein, are leaked to trigger caspase activity in apoptosis (318,319).

Normal cellular metabolism is important for the survival of cells, whereas dysregulated metabolism in cells (see Dysregulated metabolism) can induce either apoptosis or resistance to apoptotic stimuli (320). In the liver, nearly every enzyme in glycolysis, in the tricarboxylic acid cycle, in the urea cycle, in gluconeogenesis and in fatty acid and glycogen metabolism is found to be acetylated, and this N- $\alpha$ -acetylation confers sensitivity to apoptotic stimuli (321). The antiapoptotic protein, Bcl-xL reduces the efflux of acetyl-CoA from the mitochondria to the cytosol in the form of citrate and decreases N- $\alpha$ -acetylation of apoptotic proteins, which enables cells less sensitive toward apoptotic stimuli to mediate cell proliferation, growth and survival. Thus, N- $\alpha$ -acetylation might be a major factor in overcoming apoptotic resistance in cancer cells (322,323).

Death receptor ligands such as TRAIL—which is bound to DR4/DR5—induce receptor oligomerization and recruitment of Fas-Associated protein with Death Domain (FADD) and caspase-8 to form death-inducing signaling complex, which leads to subsequent cell death via apoptosis. Thus, expression of death receptors and their decoy receptors (Dcr1/2) mediates apoptosis in tumor cells (324). When normal cells lose contact with their extracellular matrix or neighboring cells, they undergo an apoptotic cell death pathway known as 'anoikis' (311). During the metastatic process, cancerous cells acquire anoikis resistance and dissociate from primary sites, travel through the vascular system and proliferate in distant target organs.

A blockage of gap junction intracellular communication (GJIC) between normal and preneoplastic cells also creates an intra-tissue microenvironment in which tumor-initiated preneoplastic cells are isolated from growth controlling factors of normal surrounding cells resulting in clonal expansion (325). Gap junction channels and Cxs control cell apoptosis by facilitating the influx and flux of apoptotic signals between adjacent cells and hemi-channels between the intracellular and extracellular environments, and Cx proteins (in conjunction with their intracytoplasmic localization), may act as signaling effectors that are able to activate the canonical mitochondrial apoptotic pathway (326).

Several anthropogenic chemicals can affect resistance to cell death. For example, BPA has been shown to strikingly impair TP53 activity and its downstream targets, cell cycle regulators, p21WAF1 and RB, or pro-apoptotic BAX, thereby enhancing the threshold for apoptosis (172).

Chlorothalonil, a broad-spectrum fungicide that is used on vegetables, fruit trees and agricultural crops, is considered to be non-genotoxic but classified as 'likely' to be a human carcinogen by all routes of exposure (29). In a eukaryotic system, chlorothalonil reacted with proteins and decreased cell viability by formation of substituted chlorothalonil-reduced glutathione derivatives and inhibition of specific nicotinamide adenine dinucleotide thiol-dependent glycolytic and respiratory enzymes (327). Caspases (cysteine-dependent proteases) and transglutaminase are some of the thiol-dependent enzymes involved in apoptosis, so inhibition of these thiol-dependent enzymes in tumor-initiated cells may disrupt apoptotic cell death and aid in tumor survival.

Dibutyl phthalate and diethylhexyl phthalate (DEHP) are diesters of phthalic acid and commonly referred to as phthalates. In general, they mimic the function or activity of the endogenous estrogen 17 $\beta$ -estradiol (E2) and bind to estrogen receptors. Interestingly, phthalates can mimic estrogen in the inhibition of TAM-induced apoptosis in human breast cancer cell lines by increasing intracellular Bcl-2/Bax ratio in breast cancer (328).

Lindane, an organochlorine pesticide, bioaccumulates in wildlife and humans. Exposure to lindane induces tumor formation in the mouse 42GPA9 Sertoli cell line by disrupting the autophagic pathway and sustained activation of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway (329).

MXC (1,1,1-trichloro-2,2-bis(4-methoxyphenyl)ethane) is a DDT derivative that was developed after the ban of DDT and it exhibits antiandrogenic and estrogenic activity. MXC stimulates proliferation and human breast cancer cell growth by the up-regulation of genes that involve cell cycle (cyclin D1), and the down-regulation of genes p21 and Bax affecting G<sub>1</sub>/S transition and apoptosis, respectively, through ER $\alpha$  signaling (330).

### Replicative immortality

Cellular senescence is a state of irreversible arrest of cellular proliferation characterized by changes in transcription, chromatin conformation, cytoplasmic and nuclear morphology, DNA damage signaling and a strong increase in the secretion of proinflammatory cytokines (331). Senescence is the first line of defense against potentially transformed cells (332). Progression to malignancy correlates with a bypass of cellular senescence. Thus, senescence inhibits the activation of the tumorigenic process (332). Senescence has been observed *in vitro* and *in vivo* in response to various stimuli, including telomere shortening (replicative senescence),

oncogenic stress, oxidative stress and chemotherapeutic agents (333).

Cellular senescence exhibits several layers of redundant regulatory pathways. These pathways converge to arrest the cell cycle through the inhibition of CDKs. The best-known effector pathways are the p16INK4a/pRB, the p19ARF/p53/p21CIP1 and the PI3K/mammalian target of rapamycin (mTOR)/FOXO pathways (334–337), which show a high degree of interconnection. Additionally, the pRB and the mTOR pathways are two routes that have been proposed to be responsible for permanent arrest of the cell cycle (338). More pathways and genes are being discovered, increasing the complexity of our knowledge of this physiological process (336). Most, if not all of these genes have been related to human tumorigenesis.

Despite the relevance of senescence as a gatekeeper in the process of tumorigenesis, there is not a large body of information exploring the effect of chemicals on this safeguard. Little research has been undertaken on chemicals that alter gene expression regulating senescence and few genes have been identified (e.g. telomerase, p53, pRB, INK4a) (83,339,340). Traditional protocols for the assessment of the carcinogenic risk rely on the detection of tumors induced by agents that alter many different pathways at the same time (including senescence). These agents are mainly unspecific mutagens or epigenetic modifiers. The effect of some compounds is being explored including nickel-derived compounds (e.g. nickel chloride), diethylstilbestrol, reserpine or phenobarbital (83,341–344).

There may be environmental chemicals that are not mutagens or epigenetic modifiers, but that target specific proteins on the senescence pathways and may affect the initiation of tumorigenesis by other compounds allowing senescence bypass. The contribution of these compounds to the carcinogenesis process is largely unknown. A few compounds bypass senescence in this specific manner—acetaminophen, cotinine, nitric oxide, Na-selenite and lead. Other chemicals known to alter senescence only are mostly unknown (86,88–91,345–348).

Senescence has strong fail-safe mechanisms, and experimental attempts to bypass senescence are usually recognized as unwanted signals and trigger a senescence response anyway. However, these conclusions are based on the interpretations of experimental designs in which acute molecular or cellular alterations are produced. There are few experiments regarding the effects of chronic, low-dose alterations and even fewer studies that consider the different cellular and molecular contexts that can arise over the course of a lifetime.

### Dysregulated metabolism

The highly glycolytic cancer phenotype described by Warburg *et al.* (25) in the early 20th century determined much of the initial direction in cancer research (26). Other characteristic metabolic abnormalities have also been described (25,26,349,350) and have recently garnered increased attention (351–355). These changes are neither fixed nor specific for cancer (356–358), but the universality of metabolic dysregulation suggests major roles in cancer genesis, maintenance and progression. Precise definitions of what constitutes cancer metabolism, and when such changes first occur during the course of cancer development, are lacking. From a teleological perspective, alterations in both intermediary metabolism and its control are not surprising insofar as highly proliferative cancer cells exhibit increased energy demands and expanded requirements for macromolecular precursors to support nucleic acid and protein biosynthesis, as well as membrane biogenesis, for increased biomass. Metabolic reprogramming ostensibly equips cancer cells to cope with these demands, as



well as accompanying cellular stresses. Although much of the attention on cancer metabolism has focused on enhanced glucose utilization via glycolytic and pentose phosphate pathways, cancer cells are also capable of the oxidative utilization of carbohydrates, lipids and peptides, and the metabolism of these individual substrate classes remains intimately intertwined as in normal cells (26,352,359).

Major control of glycolysis is traditionally ascribed to glucose transport, hexokinase, phosphofructokinase and pyruvate kinase (359). Glyceraldehyde-3-phosphate dehydrogenase also normally couples glycolytic flux to mitochondrial metabolism in the presence of oxygen and to lactate generation in its absence, but this relationship is fundamentally altered in cancer (26,352,360,361). Given the central importance of the pentose phosphate pathway to anabolic metabolism and redox homeostasis, glucose-6-phosphate dehydrogenase and its redox coupling partners represent similarly attractive carcinogenic targets (362). In addition, the enzymes of the tricarboxylic acid cycle, such as fumarate hydratase, succinate dehydrogenase and isocitrate dehydrogenase, play crucial roles in oxidative energy metabolism and the interconversion of metabolic intermediates, making them appealing candidates for study as well (363,364).

The central importance of the mitochondrial electron transport chain to oxidative energy metabolism and its established role in toxic responses and dysregulated mitochondrial function in cancer makes its assembly and function attractive topics for study (365–367). Despite well-established roles for lipid and amino acid metabolism in cancer development and progression, they have historically received less attention than carbohydrate metabolism (26). Lipogenic, lipolytic and lipophagic phenotypes are now widely recognized (351,368–370), so targets such as acetyl-CoA carboxylase, fatty acid synthase, cellular lipases and lipid transporters represent additional attractive targets for study. Amino acid metabolism—particularly glutamine and serine metabolism—also has well-established roles in cancer (371–373), providing additional potential targets for study that include 3-phosphoglycerate dehydrogenase (353,372,374,375) and cellular transaminase coupling mechanisms. Study of both lipid and protein metabolism must accommodate the fact that cancer cells exhibit substrate preferences, including well-described endogenous lipid- and protein-sparing effects of exogenous glucose availability in cancer cells.

The metabolic capacity of both normal cells and cancer cells generally exceeds their catabolic and anabolic requirements (371,376,377), and only a fraction of the available potential energy is ultimately required for cell survival (378,379). Moreover, very small changes in metabolic flux can have profound phenotypic consequences, and metabolic control analysis has suggested that the importance of increased cancer-associated glycolytic and glutaminolytic fluxes may lie not in their magnitudes, but in the maintenance and control of smaller branched pathway fluxes (371). For these reasons, rigorous functional validation is needed for all cancer-associated changes in gene expression or metabolite accumulation. Well-described moonlighting functions for many metabolic enzymes (380–382), including the novel antiapoptotic roles of mitochondrial hexokinases (383), cannot be simply extrapolated from our knowledge of classical roles in cellular metabolism.

These enzymes and their pathways constitute broad categories of potential targets for disruption that could serve to enable the observed metabolic phenotypes of cancer cells (384). Although metabolic control is broadly distributed over all individual steps for a given pathway (359,385), the most obvious

targets for conceptual and experimental scrutiny involve major rate-controlling elements of pathways capable of supporting the anabolic and catabolic needs of rapidly proliferating cancer cells.

Numerous studies have demonstrated cancer-associated changes in metabolism or related gene expression (26). We looked at acrolein, copper, cypermethrin, diazinon, hexythiazox, iron, malathion and rotenone as chemicals that had been reported to show relevant disruptive potential (51,386–390); however, the toxicological data that are available for many suspected or known environmental disruptors, generally lack mechanistic information regarding their potential roles as determinants of the observed metabolic hallmarks of cancer. Even prior metabolic screening platforms, including tetrazolium reduction assays, have limited specificity and can be profoundly influenced by experimental screening conditions. Unfortunately, standardized chemical screening has typically not been conducted under controlled or limiting substrate conditions that would directly inform our understanding of the functional relevance of observed changes. None have established unambiguous causal relationships between specific chemical exposures and the parallel or sequential development of dysregulated metabolism of cancer in the same model, and most observed changes in gene expression with potential relevance to cancer metabolism have not been accompanied by validating functional studies.

## Angiogenesis

Angiogenesis, the process of formation of new blood vessels from existing blood vessels, is a critical process for normal organ function, tissue growth and regeneration (e.g. wound healing, female menstruation, ovulation and pregnancy) as well as for pathological conditions (e.g. cancer and numerous non-cancerous diseases, such as age-related macular degeneration, diabetic retinopathy, rheumatoid arthritis, endometriosis, diabetes and psoriasis) (391,392).

Tumor angiogenesis is an early critical event for tumor development: A tumor cannot grow beyond 1 mm<sup>3</sup> (by estimate) without angiogenesis (393). Tumor growth, invasion and metastasis depend on blood vessels and neovascular development to provide nutrients, oxygen and removal of metabolic waste as tumors grow in primary sites, invade adjacent tissues and metastasize to distant organs (394,395). Inhibition or eradication of tumor angiogenesis by antiangiogenic inhibitors (396,397) or by antineovascular agents (such as vascular-disrupting agents (398–400) and fVII/IgG Fc (401), the latter also called ICON (402–404)) can treat pathological angiogenesis-dependent diseases, including cancer and many non-cancerous diseases.

Under physiological conditions, angiogenesis is well balanced and controlled by endogenous proangiogenic factors and antiangiogenic factors. Factors produced by cancer cells can shift the balance to favor tumor angiogenesis. Such factors include vascular endothelial growth factor (VEGF) and tissue factor (TF). VEGF, one of the most potent proangiogenic factors produced by cancer stem cells and cancer cells, binds to vascular endothelial cells via its receptor VEGFR, initiating VEGF/VEGFR intracellular signal transduction pathways and activating many gene transcriptions and translations toward angiogenesis. TF is a transmembrane receptor (405) not expressed on quiescent endothelial cells (406,407). Upon stimulation of VEGF, TF is selectively expressed by angiogenic endothelial cells, the inner layer of the tumor neovasculature. Thus, TF is a specific biomarker for tumor angiogenesis (408–410). Both of the membrane-bound receptors VEGFR and TF can mediate separate intracellular signaling pathways that contribute to tumor angiogenesis.



Environmental exposures can promote tumor development, but the role of chemicals in tumor angiogenesis, particularly the role of low-dose *non-carcinogens*, is largely unknown. Some food-use pesticides that are non-genotoxic act as tumor promoters, and other chemicals affect various hallmarks such as apoptosis, proliferative signaling, evading growth suppression, enabling replicative immortality, metastasis, avoiding immune destruction, tumor-promoting inflammation and deregulating cellular energetics—in addition to tumor angiogenesis.

Chemical disruptors that may promote tumor angiogenesis included diniconazole, 2,2-bis-(p-hydroxyphenyl)-1,1,1-trichloroethane (HPTE), methylene bis(thiocyanate), perfluorooctane sulfonate (PFOS), ziram, biphenyl, chlorothalonil, tributyltin chloride and bisphenol AF. Diniconazole (pesticide), for example, targets certain angiogenic molecules (CXCL9, CXCL10, MMP1, uPAR, VCAM1 and THBD) *in vitro* (29). MXC (the parent compound to HPTE) induces histological expression of angiogenic factors such as VEGF, VEGFR2 and ANG1 in rat pituitary and uterus (39), and exposure to PFOS induces actin filament remodeling, endothelial permeability changes and ROS production in human microvascular endothelial cells (41). ziram can induce angiogenesis through activation of MAPK and decreases cytolytic protein levels in human natural killer (NK) cells (411,412).

### Tissue invasion and metastasis

Tissue invasion and metastasis are also key processes of tumor progression. In normal cells, E-cadherin holds the epithelial cells together as a society of cells that are well differentiated and otherwise quiescent (413). Carcinomas constitute almost 90% of cancers and upon oncogenic transformation, the process of tissue invasion and metastasis begins with the down-regulation of E-cadherin. Concomitant with this down-regulation of E-cadherin is the conversion of epithelial to mesenchymal cells (EMT) (414). The transcription factors that control EMT, such as Snail, Slug, Twist and Zeb1/2, are some of the best-characterized signaling molecules in biology (415,416). During the process of EMT, a number of inflammatory cells are attracted to the growing tumor mass (417). Upon attaining mesenchymal characteristics, tumor cells are able to move out of their natural environment, aided by cross talk between them and stromal cells, resulting in the secretion of matrix degrading enzymes such as matrix metalloproteinases (418). This process is accelerated by chronic inflammation mediated by NF- $\kappa$ B (417). Other invasion mediating molecules include hepatocyte growth factor, secreted mainly by tumor-associated fibroblasts to signal metastatic cells to move upon their interactions with their cell surface receptor cMet (419).

Attracted by chemokines, metastatic cells move to the nearest blood vessel or lymphatic vessel, where they complete the process of intravasation, entering the capillaries and are then transported to the capillary bed in their colonized site or new environment (420). In this new location, tumor cells undergo extravasation where they come out of the capillaries or lymphatic vessels, most likely again following the cues emanating from the chemokines in their new microenvironments. To survive in their new home, they may have to revert back and assume the cuboidal morphology of epithelial cells—undergoing the reversal of EMT otherwise known as mesenchymal to epithelial transition (421). At this point, they may remain dormant for a very long time until conditions for their division and growth become favorable.

Mounting evidence supports the involvement of exosomes (nano-vesicles secreted by tumor or cancer-associated fibroblasts) in adhesion and motility of metastatic cells. The secretion

of exosomes is accelerated by increases in intracellular calcium ions, and low-dose environmental mixtures that increase intracellular calcium may promote the secretion of exosomes and the subsequent invasion and metastasis processes of the tumor cells.

Environmental chemicals, such as tetrabromobisphenol A and its metabolites, BPA and tetrabromobisphenol A dimethyl ether, which mediate the activation of EMT enzymes or drive their synthesis, may also contribute to the process of tissue invasion (422). Low-dose exposure to hexavalent chromium may accelerate the EMT transition (423). Other contributing factors may also be low-dose environmental contaminants, such as formaldehyde, or bacteria, e.g. *H. pylori*, that drive the transcription of NF- $\kappa$ B and exacerbate the process (424,425).

### Tumor microenvironment

The tumor microenvironment is a complex mix of cells in addition to tumor cells themselves; it is constructed of a complex balance of blood vessels that feed the tumor, the extracellular matrix that provides structural and biochemical support, signaling molecules that send messages, soluble factors such as cytokines and many other cell types. Tumors can influence the microenvironment and *vice versa*. The micro-environmental reaction to early tumor cells begins with the recruitment and activation of multipotent stromal cells/mesenchymal stem cells, fibroblasts, endothelial cell precursors, antigen-presenting cells such as dendritic cells (DCs) and other white blood cells. All of these tumor stromal cells secrete a variety of growth factors and chemokines that, together with the tumor cells and secreted factors, culminate in the generation of the tumor microenvironment (426–429).

The tumor microenvironment is important because any cell within this process has the potential to be affected by carcinogens, either alone or in mixtures, or by the inflammation that results from the carcinogenic insult (430). Although often associated with infection, chronic inflammation can be caused by exposure to carcinogens such as irradiation or environmental chemicals. Carcinogenesis can also be fostered via effects on the tissue context surrounding preneoplastic lesions. For example, transplantation experiments of preneoplastic cells have clearly documented that a growth-constrained tissue microenvironment can promote the growth and progression of preneoplastic cell populations (431).

Several compounds appear to influence the complex heterogeneity that forms the support network for cancer growth. The exposure to nickel chloride has been associated with the generation of ROS and inflammation (432). ROS are important because they can stimulate the induction of angiogenesis growth factors, such as VEGF, and can promote cell proliferation and immune evasion and play a role in cell survival (57,433–435). Prenatal exposure to BPA in experimental animals disrupts ER $\alpha$  and triggers angiogenesis, and other BPA exposure studies have demonstrated that BPA interplays with cell proliferation (226), genomic instability (436), inflammation (437) and cell immortalization (438). Butyltins, and specifically tributyltin, which is suspected to act as an endocrine disruptor, have been found to inhibit the cytotoxic activity of NK cells (439), affect inflammation (439) and disrupt membrane metalloproteinases (439). Cooperatively, disruption of these processes can lead to proliferation, migration and angiogenesis. Methylmercury (MeHg) is a neurotoxic compound deriving from metallic mercury through bacteria-supported metabolism in an aquatic environment. Bio-concentration in fish and shellfish poses a risk for sensitive population categories such as pregnant women and infants.

MeHg-induced ROS production may be involved in inflammation and apoptosis (440) as well as endothelial cell cytotoxicity (441). We also looked at paraquat, which may also have relevance for the tumor microenvironment via its role in oxidative stress (442,443).

### Avoiding immune destruction

The concept of immune surveillance suggests that the host immune system could identify tumor cells and destroy them. If this is true, tumor cells need to be poor stimulators of or challenging targets for the host immune system. To provide an effective immune response, multiple types of the cells are involved within innate and adaptive immune 'arm' with some cells (e.g. DCs and the NK cells) 'bridging' these two types of immunity (444). To avoid a strong immune response of the host, the expression of tumor antigens may be down-regulated or altered (resulting in decreased or impossible recognition of malignant cells) (445) and various soluble factors and cytokines may be released resulting in subverted effectiveness of antitumor immune response (446–448). Tumor cells can also escape host immune response by inducing apoptosis in activated T cells (449).

Multiple genes are involved in immune evasion mechanisms and, therefore, can interfere with chemical exposures from anthropogenic environment: ADORA1 (adenosine A1 receptor), AKT1 (v-akt murine thymoma viral oncogene homolog 1), CCL2 (chemokine C-C motif ligand 2), CCL26 (chemokine C-C motif ligand 26), CD40, CD69, COL3A1 (type III collagen of extracellular matrix), CXCL10 (also called interferon-inducible protein-10), CXCL9 (monokine induced by interferon- $\gamma$ ), EGR1 (early growth response protein 1), HIF-1 $\alpha$  (hypoxia-inducible factor), IGF1R (insulin-like growth factor 1 receptor) and interleukins (IL) such as IL-1 $\alpha$  and IL-6. Based on available studies, several candidate signaling pathways that are related to the host immune response can be identified for further study; e.g. the pathways involving PI3K/Akt, chemokines, TGF- $\beta$ , FAK, IGF-1, HIF-1 $\alpha$ , IL-6, IL-1 $\alpha$ , CTLA-4 and PD-1/PDL-1.

Biologically disruptive environmental chemicals can affect the host immune responses as follows: (i) if a certain chemical is immunotoxic, and, in particular, if it affects activity of DCs, T cells or NK cells, it is also likely to affect tumor immuno-surveillance and enable malignant growth to proceed; (ii) if a chemical targets the immune system, it can increase the cancer risk related to other factors/exposures; (iii) exposures to certain toxins or toxicants can dramatically increase the number of cancerous cells and impact immuno-regulatory signals suppressing the mechanisms of immune control. Collectively, these sorts of actions suppress the immune system, so it cannot be effectively stimulated and cannot eliminate tumor cells, thus allowing some tumor cells to escape and metastasize.

We looked at several groups of environmentally ubiquitous chemicals such as pesticides and personal care products that might potentially interrelate with mechanisms of tumor immuno-surveillance. Although none of them are recognized as human carcinogens (450–452), the research on these chemicals and their interactions with the immune response may be valuable. For example, the fungicide maneb is a cortisol disruptor (453) that has shown a wide spectrum of potential effects on multiple pathways, including some that are relevant to immune evasion (139,156–158,454). By comparison, pyraclostrobin and fluoxastrobin (455) interfere with a narrower spectrum of cancer hallmarks (36,456–459). Atrazine has also shown potential to impact immune system evasion by directly targeting maturation of DCs and decreasing the levels of major histocompatibility

complex class I molecules (243,460). The insecticides pyridaben and azamethiphos can also both be disruptive to immuno-surveillance (139,140,461,462).

Commonly used in personal care products, triclosan and BPA (463), are endocrine disruptors (464–466) that are often detected in waters downstream in urban areas (467,468). In addition to immune evasion mechanisms (36,142,145), they interfere with wide spectrum of cancer-related mechanisms (36,173,436,469–471). DEHP (472) is also an endocrine disruptor (473,474) that can impact multiple hallmarks such as immune evasion, resistance to cell death, evasion of antiproliferative signaling, sustained proliferative signaling and tumor-promoting inflammation (36,288,475,476).

Knowing whether or not cumulative low-dose exposures to these chemicals interfere with the host immune response can help to stimulate further studies (e.g. on screening of lesions at the pre-malignant stage of tumor development) to determine the influence of such exposures on host immunity and to evaluate their potential to increase the risk of tumor cell survival.

### Dose-response characterizations and LDE

For all the chemicals selected and target sites for disruption that were identified, dose-response characterization results and/or relevant low-dose research evidence were reviewed and categorized using the criteria mentioned in the Materials and methods. Table 1 sets out these results and the supporting references.

In total, 85 examples of environmental chemicals were reviewed (for specific actions on key pathways/mechanisms that are important for carcinogenesis) and 59% of them (i.e. 50/85) were found to exert LDE (at levels that are deemed relevant given the background levels of exposure that exist in the environment) with 15 of the 50 demonstrating their LDE in a non-linear dose-response pattern. Indeed, all of the teams selected at least one or more disruptive chemicals that exerted their effects on the target sites at low-dose levels. In contrast, only 15% of the chemicals reviewed (i.e. 13/85) showed evidence of a threshold.

The remaining 26% of the chemicals reviewed (i.e. 22/85) were categorized as 'unknown'. Some of these chemicals (5 of the 22) had been tested using human primary cell data from ToxCast and had showed statistically significant activity across a full range of doses against the specified targets (i.e. they were active even at the lowest test concentrations of ~0.01  $\mu$ M). However, even though no threshold could be discerned for these chemicals, we did not characterize them as having LDE (because it was not clear that the lowest test concentrations were low enough to be equated to levels of exposure that are normally seen in the environment).

### Evidence of cross-hallmark relationships

Teams then evaluated the chemicals selected and target sites for disruption for known effects on the other cancer hallmark pathways. Evidence in the literature that showed procarcinogenic actions or anticarcinogenic actions in other hallmark areas were reported, and in instances where no literature support was found, this was documented as well. The same approach was used for the chemicals that were reviewed. A sample of these cross-hallmark results is provided in Table 2—Sample of cross-hallmark relationships of target pathways/mechanisms and in Table 3—Cross-hallmark relationships of selected chemical disruptors.

Note that Tables 2 and 3 contain just a single set of unreferenced results from the review on the hallmark insensitivity to

Table 2. Sample of cross-hallmark relationships of target pathways/mechanisms

Insensitivity to antiproliferative signals (targets)	Antiproliferative	Dysregulation	Genetic instability	Angiogenesis	Cell death	Immune	Immortality	Proliferation	Metastasis	Inflammation	Tumor microenvironment	PRO	ANTI	MIX
p53	n/a	+/-	-	+/-	-	+/-	-	-	-	+	+	2	5	3
pRB	n/a	+/-	-	-	-	0	-	-	-	+	+	2	6	1
TGF-β	n/a	+	-	+	-	+	-	+	+	+	+	7	3	0
LKB1	n/a	+	-	+	+/-	0	0	+	-	+	+	5	2	1
Connexins	n/a	-	-	0	0	0	0	-	+/-	+	+	2	3	1
Contact inhibition	n/a	+/-	-	0	0	+	0	-	-	+	-	2	4	1

One set of results (from the insensitivity to antiproliferative signals review) is shown here without references to support a discussion on the range of effects that have been reported for the selected targets in each article. Specific references supporting these effects for any given hallmark area can be found in the individual reviews within this special issue. Cross-hallmark relationships are reported in the first 11 columns of the table—table heading abbreviations are as follows:gen instability; dysregulation; genetic instability; proliferation; sustained proliferative signaling; metastasis; tissue invasion and metastasis; inflammation; tumor-promoting inflammation; tumor microenvironment. The number of procarcinogenic (PRO), anticarcinogenic (ANTI) and mixed (MIX) (i.e. procarcinogenic and anticarcinogenic reports) cross-hallmark relationships for each target have been summed and are reported in the last three columns of the table. Target pathways/mechanisms for each hallmark area were evaluated by each team for known effects in other cancer hallmark pathways. Targets that were found to have anticarcinogenic actions in another hallmark area were indicated with ‘-’, whereas targets that were found to have procarcinogenic actions in another hallmark area were indicated with ‘+’. In instances where reports on relevant actions in other hallmark areas were mixed (i.e. reports showing both procarcinogenic potential and anticarcinogenic potential), the symbol ‘+/-’ was used. Finally, in instances where no literature support was found to document the relevance of a target in a particular aspect of cancer’s biology, we documented this as ‘0’.

AQ24

Table 3. Cross-hallmark relationships of selected chemical disruptors

Insensitivity to antiproliferative signals (disruptors)	Antiproliferative	Deregulation	Genetic instability	Angiogenesis	Cell death	Immune	Immortality	Proliferation	Metastasis	Inflammation	Tumor microenvironment	PRO	ANTI	MIX
BPA	n/a	+	+	+	+/-	0	+	+	+	+	0	7	0	1
DDT	n/a	0	+	+	+	+	+	+	0	+	0	7	0	0
Folpet	n/a	0	+	0	+	0	0	+	0	+	0	4	0	0
Atrazine	n/a	0	+	0	0	0	0	+	0	+	0	3	0	0

One set of results (from the insensitivity to antiproliferative signals review) is shown here without references to support a discussion on the range of effects that have been reported for the selected disruptors in each review. Specific references supporting these effects for any given hallmark area can be found in the individual reviews within this special issue. Cross-hallmark relationships are reported in the first 11 columns of the table—table heading abbreviations are as follows:gen instability; deregulation; dysregulation; genetic instability; proliferation; sustained proliferative signaling; metastasis; tissue invasion and metastasis; inflammation; tumor-promoting inflammation; tumor microenvironment. The number of procarcinogenic (PRO), anticarcinogenic (ANTI) and mixed (MIX) (i.e. procarcinogenic and anticarcinogenic reports) cross-hallmark relationships for each target have been summed and are reported in the last three columns of the table. Prototypical chemical disruptors selected by each team were evaluated for reported actions in other cancer hallmark pathways. Disruptors that were found to have anticarcinogenic actions in a particular hallmark area were indicated with ‘-’, whereas disruptors that were found to have procarcinogenic actions in a particular hallmark area were indicated with ‘+’. In instances where reports on relevant actions in other hallmark areas were mixed (i.e. reports showing both procarcinogenic potential and anticarcinogenic potential), the symbol ‘+/-’ was used. Finally, in instances where no literature support was found to document the relevance of a chemical in a particular aspect of cancer’s biology, we documented this as ‘0’. Specific references supporting these effects for any given area can be found in the individual reviews in this special issue.

AQ23

*antigrowth signals*. This is intended only to illustrate the categories of cross-hallmark effects that were reviewed and to show how they were presented. Fully referenced results for each hallmark area can be found in each of the individual reviews within this special issue.

The decision to review target sites for disruption and prototypical disruptors for cross-hallmark effects was driven by the fact that many individual studies and reviews of chemical exposures fail to account systematically for the spectrum of incidental actions that can result from exposures to a single given chemical. It was our belief that this approach constitutes a better way to ensure that we had assembled a reasonably complete view of the literature (i.e. where any sort of evidence of cross-hallmark activity had been reported). Future research will likely involve empirical testing of mixtures, so we wanted to create a heuristic that could serve as a starting point for other researchers who might be considering such research.

For researchers focused on low-dose exposure research intended to produce carcinogenesis, we anticipated that there would be interest in chemicals that had been reported to exhibit a large number of procarcinogenic actions across a number of hallmarks and we anticipated that a lack of anticarcinogenic potential would be important to identify (as targets or approaches that exert anticarcinogenic actions would potentially represent a confounding influence/factor in empirical research aimed at the identification of carcinogenic synergies). To that end, [Table 4](#) provides a summary of the aggregated number of procarcinogenic actions, anticarcinogenic actions and instances where mixed actions (i.e. procarcinogenic and anticarcinogenic) have been found for each pathway/mechanism (across the full range of hallmark domains—i.e. from all of the areas covered by the reviews in this special issue). Similarly, [Table 5](#) provides a summary of the aggregated number of procarcinogenic actions, anticarcinogenic actions and mixed actions (i.e. procarcinogenic and anticarcinogenic), where cross-hallmark effects have been reported for each chemical (across the full range of hallmark domains—i.e. from all of the areas covered by the reviews in this special issue).

Note that, in some instances, the underlying evidence used to support the indication of cross-hallmark relationships was robust, consisting of multiple studies involving detailed *in-vitro* and *in-vivo* findings. In other instances, the underlying evidence that was used to report the existence of a cross-hallmark relationship was quite weak (e.g. consisting of only a single *in-vitro* study involving a single cell-type). The selected prototypical disruptors are likely biased towards agents that have been extensively studied, and not necessarily those that will prove to be the most important biologically. Finally, there are examples of chemicals that are known to exert different effects at different dose levels, but dose levels were not used to discriminate when gathering evidence of cross-hallmark effects. So, the referenced cross-validation results in the individual tables (reported in the many reviews within this special issue) should be seen only as a starting point for those who are pursuing mixtures research (e.g. references would need to be further scrutinized to determine whether or not the dose levels noted for specific results are suitable points of reference for the type of research that is being undertaken).

Particular attention should also be given to results related to the endocrine system due to mechanistic complexity. For example, xeno-estrogen compounds are typically compared with estradiol based on binding affinity strength. However, many xeno-estrogens that are 'weak' by this measure can alter the steroidogenic cascade (e.g. significantly up-regulate the activity of P450 aromatase, the enzyme that increases intracellular

estradiol synthesis within estrogen-sensitive cells (477–480) or alter levels of ER $\alpha$  or the ratio of ER $\alpha$ :ER $\beta$  (260)). In other words, a weak xeno-estrogen can stimulate the production of estradiol, a potent endogenous carcinogen (481) or alter the receptors with which a cell will respond to estrogen.

Nonetheless, given that the overarching goal in this project was to create a foundation that would allow researchers to look systematically across the literature in each of these areas, the tables should serve as a useful starting point as long as they are approached with these caveats in mind. We believe that this heuristic will be useful to consider synergies that might be anticipated in testing that involves certain target sites for disruption and/or mixtures of chemical constituents that are being considered for procarcinogenic effects. Future research efforts to improve this approach could involve a large-scale collaborative effort to generate high-quality *in-vitro* data and low-dose *in-vivo* data in a range of predefined tissues.

## Discussion

Getting to Know Cancer hosted the initial project meeting in Halifax, Nova Scotia giving participants an opportunity to have presentations, break-out sessions, and chances for conversation and debate among experts who came from a range of different disciplines. Cancer biologists with specialized expertise in areas related to individual hallmarks met with specialists from other areas such as environmental health, toxicology and endocrinology. Although some researchers in the field of environmental health are cancer scientists in their own right, many conference participants commented on the novelty of having an opportunity to work so closely with cancer biology specialists. As a result, many interdisciplinary barriers were removed and the discussions that ensued were challenging but productive.

At the outset, participants overwhelmingly agreed that the Hallmarks of Cancer provides a useful organizing heuristic for systematic review of ways that biologically disruptive chemicals might exert procarcinogenic and anticarcinogenic influences in biological systems. Most of the individual writing teams were then readily able to identify ubiquitous environmental contaminants with disruptive potential in their respective areas of study. The only teams that had significant challenges in this regard were the ones that focused on the bypassing of senescence (i.e. *replicative immortality*) and deregulated metabolism, both being areas of cancer research that have not yet received a lot of attention from researchers in the field of toxicology.

Considerable discussion was devoted to the criteria that were used to select prototypical disruptors from the long list of known potential contaminants. Indeed, it seems that much of the population is now exposed to a wide variety of exogenous chemicals that have some disruptive potential, but we did not have any intention of implicating any of the selected chemicals as being carcinogenic *per se*. It was simply agreed that chemicals would be chosen that met the basic criteria and that then could be used as 'prototypical' disruptors. In other words, the chemicals that were selected for this review were not deemed to be the most important, and they were not selected to somehow imply (based on current information) that they are endangering us. Rather, we simply wanted to illustrate that many non-carcinogenic chemicals (that are ubiquitous in the environment) have also been shown to exert effects at low doses, which are highly relevant to the process of carcinogenesis. We also wanted to lay out a heuristic framework that would be helpful for other researchers who are interested in considering these and other chemicals as potential constituents for low-dose mixtures research.



Table 4. Aggregated evidence of cross-hallmark effects for selected pathways/mechanisms

Key targets	Originating review	Procarcinogenic	Anticarcinogenic	Mixed
Adenosine A1 receptor (ADORA1)	ISE	3	1	0
AhR	Ang	7	0	2
	SPS	7	0	2
Bcl-2/p53	RCD	6	2	1
Cell cycle/cell division: spindle defect	GI	6	0	1
Checkpoint kinase 1 and checkpoint kinase 2 (Chk1/2)	EAS	4	3	1
Chemokine (C-C motif) ligand 2 (CCL2)	Ang	8	1	0
Chemokine (C-XC motif) ligand 10 (CXCL10)	Ang	4	1	1
Chemokine (C-XC motif) ligand 9 (CXCL9)	Ang	3	2	0
Chemokine signaling pathway (CCL2, CCL26, CXCL9, CXCL10)	ISE	6	1	2
Chronic oxidative stress	TM	6	1	1
Clock-genes-mediated metastasis	TIM	5	1	0
Collagen type III (COL3)	Ang	3	0	0
Contact inhibition	EAS	4	3	0
cSrc/Her1/STAT5B/ERK1/2	TIM	3	1	1
Cyclin D, IL8, CXCL	SPS	4	0	2
Cyclooxygenase expression and stimulation calcium signaling in migration.	TIM	8	1	0
Cyclooxygenase-2	TPI	8	1	0
DNA damage signaling: disturbed by Redox signaling (NF-κB, Nrf, EGR)	GI	8	1	0
DNA repair pathways	GI	6	2	1
Eck fatty acid metabolism	DM	6	1	2
Electron transport chain complexes II and IV	DM	3	2	0
Epidermal growth factor receptor	SPS	6	0	1
Epigenetic pathways				
Disturbed miRNA binding	GI	6	0	2
DNA methylation	GI	7	0	1
Histone acetylation	GI	6	1	1
EMT	TIM	5	0	1
EMT, catenin-Wnt pathway	TIM	6	1	1
ErbB-2/HER-2 tyrosine kinase	RCD	6	1	0
ERK/MAPK	RCD	8	2	0
Estrogen receptor	TPI	5	3	1
Estrogen receptor α (binding to)	RCD	5	1	1
Gap junction connexins	EAS	2	2	2
GJIC	RCD	2	1	1
Gluconeogenesis	DM	5	3	0
Glycolysis	DM	8	1	0
Hexokinase 2	DM	6	1	0
H-Ras	SPS	6	1	2
Hypersecretion of luteinizing hormone by gonadotroph cells in pituitary gland	RCD	2	1	0
HIF-1-α pathway	ISE	8	0	2
Inducible nitric oxide synthase	TPI	6	1	0
IGF-1 signaling pathway	ISE	6	2	1
Intercellular adhesion molecule 1 (ICAM1)	Ang	6	3	0

Table 4. Continued

Key targets	Originating review	Procarcinogenic	Anticarcinogenic	Mixed
IL-6	TPI	7	0	0
IL-6 expression, improper DC maturation and polarization	TM	5	2	0
Jun/Fos/AP1	SPS	4	1	3
Lipid metabolism/cholesterol metabolism	DM	4	2	1
Liver kinase B1 (Lkb1)	EAS	4	2	2
MMP 1	Ang	6	1	0
MMP-9 activation	TIM	5	1	1
Mitochondrial function	GI	5	2	2
MAPK	RCD	9	0	1
mTOR activation	DM	7	1	1
mTOR inactivation	RI	3	6	1
NK cell inhibition	TM	4	3	0
NF-κB	TPI	4	2	0
Oxidative stress and IL-6 production	TM	3	1	1
P16/p53	RCD	4	4	0
P53 inactivation	EAS	10	0	0
	RCD	10	0	0
	RI	10	0	0
PPAR	SPS	5	2	0
PPAR-α	RCD	3	3	1
PI3K/Akt signaling pathway	ISE	9	0	1
Pyruvate dehydrogenase (PDH)	DM	1	5	0
ROS (increase)	DM	6	0	4
ROS and cellular stress	TM	5	0	4
Retinoblastoma protein (pRb) inactivation	EAS	9	0	0
	RI	9	0	0
Steroid hormone receptors	SPS	5	0	1
Telomerase activation	RI	9	1	0
Telomere loss	GI	4	4	0
The tricarboxylic acid cycle	DM	5	4	0
Thrombomodulin	Ang	2	3	0
Transforming growth factor β	EAS	6	3	1
Tumor necrosis factor α	TPI	8	0	1
Urokinase receptor (uPAR)	Ang	6	2	0
Vascular cell adhesion molecule 1 (VCAM1)	Ang	6	0	0

Aggregated number of procarcinogenic actions, anticarcinogenic actions and instances where mixed actions (i.e. procarcinogenic and anticarcinogenic) where cross-hallmark effects have been reported (for each pathway/mechanism across the full range of hallmark domains—i.e. from all of the areas covered by the reviews in this special issue)—see samples of this data in Table 2. Note: fully referenced data for these cross-hallmark effects can be found in each of the reviews in this special issue. ANG, angiogenesis; DM, deregulated metabolism; EAS, evasion of antitumor growth signaling; GI, genetic instability; ISE, immune system evasion; RCD, resistance to cell death; RI, replicative immortality; SPS, sustained proliferative signaling; TIM, tissue invasion and metastasis; TM, tumor microenvironment; TPI, tumor-promoting inflammation.

**Table 5.** Aggregated evidence of cross-hallmark effects for selected chemical disruptors

Chemicals	Originating review	Procarcinogenic	Anticarcinogenic	Mixed
12-O-Tetradecanoylphorbol-13-acetate	SPS	5	1	0
HPTE	ANG	4	0	0
Acetaminophen	RI	0	4	2
Acrolein	DM	3	3	3
Acrylamide	GI	3	1	1
Atrazine	ISE	3	0	1
	EAS	4	0	1
	TPI	3	0	1
Azamethiphos	ISE	1	0	0
Benomyl	GI	0	3	1
Benzo(a)pyrene	SPS	8	1	0
Biorhythms	TIM	3	2	0
Biphenyl	ANG	2	2	1
BPA	EAS	6	0	1
	GI	6	0	1
	ISE	7	0	1
	RCD	7	0	0
	SPS	6	0	1
	TIM	7	0	1
	TM	7	0	1
	TPI	6	0	1
Bisphenol AF	ANG	5	1	0
Butyltins (such as tributyltin)	TM	4	2	0
C.I. solvent yellow 14	ANG	4	0	0
Carbendazim	GI	0	2	1
Carbon black	GI	5	1	0
Chlorothalonil	ANG	5	1	0
	RCD	5	0	0
Cobalt	GI	5	2	0
Copper	DM	6	0	3
Cotinine	RI	4	1	0
Cypermethrin	DM	5	0	0
DDT	EAS	6	0	0
Diazinon	DM	2	3	0
Dibutyl phthalate	RCD	4	0	0
Dichlorvos	RCD	4	0	0
DEHP	ISE	4	0	1
	RCD	4	0	0
Diniconazole	ANG	2	0	0
Fluoxastrobin	ISE	2	1	0
Folpet	EAS	2	1	0
Hexachlorobenzene	TIM	5	2	0
Hexythiazox	DM	0	0	0
Imazalil	SPS	3	1	0
Iron	DM	5	1	3
	TIM	5	1	2
Lactofen	SPS	2	0	0
Lead	GI	3	1	0
	RI	3	1	0
Lindane	RCD	5	0	0
Linuron	RCD	2	0	0
Malathion	DM	5	0	0
Maneb	ISE	4	2	0
Mercury	GI	3	2	1
MXC	RCD	3	0	0
Methylene bis(thiocyanate)	ANG	2	1	0
MeHg	TM	5	2	0
Na-selenite	RI	0	4	2
Nickel	GI	6	1	1
	TM	6	1	1
Nickel chloride	RI	6	0	2
Nitric oxide	RI	5	2	2
4-NP	TPI	2	1	0
Oxyfluorfen	RCD	4	0	0

Table 5. Continued

Chemicals	Originating review	Procarcinogenic	Anticarcinogenic	Mixed
Paraquat	GI	4	2	0
	TM	4	2	0
PFOS	ANG	4	1	0
	SPS	4	1	0
Phosalone	SPS	1	1	0
Phthalates	TIM	6	0	1
	TPI	6	0	1
PBDEs	TPI	2	0	2
Pyraclostrobin	ISE	2	1	0
Pyridaben	ISE	1	3	1
Quinones	GI	1	6	1
Rotenone	DM	2	5	1
Sulfur dioxide	TIM	5	1	0
Titanium dioxide NPs	GI	3	1	1
Tributyltin chloride	ANG	3	1	0
Triclosan	GI	2	2	1
	ISE	3	2	1
Tungsten	GI	2	1	1
Vinclozolin	TPI	2	1	0
Ziram	ANG	3	1	1

Aggregated number of procarcinogenic actions, anticarcinogenic actions and mixed actions (i.e. procarcinogenic and anticarcinogenic) where cross-hallmark effects have been reported (for each chemical across the full range of hallmark domains—i.e. from all of the areas covered by the reviews in this special issue)—see samples of this how this data were reported in Table 3. Note: fully referenced data for these cross-hallmark effects can be found in each of the reviews in this special issue.

ANG, angiogenesis; DM, deregulated metabolism; EAS, evasion of antiproliferative signaling; GI, genetic instability; ISE, immune system evasion; RCD, resistance to cell death; RI, replicative immortality; SPS, sustained proliferative signaling; TIM, tissue invasion and metastasis; TM, tumor microenvironment; TPI, tumor-promoting inflammation.

### LDE, chemical mixtures and carcinogenicity

Although we did not specifically ask the teams to focus on disruptive chemicals that were known to exert LDE, the summary of dose-response characterizations for the chemicals that were selected by these teams is dominated by chemicals (i.e. 50/85) that have been shown to produce LDE, and 15 of the 50 showed evidence of a non-linear dose-response. Surprisingly, only 15% of the chemicals reviewed (i.e. 13/85) showed evidence of a threshold. We believe that this helps to validate the idea that chemicals can act disruptively on key cancer-related mechanisms at environmentally relevant levels of exposure.

Historically, the axiom ‘the dose makes the poison’ has had some merit, so many people remain skeptical about the idea that adverse outcomes can result from minute exposures to commonly encountered chemicals. But we are now at a point in time where our knowledge of the biology of cancer has advanced considerably, and we know that carcinogenesis can begin when key events have occurred in a single cell, between cells or in the surrounding microenvironment. So the idea that LDE from many environmental chemicals (acting together) might serve to instigate, support or fully enable carcinogenesis, no longer appears to be an unreasonable assertion.

At this stage, we are not making any assumptions about whether or not future empirical research will find support for this hypothesis, nor are we assuming that this is a significant problem. We are simply impressed by the fact that we are now starting to see evidence of a wide range of LDE (that are directly related to carcinogenesis) that can be exerted by chemicals that are ubiquitous and unavoidable in the environment. As a result, we are compelled to explore and consider this possibility.

### In-utero exposures and transgenerational effects

Additionally, a number of the teams cited *in-utero* exposure studies in their reviews and presented evidence on transgenerational

effects. Although this detail is not fully captured in the team summaries offered in this capstone paper (please see the individual reviews in this special issue for complete details), these effects are important to acknowledge. For example, the inflammation team noted that transient early life exposures *in utero* to vinclozolin have been linked to both adult-onset disease and transgenerational disease that involves inflammation. Similarly, the immune system evasion team reported that there is increasing evidence from animal studies that *in-utero* or neonatal exposures to BPA are associated with higher risk of immune system dysregulation that may develop later in life.

Taken together, these and other similar types of examples raise intriguing possibilities about vulnerabilities at the population level, and the contributions that *in utero* and early life exposures to mixtures of those chemicals might make towards cancer susceptibility. Single-generation experimental models are inadequate to detect this sort of disruptive activity (for exposures to a given chemical or to mixtures of chemicals), but these sorts of effects may increase cancer risks by promoting and/or enabling tumorigenesis.

### The interplay between genetic factors and environmental factors

Given the number of key cancer-related mechanisms that can apparently be disrupted by chemicals that are commonly found in the environment, and the possibility that *in-utero* and/or early life exposures may also contribute to population vulnerability, the interplay between genetic factors and environmental factors should also be mentioned. For example, a hereditary genetic vulnerability (such as mutations to BRCA1/2 genes which greatly increase the lifetime risk of breast and ovarian cancer (482)) can predispose someone to a higher risk of cancer. But many hereditary genetic mutations and somatic mutations do not result in cancer, presumably because additional actions (e.g. sustained proliferative signaling) are needed or additional



biological safeguards still need to be suppressed or defeated (e.g. apoptosis, senescence, immuno-surveillance and so on) before a fully immortalized cellular phenotype can emerge. In these instances, cancer may not be assured, but it is easy to see how the disruptive effects of low-dose exposures to certain chemicals might act on key pathways/mechanisms and play a supporting role in the steps involved in carcinogenesis and/or increase the overall risk of getting cancer.

This same issue applies to other sensitive subpopulations who might be predisposed to higher levels of cancer risk. In some instances, vulnerabilities that exist are genetic in nature (e.g. cancer patients in remission), due to endogenous factors (e.g. due to obesity) or due to external influences (i.e. smoking). But in all cases, the enhanced risks in these subpopulations leave the affected individuals vulnerable to carcinogenesis. Although a detailed investigation of this type of interaction is beyond the scope of this project, it is important to consider that low dose, disruptive chemical effects on key pathways and mechanisms in these subpopulations may serve to further enhance cancer susceptibility, or even fully enable carcinogenesis.

### The low-dose carcinogenesis hypothesis

It is important to reiterate that this group has no interest in implicating any of the chemicals that were reviewed in this project as individual carcinogens *per se*. We fully realized at the outset that much of the evidence in the toxicological literature that documented the disruptive actions of these chemicals had been produced under a wide range of differing experimental circumstances. So it was agreed at the beginning that we would not make leaps between different lines of evidence nor draw any specific conclusions about chemical mixtures that might prove to be carcinogenic. Nonetheless, we are intrigued by the number of chemicals that we reviewed that were found to be capable of disruptive LDE on key pathways/mechanisms across all of the areas that were reviewed. Many of the environmental chemicals that we chose are well known as environmental contaminants, but they represent only a small fraction of the thousands of chemicals that are now ubiquitous and unavoidable in the environment. So although we cannot draw any firm conclusions at this stage, we emerge from this effort with a better understanding of the evidence that is available to support the merits of our initial hypothesis (i.e. that low-dose exposures to disruptive chemicals that are not individually carcinogenic may be capable of instigating and/or enabling carcinogenesis).

Although the breadth and scope of this review effort was daunting, we now believe that we have enough supporting evidence to offer a holistic overview of this issue. At a minimum, we hope that the studies cited in this review, the gaps that we have identified and the framework that we have proposed for future research will be useful to researchers who are encouraged to explore this hypothesis in greater detail.

### The implications for risk assessment

Thirty-five years ago, the work of Ames and others who followed set in motion a quest for individual chemicals as (complete) 'carcinogens' that became a dominant paradigm that has shaped our thinking for decades (226). So dominant has the focus been on single chemicals, that combinations of chemicals are rarely tested or even considered. For example, although IARC has focused on extensive monographs of the carcinogenic nature of individual chemicals, little has been done to evaluate the possibility of carcinogenic effects attributable to chemical mixtures except in a few instances where mixtures of concern are encountered during occupational exposures (e.g.

polychlorinated dibenzo-*p*-dioxins and polychlorinated dibenzofurans) or as a result of personal and cultural habits (e.g. cigarette smoke, diesel and gasoline engine exhausts).

But the search for mutagenic carcinogens was never matched with a corresponding search for chemicals that might contribute to the promotion of carcinogenesis along with other chemicals. We now know that individual chemicals can produce unique disruptions of cellular biology and specific combinations of non-carcinogenic chemicals have been able to demonstrate potent carcinogenic effects. Yet, we have only scratched the surface of the biology of mixtures, and we need to look carefully at the synergistic effects.

In risk assessments, the risks associated with exposures to mixtures of chemicals are often estimated using relatively simple, component-based approaches (483). Risk analysts evaluate information regarding the mode of action associated with individual mixture components and then use either 'dose addition' or 'response addition' to predict effects. Dose addition is an appropriate approach to assess mixtures risks, when the chemicals of interest act through a common mode of action. Although response addition assumes that constituent agents act independently of each other (cause the same outcome via different modes of action). In general, a dose addition approach would be appropriate for mixtures risk assessment if we wanted to consider a series of chemicals that were carcinogenic in their own right, and if they all produced the cancer by the same mode of action. The Hallmarks of Cancer framework suggests that we should be equally, if not more, concerned about mixtures of chemicals that are not individually carcinogenic but disruptive in a manner that is collectively procarcinogenic (i.e. potentially capable of producing carcinogenic synergies when combined with other chemicals that are acting on the diverse series of mechanisms involved in carcinogenesis).

With this in mind, there should be concern that the World Health Organization International Programme on Chemical Safety (WHO IPCS) has spent the past decade developing a risk analysis agenda predicated mainly on a 'Mode of Action' framework (484–487), where 'mode of action' is defined as a sequence of key events and processes, starting with interaction of an agent with a cell, proceeding through operational and anatomical changes and resulting in an adverse outcome, in this case, cancer formation. The OECD guidance on the conduct and design of chronic toxicity and carcinogenicity (which is followed by many nations) now also reflects this approach (487). This analysis of risks from cumulative effects of chemical exposures is restrictive because it suggests that regulators should only focus on groupings of individual chemicals that are as follows:

- (a) known to act via a common sequence of key events and processes;
- (b) known to act on a common target/tissue and
- (c) known to produce a common adverse outcome (e.g. cancer).

So, for example, in the USA, the Food Quality Protection Act provides legislated guidance on testing for cumulative effects by using the term 'common mechanism of toxicity' (488), which is interpreted to mean 'mode of action' or 'the major steps leading to an adverse health effect following interaction of a pesticide with biological targets'. Similarly, in Canada, the Pest Control Products Act requires the government to assess the cumulative effects of pest control products that have a 'common mechanism of toxicity'. In the USA, there has also been a tradition of employing an additional restriction requiring chemical structural similarity when selecting groups of chemicals to be subjected to mixtures risk assessment (other than a few instances

where whole mixtures have been assessed, e.g. diesel exhaust, combinations of chemicals that are not similar structurally have been largely ignored (489). In light of current knowledge of cancer biology, these criteria appear to be inappropriately restrictive, and thus demand a number of considerations—as follows:

**Cumulative risk assessment should anticipate synergies of chemicals acting via dissimilar sequences/processes**

From the Hallmarks of Cancer framework, it becomes evident that chemicals that act via dissimilar pathways/targets or that produce different sorts of key events and/or employ different processes could very well produce synergies within carcinogenesis that would be relevant for cumulative risk assessment purposes. For example, ethylenediaminetetraacetic acid is a ubiquitous, presumably non-carcinogenic chemical that disrupts DNA repair (490,491), and it is well established that ethylenediaminetetraacetic acid influences chromosome breakage by mutagenic agents. In particular, when applied in combination with chemical mutagens, ethylenediaminetetraacetic acid enhances mutagen-induced aberration frequencies and contributes to genetic instability (492). But within the mode of action framework, a chemical that is a mutagenic carcinogen, would not be assessed for the cumulative risks associated with an additional exposure to a chemical that disrupts DNA repair (a key layer of cancer defense) because it is not known to produce a common sequence of key events and processes.

A 2008 report on phthalates and cumulative risk assessment emphasized that the chemicals considered for cumulative risk assessment should be ones that cause the same health outcomes or the same types of health outcomes, not ones that cause the health outcomes only by a specific pathway (493). Similarly, The European Food Safety Authority Panel on Plant Protection Products and their Residues (PPR Panel) produced a scientific opinion on the relevance of dissimilar modes of action and their relevance for cumulative risk assessment of pesticides residues in food (489). The PPR Panel found good evidence that combination effects can arise from co-exposure to chemicals that produce common (adverse) outcomes through entirely different modes of action and recommended cumulative risk assessment methods to evaluate mixtures of pesticides in foods that have dissimilar modes of action (403).

**Cumulative risk assessment should anticipate synergies of chemicals acting on different targets/tissues**

The Hallmarks of Cancer framework suggest that spatiotemporal aspects of chemical exposures are likely important as well. For example, the many constituent parts of the immune system and its distributed nature (e.g. lymph vessels, thymus, bone marrow and so on), the hypothalamic–pituitary–adrenal axis and cortisol in circulation, which are used to suppress macrophage migration inhibitory factor and control inflammation (494–496) and the surrounding tissues of the tumor microenvironment, are all relevant targets that could be chemically disrupted to produce procarcinogenic contributions to carcinogenesis.

For example, as noted previously, maneb is a fungicide with a potentially disrupting effect on cortisol (453), which could impact the body's response to inflammation suppression, whereas atrazine affects the host immune response by directly targeting maturation of DCs and decreasing the levels of major histocompatibility complex class I molecules (243,460). Both are highly relevant forms of disruption for carcinogenesis, but within the mode of action framework, the cumulative effects of these chemicals (and other chemicals acting on these and

similarly distributed targets) would never be assessed together because they do not act on a common biological target.

The PPR Panel recently pointed out that there is no empirical evidence for the validity of independent action as a predictive concept for multicomponent mixtures in the mammalian toxicological literature. Further, they argued that although overlapping toxic effects in different organs/systems may exist, it is difficult to identify a combination effect. Thus, the panel specifically restricted their focus to chemicals that ultimately produce a common adverse outcome (e.g. cancer) in the same target organ/system (489). Although it may be difficult to identify this sort of an effect, that does not mean, however, that we should ignore this possibility (i.e. now that our understanding of the biology of cancer has improved).

**Cumulative risk assessment should anticipate synergies of non-carcinogens**

The WHO IPCS mode of action framework accepts the notion of a common toxic endpoint and therefore that chemicals need to first be carcinogens themselves before they can be considered as possible constituents of carcinogenic mixtures. However, it is now evident that not every procarcinogenic action resulting from a chemical exposure must be the result of a chemical that is a carcinogen itself. Continued focus on individual carcinogens reflects a lingering paradigm that overlooks the examples of synergies such as those highlighted in this project. Low-dose mechanistic effects may be very important so approaches are needed that take this into account. In chronic and complex diseases, establishing dose thresholds using the whole disease as the endpoint (e.g. cancer) may be inappropriate, especially when exposures to individual chemicals can produce relevant (but not disease causing) mechanistic effects at much lower dose levels.

**Cumulative risk assessment should anticipate synergies of structurally dissimilar chemicals**

The EPA's emphasis on structurally similar classes of chemicals for mixtures risk assessments is unnecessarily restrictive. The dissimilar chemicals reviewed within this special issue are testament to the fact that similar disruptive effects can be produced by a wide range of chemical structures and failure to adapt testing to this fact is no longer acceptable (493).

In sum, it is concerning that the WHO IPCS approach is so highly restrictive when it comes to the assessment of cumulative effects. The OECD guidelines acknowledge that cancers originating from at least some cell types may arise by a variety of independent pathways, but the guidance is fundamentally focused on the identification of individual carcinogens and cumulative effects of carcinogens, specifically noting that the approach is intended to 'avoid misidentification of non-tumorigenic compounds as possible human carcinogens' (487). But in practice, as *in-vitro* and *in-vivo* evidence for many chemicals is frequently not available (i.e. to prove that they individually act via a common sequence of key events or process a common target/tissue to produce cancer), it means that risk assessments of the cumulative effects of exposures to mixtures of chemicals on carcinogenesis are rarely conducted.

The International Life Sciences Institute, which is a non-profit organization with members comprised largely of major corporate interests from the food and beverage, agricultural, chemical and pharmaceutical industries, has worked closely with the WHO IPCS to support this approach. But while it may serve to ensure the avoidance of the misidentification of (non-tumorigenic) chemicals/compounds as possible human carcinogens, it simultaneously discourages regulatory agencies

from exploring the sorts of synergies that might plausibly be expected to occur. Indeed, the biology of cancer suggests that the cumulative effects of non-carcinogenic chemicals acting on different pathways that are relevant to cancer, and on a variety of cancer-relevant systems, organs, tissues and cells may very well conspire to produce carcinogenic synergies that will be overlooked entirely as long as the mode of action framework (and the restrictions that it imposes) remains in use.

As mentioned briefly previously, a considerable effort has been made by toxicologists to advance a new approach called the Adverse Outcome Pathway framework. This is an extension of the Mode of Action framework and is primarily being developed as an alternative solution to *in-vivo* toxicity testing. The framework is based on the idea that any adverse human health effect caused by exposure to an exogenous substance can be described by a series of causally linked biochemical or biological key events with measurable parameters (28,497). Although the Adverse Outcome Pathway framework anticipates the possibility that multiple pathways may need to be defined (i.e. different pathways that can produce the same adverse human health effect), the concept is currently aligned with the mode of action approach and focuses mainly on individual chemical effects that follow a well-described pathway to produce an adverse health outcome. So as it is currently conceived, it has some of the same limitations that apply to the mode of action framework.

Nonetheless, this focus at a mechanistic level is progressive in nature and some researchers in this area are starting to call for the adoption of practices within the framework that can account for epigenetic effects, transgenerational effects and chronic toxicity (detrimental effects arising in individuals or at the population level following long-term continuous or fluctuating exposure to chemicals at sublethal concentrations—i.e. concentrations not high enough to cause mortality or directly observable impairment following acute, short-term exposure, but able to induce specific effects potentially leading to adverse outcomes occurring at a later point in time) (28).

So this framework may be suitable for research that is focused on mixtures of chemicals and the pathways involved in carcinogenesis, so long as the adherents to this approach are open to the possibility that all relevant pathways need not have adverse health outcomes as endpoints, and that synergies between pathways may need to be anticipated. In other words, a series of seemingly benign actions on different pathways may be needed to conspire to produce the adverse health outcome that is of interest. This is the case in cancer. There are so many layers of redundancy and safeguards in place that individual disruptions of certain pathways may never cause disease on their own. Yet, when a number of these pathways are enabled, they can produce a discernable adverse health outcome (i.e. cancer). If the adverse outcome pathway is robust enough to anticipate this type of complexity, it may be a model that will allow us to move past the limitations imposed by the mode of action model.

Many regulatory agencies that conduct chemical risk assessments also have a mandate to ensure that adequate safety margins are in place to protect sensitive subpopulations. So they will need to place an increasing emphasis on the interplay between environmental factors and genetic factors and also consider *in-utero* exposures and the potential for transgenerational effects. Some progress has been made in tackling the gene-environment interaction problem using pathway analysis to demonstrate the role of genetic variants in exposure-related cancer susceptibility (c.f. Malhotra et al. (498)), but very little research has been done on *in-utero* exposures to mixtures of chemicals that act on cancer-related mechanisms. An approach that focuses on

defining mixtures of constituents that act disruptively on key mechanisms that are related to individual hallmarks may serve as a useful starting point to find evidence of relevant transgenerational effects (c.f. Singh et al. (499)). This is definitely an area where additional research and regulatory input is needed.

## Research needs: cancer versus carcinogenesis

One of the main challenges in this project has been the need to better understand *carcinogenesis* as a process characterized by a long latency—and the corollary possibility of both direct and indirect effects—rather than cancer as a disease endpoint that must occur rapidly and in the majority of exposed persons to be relevant. This is further complicated by the fact that the Hallmarks of Cancer are frequently neither fixed nor specific for cancer (356–358). Numerous experimental models have been used in cancer research over the years, and Vineis et al. (500) summarized them into at least five separate classes of models—see below:

- (a) Mutational models
- (b) Genome instability
- (c) Models based on non-genotoxic mechanisms, clonal expansion and epigenetics
- (d) ‘Darwinian’ or ‘somatic cellular selection’, and
- (e) ‘Tissue organization’.

All of these models have had significant support in the scientific literature (based upon empirical evidence) and there is considerable overlap between them. But our collective understanding of carcinogenesis is still largely constrained by a historically monolithic toxicology-based approach that has been focused on the effects of mutagens and the disease itself. So although the Hallmarks of Cancer framework helps us to better conceptualize the many acquired capabilities of the disease, it leaves much to the imagination when it comes to advancing our understanding of carcinogenesis *per se*. This lacuna was recently highlighted by Brash et al. (501,502) in an article on what they called ‘the mysterious steps in carcinogenesis’.

Carcinogenesis appears to be an evolution of factors that ultimately conspire towards various acquired capabilities (i.e. those delineated within the Hallmarks of Cancer framework), but how much does the sequencing of these acquired capabilities matter and in what order are these capabilities acquired? Figure 1 implies a rough sequencing of these capabilities, but do we know for certain that all hallmarks for established cancer are important for carcinogenesis as well (i.e. which hallmarks are necessary for all tumors, and of those, which are sufficient or perhaps distinct for certain cancers?). Other important questions to ask relate to whether or not the individual hallmarks are a cause or a consequence of cancer development? Do the individual hallmarks need to be expressed simultaneously or sequentially along the continuum of carcinogenesis (from exposure to unambiguous cancer phenotype development)? More importantly, how does our understanding of this framework inform our general approach to the study of carcinogenesis?

We have partial answers to some of these questions, but some of these questions remain unanswered, and given the prolonged latency of many cancers, these are important questions. Our lack of knowledge in this regard makes it difficult to draw immediate conclusions about the effects that exposures to mixtures of disruptive chemicals might cause and the synergies they might produce. Public health protection is challenged by the combinatorial complexity posed, not only by multiple exposures to chemicals at environmentally relevant doses (either simultaneously or sequentially) but also through the different



mechanisms played out in temporospatial manners (including life stages of development, which are different from those applied in traditional toxicologic and carcinogenic screening).

We, therefore, need to consider an expanded research agenda to include the origins, determinants and temporospatial evolution of the various cancer hallmarks and their interrelatedness. The key questions of reversibility and of cause versus consequence must also be rigorously addressed at every step from initiating carcinogenic exposure to established cancer, recognizing that not all hallmarks are either fixed or specific for any given cancer type.

### Research needs: the Hallmarks of Cancer

Current approaches to the study of chemical exposures and carcinogenesis have not been designed to address effects at low concentrations or in complex mixtures. Procarcinogenic agents may be directly genotoxic, indirectly genotoxic or non-genotoxic. In principle, not every disruptive effect resulting in a change that mimics a cancer hallmark is necessarily carcinogenic. Such associations, when observed, still require rigorous validation to ensure that exposures are unequivocally linked to the development of both cancer and accompanying phenotypic hallmarks. These complex interactional possibilities, coupled with the fact that low-dose combinatorial effects on cancer development and progression have not been rigorously or comprehensively addressed, speak to major gaps in our understanding of environmental cancer risk and the specific role that mixtures of environmental chemical exposures might play in the incidence of cancer at the population level.

Unfortunately, the known effects for chemicals examined in isolation and at higher concentrations cannot be readily extrapolated to effects at lower concentrations. Interactions within complex mixtures will also occur against the backdrop of complex interactions with other environmental, genetic and epigenetic factors, so there is a need for expanded or complementary conceptual and experimental frameworks to better understand the determinants and specific functional contributions of environmental exposures in cancer.

A considerable amount of energy is now being placed on the development of research and technologies that can support the 'exposome' (503), an emerging concept aimed at representing the totality of chemical exposures received by a person during a lifetime. This approach encompasses all sources of toxicants and is intended to help researchers discern some of the contributing factors that are driving chronic diseases such as cancer. Related projects are expected to involve extensive biomonitoring (e.g. blood and urine sampling) and other techniques to assess biomarkers that might be relevant, and this information should be extremely helpful. Longitudinal studies should also be carried out in animal models to assess the tissue distribution of mixtures of chemical metabolites. To truly make good use of this information, we are going to need a better mechanistic understanding of the process of carcinogenesis itself and better early markers of cancer development.

It therefore makes sense to pursue empirical research based on our current understandings of the disease to test the effects of real-world environmental mixtures at relevant dose levels. Basic studies should be designed to test joint toxic action (of carefully designed combinations of chemicals) to assess both dose additivity (via common mode of action) and response additivity (via disparate modes of action). Research designs should anticipate the many layers of inherent defense and incorporate chemical constituents specifically intended to demonstrate predictable synergies and mechanistic relevance. It would also be

useful to know whether or not the chemical induction of certain numbers/combinations of hallmarks is sufficient to consistently produce *in-vivo* carcinogenesis.

Mixtures research that focuses on the carcinogenic synergies of non-carcinogenic constituents would be particularly useful. In addition, compounds or classes of chemicals already considered to be (complete) carcinogens in the classical sense may also contribute to carcinogenesis in complex mixtures at concentrations not traditionally deemed carcinogenic. For this reason and for completeness, 'classic' carcinogens with an established environmental presence at levels that are presumed to be inconsequential may still have pathogenic relevance and should be routinely included in the analysis.

Target sites that are being manipulated and disruptive chemicals that are being selected to produce carcinogenic effects should be scrutinized for confounding effects. Table 4 contains aggregated evidence of cross-hallmark effects for selected pathways/mechanisms, and although some target sites for disruption may be compelling starting points for researchers focused on a given phenotype (e.g. genetic instability), cross-hallmark relationships should be explored. So, for example, telomere loss is seen as a disruptive (procarcinogenic) effect from the perspective of the genetic instability team (i.e. the group in this project who selected this target) and it has also been shown to exert procarcinogenic effects in four other hallmark areas. But evidence also exists that suggests that telomere loss can have anticarcinogenic effects in four other hallmark areas. The exact circumstances of the various studies that support these cross-hallmark relationships would need to be reviewed to better understand the implications/relevance of these reported effects. But checking planned disruptions of each target across all of the other hallmark areas is a way to ensure that confounding (i.e. anticarcinogenic) effects are not inadvertently introduced into experiments that are aimed at producing carcinogenesis, or phenotypes that can support/contribute to carcinogenesis. Similarly, Table 5 contains aggregated evidence of cross-hallmark effects for the chemical disruptors in this review, so this table can be used for the same purpose.

It may also be productive to identify 'reference compounds' (ideal and prototypical disruptors) for each hallmark pathway as a guide to predict different combinations of chemicals that might act in a procarcinogenic manner on any one of the hallmarks. This may involve different systems and organs that have relevance to cancer and this sort of research could also be combined with similar sorts of research on other reference compounds or mixtures that are shown to enable other hallmarks. In doing so, researchers should evaluate epigenetic changes in multiple samples/organs/tissues from exposed animals/other experimental models using gene array technology, 'omics' approaches, real-time imaging of tumors in 3D both *in-vitro* (primary cells) and *in-vivo* models combined with molecular biomarkers of disease progression, and cellular immune parameters. The combination of use of computational chemical genomics (504), system biology/pharmacology and high-quality imaging techniques, quantitative-structure-activity-relationship studies through ligand-, target-based virtual ligand screening and mathematical models should help in finding quantitative-structure-activity-relationship correlations between the chemical structure of dissimilar disruptors and experimental data on biological activity, physiological changes, *in-vivo* toxicity endpoints and 3D cellular protein dynamics.

It is also conceivable that the combined effects of hundreds of chemicals in the environment may be involved in the process of enabling carcinogenesis at the population level, so basic

empirical research that can demonstrate carcinogenic effects with minimalistic combinations may initially be needed to reveal the more granular aspects of carcinogenesis. For example, initial research might test our assumptions of the step-wise progression of carcinogenesis using targeted mixtures of chemicals that exert LDE to test combinations of two, three, four chemicals etc. against specific hallmarks and then adding additional targets to move through the various steps that are believed to be needed to fully enable the process. Experiments of this nature may reveal increases as well as decreases in cancer risk when different mechanisms are disrupted and corresponding hallmark phenotypes are enabled (depending on the timing of various disruptive exposures). Batteries of tests may ultimately be needed to evaluate whole mixtures and key components individually and in various combinations. HTS approaches will be particularly helpful here, and a tiered approach may make sense to look for disruptive combinations, which can then be applied *in vivo*. Exposure sequencing and dosage may also be important and should be evaluated based on our current understandings of the biology of cancer.

In terms of setting research priorities, tissue fate is also a matter for consideration. It has been known for many years that certain chemicals have affinities for certain tissues, and radiotracer labeling studies that have been conducted on chemicals for regulatory purposes illustrate how certain chemicals tend to accumulate in certain tissues (c.f. Nolan, R. *et al.*, unpublished report). Additionally, it is well known that some tissue types give rise to human cancers millions of times more often than other tissue types (505). So, researchers may want to focus their work on mixtures of disruptive chemicals that prove to be complementary at a mechanistic level and individually known to accumulate in the same types of tissues, while at the same time choosing tissue types that are known to produce cancers more rapidly.

The work that has been done by the WHO IPCS on mode of action has been very useful. Understanding when chemicals operate through the same mode of action is definitely good information for analytical purposes, but given that we now recognize that non-carcinogens acting at very low-dose levels on different targets and mechanisms can still activate carcinogenesis-related pathways, the combined (carcinogenic) potential of the many commonly encountered chemicals within the environment still needs to be evaluated.

Increasingly, our information is improving and there are several tools that researchers can use to improve their research designs. For example, ToxCast™ is an approach launched by the EPA in 2007 to develop ways to predict potential toxicity of chemicals and to develop a cost-effective approach for prioritizing the thousands of chemicals that need toxicity testing. The ToxCast™ database was used in this project by a number of the teams and an enormous amount of data are available on *in-vitro* tests (produced using HTS) for a wide range of chemicals. For example, there are many results that are direct measures of actions related to important mechanisms found within the Hallmarks of Cancer framework, which would be useful for research focused along these lines.

Although the hallmark phenotypes in this project represent areas of cancer research for which there is considerable agreement, one critique of this framework is that it ignores the ‘missing hallmark’ of dedifferentiation (358). As well, the complexity encompassed by each of these areas of research is humbling. Moreover, cancer is not a singular or fixed entity, which frequently limits the ability to generalize about cancer biology (356–358). In a recent reflection on his career, Weinberg *et al.*

(506) noted not only widespread acceptance of the ‘Hallmarks of Cancer’ heuristic but also that this attempt to simplify the disease is rapidly being eclipsed by calls from the next generation of researchers who are now focused on assembling and analyzing enormous data sets to gain an increasingly sophisticated understanding of cancer (e.g. genomes, transcriptomes, proteomes—including isoforms, post-translational modifications and proteoforms, epigenomes, kinomes, methylomes, glycomes and matrisomes—each one of which encompasses staggering amounts of accumulated information) (506).

Many researchers have called for an analytical use of systems biology to transcend the study of individual genes/proteins and to integrate this complexity into higher order phenotypes (507,508). Systems biology enables researchers to identify properties that emerge from complex chemical-biological systems by probing how changes in one part affect the others and the behavior of the whole system. The combined effects of tens, if not hundreds, of simultaneous exposures may need to be accounted for. The fundamental challenge is that such models require parameters that are driven by data, but there are very few good examples of research on mixtures at environmentally relevant dose levels (509) (c.f. Porter *et al.* (510)), and there are fewer still that are focused on cancer.

Nonetheless, in the near term, this basic framework should serve as a useful starting point for foundational research and government funding agencies should consider new ways to support large-scale, team-based holistic approaches to this problem.

AQ8

### Regulatory priorities (in the face of combinatorial complexity)

It will take time before we fully understand the carcinogenic potential of low-dose exposures to chemical mixtures in the environment. Nonetheless, we cannot afford to lose sight of the fact that the incidence of cancer remains unacceptably high, and that the unavoidable (i.e. not lifestyle related) causative factors that are, in part, underpinning this trend are still not fully understood (9–11,511,512). Populations worldwide are continually exposed to a wide range of chemicals, so keeping the precautionary principle in mind (513), there is a need to take the risks related to the cumulative effects of these chemicals seriously (429). Of primary concern is the fact that WHO IPCS mode of action framework (484) and the OECD guidelines for risk assessment (487) are restrictive to the point that regulators could be underestimating the risks posed by exposures to low doses of mixtures of chemicals.

National regulatory agencies and cancer research foundations must proactively pursue empirical research programs to assess any basic relationships that can be discerned between exposures to mixtures of commonly encountered chemicals and carcinogenicity. For example, systematic exploratory research in appropriate rodent models exposed to ‘whole-mixtures’ that consist of multiple chemical constituents at environmentally relevant dose levels could demonstrate the carcinogenic potential of complex mixtures that are relevant to the population. There is also a compelling need for complementary basic research to address specific causal relationships between environmental exposures and the associated development of cancer and its characteristic hallmarks.

Hypothetically speaking, such a ‘whole mixture’ should be composed of non-carcinogens and potential carcinogens given that individual chemicals that are not carcinogenic could act on a range of different systems, tissues and/or cells and act synergistically with other chemicals to instigate carcinogenesis. The

goal of such investigations would not be to single out any given chemical as a carcinogen, but rather to determine whether or not unanticipated (procarcinogenic) synergies of many commonly encountered chemicals when combined are endangering public health.

In line with the 3Rs (Reduction, Replacement and Refinement) guiding principles for more ethical use of animals in scientific experiments, there has been a significant push for researchers and regulatory agencies to move away from *in-vivo* testing (e.g. European Union REACH legislation and in the USA, the NRC Toxicology for the 21st Century vision (514)) to take advantage of HTS and other new technologies. The EPA's effort to search for environmental chemicals that are most active in relevant assays across the various cancer hallmarks, and then to compare those results with *in-vivo* rodent carcinogenicity data for the same chemicals, was a definite step in this direction (29). However, HTS models of carcinogenicity will require validation, and significant hurdles remain before this sort of testing will be ready to replace *in-vivo* research (515). Therefore, in the near term, *in-vivo* testing still remains an important avenue for developing data sets to address cancer risks of complex mixtures.

## Summary/Conclusions

For several decades, there has been a concerted effort to identify individual chemicals and other agents that are carcinogenic. At the same time, however, little has been done to determine whether or not chronic lifetime exposures to mixtures of non-carcinogenic chemicals in the environment (at low-dose levels) have carcinogenic potential. Many chemicals are known to accumulate in bodily tissues over time, but little is known about their combined effects at a mechanistic level and their impact on cancer-related mechanisms and carcinogenesis. In this project, teams of cancer biologists worked with researchers in the field of environmental health for the very first time to explore this possibility.

Teams that reviewed these cancer-related phenotypes (i.e. genetic instability, tumor-promoting inflammation, sustained proliferative signaling, insensitivity to antigrowth signals, resistance to cell death, angiogenesis, tissue invasion and metastasis, the tumor microenvironment and avoiding immune destruction) readily identified individual (non-carcinogenic) chemicals that are ubiquitous in the environment that have some potential to act on key/priority functional targets in each of these domains. In contrast, the teams focused on *replicative immortality* and *dysregulated metabolism* found examples of chemicals to consider but noted a significant lack of useful toxicological research in these areas.

In total, 85 examples of environmental chemicals were reviewed as prototypical disruptors (for specific actions on key pathways/mechanisms that are important for carcinogenesis) and 59% of them (i.e. 50/85) were found to exert LDE (at levels that are deemed relevant given the background levels of exposure that exist in the environment) with 15 of the 50 demonstrating their LDE in a non-linear dose-response pattern. Only 15% of the chemicals reviewed (i.e. 13/85) were found to have a dose-response threshold and the remaining 26% (i.e. 22/85) were categorized as 'unknown' due to a lack of dose-response information.

Cross-hallmark effects for all target sites for disruption and for all chemicals were found, but the evidence supporting these results varied considerably in strength and in context.

A number of the teams also cited relevant *in-utero* exposure studies in their reviews and presented data on transgenerational

effects related to different aspects of the disease (e.g. inflammation, immune evasion and so on). These examples raise intriguing possibilities about vulnerabilities at the population level, and the contributions that *in-utero* and early life exposures to mixtures of those chemicals might make towards cancer susceptibility.

Therefore, current regulations in many countries (that consider only the cumulative effects of exposures to individual carcinogens that act via a common sequence of key events and processes on a common target/tissue to produce cancer) should be revisited. Our current understanding of the biology of cancer suggests that the cumulative effects of (non-carcinogenic) chemicals acting on different pathways that are relevant to cancer, and on a variety of cancer-relevant systems, organs, tissues and cells could conspire to produce carcinogenic synergies that will be overlooked using current risk assessment methods. Cumulative risk assessment methods that are based on 'common mechanisms of toxicity' or common 'modes of action' may therefore be underestimating cancer-related risks. *In-utero* and early life exposures, transgenerational effects and the interplay between the low-dose mechanistic effects of chemical mixtures in the environment and the vulnerabilities of subpopulations who are predisposed to cancer (i.e. via genetics or other influences) must also be considered. Current policies and practices do not adequately address these issues and should therefore be revisited if regulatory agencies hope to better understand and assess these risks.

Finally, given the long latency period in most cancers, early detection of cancer is key so an improved understanding of the biology within originating tissues (during the latency period) would be very helpful. If we can use the heuristic presented in this review to better assess the combined effects of common exposures to chemical mixtures in the environment, it will help us improve our understanding of carcinogenesis and identify exogenous triggers and enabling factors (*in utero* and during this important latency period), all of which will be key for the development of effective strategies for prevention and early detection.

## Contributions

The Halifax Project Task Force that worked on this manuscript involved nearly 200 people, many of whom contributed to, and signed on to this capstone article. The design of the Halifax Project was conceived by L.Lo. with scientific advice from M.G. Funding provided by the National Institute for Environmental Health Sciences was arranged by D.O.C., and this manuscript was first drafted by W.H.G. Starting with the Hallmarks of Cancer framework (Hanahan *et al.* (21)), 11 teams of international cancer biologists and toxicologists were established to review the literature on key cancer-related mechanisms/pathways in their respective domains and to also look at the disruptive potential of low-dose exposures to chemicals commonly encountered in the environment (i.e. as it relates to those same mechanisms/pathways). Each team had a leader and each team was responsible for contributing a section of related content within the capstone manuscript. The contributing authors from these teams are as follows: (1) Angiogenesis (Z.H., C-W.H., H-Y.H., L-T.L., M.X., N.K., S.A.B., T.M., V.D., W.K.R.); (2) Dysregulated metabolism (R.B.R., A.C.S., A.B., E.Ry., D.B., F.C., F.L.M., G.Wi., J.We., N.B.K., R.P.); (3) Evasion of antigrowth signaling (R.N., A.L., C.C.N., D.W.L., D.R., G.S.G., G.M.C., H.Kr., J.V., K.A.C-S., M.W., N.C., P.A.M., P.De., R.A-V., R.V., R.D.F., R.P-C., R.C.C., S.N.B.), (4) Genetic instability (S.A.S.L., A.L.d.C.S., A.Az., A.K.C., A.R.C., A-K.O., E.Ro., F.D., F.J.V.S., G.K.,

AQ9



G.B., L.Go., L.Le., L.Z., M.Val., M.K-V., N.v L., P.O-W., S.Pav., T.C.); (5) Immune system evasion (H.K.L., E.C., J.K., M.A.W., M.H.M., T.O., W.K.D.); (6) Replicative immortality (A.Ca., C.B-A., H.Y., H.Ko., J.P.W., J.F.M-L., M.L., S.S.W.); (7) Resistance to cell death (H.H.P., A.M.A., B.J.B., C.Y., E.R., K.B.N., L.S.D'A., L.Li., M.F.R., M.J.G., P.M.G., P.S.L., Q.(S.) C., R.K.S., R.D., S.Ro., S.L., T-J.L., Y.R.); (8) Sustained proliferative signaling (W.E., A.W., G.Wa., H.S., J.E.K., J.R., K.M., L.Gu., M.V.K., P.V., P.Da., R.M., S.Er., T.S., T.H.); (9) Tissue invasion and metastasis (J.O., B.P.Z., C.D., G.N., G.T.W., I.K., I.R.M., L.J.M., N.A., O.O., P.N-M., S.El., S.Pap., V.O-M., Y.L., Z.C.); (10) Tumor microenvironment (D.W.F., C.S.C., D.C.K., E.L., F.M., J.Ro., J.A.C., J.R.W., L.S., L.V., M.C., P.K.K., P.H., S.Ry., S.C.C., V.M-S.) and (11) Tumor-promoting inflammation (P.T., C.J.B., E-Y.M., J.S., L.J., M.K., S.H., T.G., V.S.).\*\* Additionally, a special cross-functional team was established to investigate whether or not the chemicals that were identified by the teams as having disruptive potential for key mechanisms/pathways in a particular domain might also have been shown in other research to exert relevant effects on mechanisms/pathways in other domains. The results of the efforts from this team have been compiled and summarized in this article and can be found within Table 4. This team was comprised as follows: W.H.B., A.Am., A.I.S., A.Co., C.M., D.G.B., E.Ry., F.A-M., H.A.H., H.K.S., J.R., J.Wo., K.R.P., L.M., M.Vac., N.S., R.A-T., R.R., R.A.H. and S.F.\*\* Note that team leaders are denoted by the first set of initials in each team list.

The first draft of this manuscript (prepared by W.H.G.) was distributed to all of the contributors within the task force for feedback and additional inputs. The many responses that followed were managed by W.H.G. (with the assistance of L.Lo., M.G. and D.O.C.). Then, multiple rounds of inputs were solicited from the entire task force with several subsequent rounds of revisions and refinements prior to submission.

In addition to the contributions mentioned above, The Halifax Project also benefited from the involvement of D.J.C. At the workshop in Halifax, Nova Scotia, Canada, she provided details related to NIEHS priorities and the agency's interest in unravelling the health effects of environmental mixtures. As well she provided inputs for the manuscript.

Finally, the journal's peer-review process was important, and resulted in the collection of additional evidence from the teams that related to thresholds, LDE and of non-monotonic dose-response relationships. The reviewer's critical analysis on these topics resulted in a substantial improvement to the data presented in this capstone document, which ultimately served to highlight the extent to which low-dose exposures to individual chemical constituents (within mixtures of environmental chemicals) might have relevance for the process of carcinogenesis. Dose-response characterization data and inputs were then submitted by all teams and subsequently reviewed and compiled by N.K., A.Co. and R.M.

## Funding/Acknowledgements

We gratefully acknowledge the support of the National Institute of Health-National Institute of Environmental Health Sciences (NIEHS) conference grant travel support (R13ES023276); Glenn Rice, Office of Research and Development, United States Environmental Protection Agency, Cincinnati, OH, USA also deserves thanks for his thoughtful feedback and inputs on the manuscript; William H.Goodson III was supported by the California Breast Cancer Research Program, Clarence Heller Foundation and California Pacific Medical Center Foundation; Abdul M.Ali would like to acknowledge the financial support of the University of Sultan Zainal Abidin, Malaysia; Ahmed Lasfar was supported by an award from the Rutgers Cancer Institute of New Jersey; Ann-Karin Olsen and Gunnar Brunborg were

supported by the Research Council of Norway (RCN) through its Centres of Excellence funding scheme (223268/F50); Amancio Carnero's lab was supported by grants from the Spanish Ministry of Economy and Competitiveness, ISCIII (Fis: PI12/00137, RTICC: RD12/0036/0028) co-funded by FEDER from Regional Development European Funds (European Union), Consejería de Ciencia e Innovación (CTS-1848) and Consejería de Salud of the Junta de Andalucía (PI-0306-2012); Amaya Azqueta would like to thank the Ministerio de Educación y Ciencia ('Juande la Cierva' programme, 2009) of the Spanish Government for personal support; Amedeo Amedei was supported by the Italian Ministry of University and Research (2009FZZ4XM\_002), and the University of Florence (ex60%2012); Andrew R.Collins was supported by the University of Oslo; Annamaria Colacci was supported by the Emilia-Romagna Region - Project 'Supersite' in Italy; Carolyn Baglole was supported by a salary award from the Fonds de recherche du Québec-Santé (FRQ-S); Chiara Mondello's laboratory is supported by Fondazione Cariplo in Milan, Italy (grant n. 2011-0370); Christian C.Naus holds a Canada Research Chair; Clement Yedjou was supported by a grant from the National Institutes of Health (Grant No. NIMHD-G12MD007581 and Grant No. NIGMS- P20GM103476); Colleen Curran was supported by a National Institute of Environmental Health Sciences Grant (T32ES007015); Daniel C.Koch is supported by the Burroughs Wellcome Fund Postdoctoral Enrichment Award and the Tumor Biology Training grant: NIH T32CA09151; Dean W. Felsher would like to acknowledge the support of United States Department of Health and Human Services, NIH grants (R01 CA170378 PQ22, R01 CA184384, U54 CA149145, U54 CA151459, P50 CA114747 and R21 CA169964); Emilio Rojas would like to thank CONACyT support 152473; Ezio Laconi was supported by AIRC (Italian Association for Cancer Research, grant no. IG 14640) and by the Sardinian Regional Government (RAS); Eun-Yi Moon was supported by grants from Mid-career Researcher Program (#2012-R1A2A2A01005449) and Nuclear R&D Program (#2013M2B2A9A03051296 and 2010-0018545) through the National Research Foundation of Korea (NRF) and funded by the Ministry of Education, Science and Technology (MEST) in Korea; Fahd Al-Mulla was supported by the Kuwait Foundation for the Advancement of Sciences (2011-1302-06); Ferdinando Chiaradonna is supported by SysBioNet, a grant for the Italian Roadmap of European Strategy Forum on Research Infrastructures (ESFRI) and by AIRC (Associazione Italiana Ricerca sul Cancro; IG 15364); Francis L.Martin acknowledges funding from Rosemere Cancer Foundation; he also thanks Lancashire Teaching Hospitals NHS trust and the patients who have facilitated the studies he has undertaken over the course of the last 10 years; Gary S.Goldberg would like to acknowledge the support of the New Jersey Health Foundation; Gloria M.Calaf was supported by Fondo Nacional de Ciencia y Tecnología (FONDECYT) # 1120006, Ministerio de Educación de Chile (MINEDUC), Universidad de Tarapacá (UTA); Gudrun Koppen was supported by the Flemish Institute for Technological Research (VITO), Belgium; Hemad Yasaei was supported from a triennial project grant (Strategic Award) from the National Centre for the Replacement, Refinement and Reduction (NC3Rs) of animals in research (NC. K500045.1 and G0800697); Hiroshi Kondoh was supported in part by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, Japan Science and Technology Agency and by JST, CREST; Hsue-Yin Hsu was supported by the Ministry of Science and Technology of Taiwan (NSC93-2314-B-320-006 and NSC94-2314-B-320-002); Hyun Ho Park was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) of the Ministry of Education, Science

and Technology (2012R1A2A2A01010870) and a grant from the Korea Healthcare Technology R&D project, Ministry of Health and Welfare, Republic of Korea (H113C1449); Igor Koturbash is supported by the UAMS/NIH Clinical and Translational Science Award (UL1TR000039 and KL2TR000063) and the Arkansas Biosciences Institute, the major research component of the Arkansas Tobacco Settlement Proceeds Act of 2000; Jan Vondráček acknowledges funding from the Czech Science Foundation (13-07711S); Jesse Roman thanks the NIH for their support (CA116812); John Pierce Wise Sr. and Sandra S.Wise were supported by National Institute of Environmental Health Sciences (ES016893 to J.P.W.) and the Maine Center for Toxicology and Environmental Health; Jonathan Whitfield acknowledges support from the FERO Foundation in Barcelona, Spain; Joseph A. Christopher is funded by Cancer Research UK and the International Journal of Experimental Pathology; Julia Kravchenko is supported by a philanthropic donation by Fred and Alice Stanback; Jun Sun is supported by a Swim Across America Cancer Research Award; Karine A.Cohen-Solal is supported by a research scholar grant from the American Cancer Society (116683-RSG-09-087-01-TBE); Kim Moorwood and Andrew Ward were supported by a grant from the Medical Research Council, UK (MR/L007215/1); Laetitia Gonzalez received a postdoctoral fellowship from the Research Foundation–Flanders (FWO-Vlaanderen) and support by an InterUniversity Attraction Pole grant (IAP-P7-07); Laura Soucek is supported by grant #CP10/00656 from the Miguel Servet Research Contract Program and acknowledges support from the FERO Foundation in Barcelona, Spain; Liang-Tzung Lin was supported by funding from the Taipei Medical University (TMU101-AE3-Y19); Linda Gulliver is supported by a Genesis Oncology Trust (NZ) Professional Development Grant, and by the Faculty of Medicine, University of Otago, Dunedin, New Zealand; Louis Vermeulen is supported by a Fellowship of the Dutch Cancer Society (KWF, UVA2011-4969) and a grant from the American Institute for Cancer Research (14-1164); Mahara Valverde would like to thank CONACyT support 153781; Masoud H. Manjili was supported by the office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program under Award No. W81XWH-14-1-0087; Neetu Singh was supported by grant #SR/FT/LS-063/2008 from the Department of Science and Technology, Government of India; Nicole Kleinstreuer is supported by NIEHS contracts (N01-ES 35504 and HHSN27320140003C); P.K. Krishnakumar was supported by the Funding (No. T.K. 11-0629) of King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia; Paola A. Marignani is supported by the Dalhousie Medical Research Foundation, The Beatrice Hunter Cancer Institute and CIHR and the Nova Scotia Lung Association; Paul Dent is the holder of the Universal Inc. Chair in Signal Transduction Research and is supported with funds from Public Health Service grants from the NIH (R01-CA141704, R01-CA150214, R01-DK52825 and R01-CA61774); Petr Heneberg was supported by the Charles University in Prague projects UNCE 204015 and PRVOUK P31/2012, by the Czech Science Foundation projects P301/12/1686 and 15-03834Y; Po Sing Leung was supported by the Health and Medical Research Fund of Food and Health Bureau, Hong Kong Special Administrative Region, Ref. No: 10110021; Qiang Cheng was supported in part by National Science Foundation grant IIS-1218712; R. Brooks Robey is supported by the United States Department of Veterans Affairs; Rabindra Roy was supported by United States Public Health Service Grants (R01 CA92306, R01 CA92306-S1 and R01 CA113447); Rafaela Andrade-Vieira is supported by Cancer Research Training Program - Canadian Institutes of Health Research, the Terry Fox Foundation and the Nova Scotia Health Research Foundation - Scotia Award; Renza Vento was partially

funded by European Regional Development Fund, European Territorial Cooperation 2007–13 (CCI 2007 CB 163 PO 037, OP Italia-Malta 2007–13) and grants from the Italian Ministry of Education, University and Research (MIUR) ex-60%, 2007; Riccardo Di Fiore was a recipient of fellowship granted by European Regional Development Fund, European Territorial Cooperation 2007–2013 (CCI 2007 CB 163 PO 037, OP Italia-Malta 2007–2013); Rita Dornetshuber-Fleiss was supported by the Austrian Science Fund (FWF, project number T 451-B18) and the Johanna Mahlke, geb.-Obermann-Stiftung; Roberta Palorini is supported by a SysBioNet fellowship; Roslida Abd Hamid is supported by the Ministry of Education, Malaysia-Exploratory Research Grant Scheme-Project no: ERGS/1-2013/5527165; Sabine A.S.Langie is the beneficiary of a postdoctoral grant from the AXA Research Fund and the Cefic-LRI Innovative Science Award 2013; Sakina Eltom is supported by NIH grant SC1CA153326; Samira A.Brooks was supported by National Research Service Award (T32 ES007126) from the National Institute of Environmental Health Sciences and the HHMI Translational Medicine Fellowship; Sandra Ryeom was supported by The Garrett B. Smith Foundation and the TedDriven Foundation; Thierry Massfelder was supported by the Institut National de la Santé et de la Recherche Médicale INSERM and Université de Strasbourg; Thomas Sanderson is supported by the Canadian Institutes of Health Research (CIHR; MOP-115019), the Natural Sciences and Engineering Council of Canada (NSERC; 313313) and the California Breast Cancer Research Program (CBCRP; 17UB-8703); Tiziana Guarnieri is supported by a grant from Fundamental Oriented Research (RFO) to the Alma Mater Studiorum University of Bologna, Bologna, Italy and thanks the Fondazione Cassa di Risparmio di Bologna and the Fondazione Banca del Monte di Bologna e Ravenna for supporting the Center for Applied Biomedical Research, S.Orsola-Malpighi University Hospital, Bologna, Italy; W.Kimryn Rathmell is supported by the V Foundation for Cancer Research and the American Cancer Society; William K.Decker was supported in part by grant RP110545 from the Cancer Prevention Research Institute of Texas; William H.Bisson was supported with funding from the NIH P30 ES000210; Yon Rojanasakul and Sudjit Luanpitpong were supported by NIH Grant (R01-ES022968) and National Science Foundation Grant (CBET-1434503); Zhenbang Chen was supported by NIH grant (R01-MD004038); Zhiwei Hu is grateful for the grant support from an institutional start-up fund from The Ohio State University College of Medicine and The OSU James Comprehensive Cancer Center (OSUCCC) and a seed award from the OSUCCC Translational Therapeutics Program.

## Disclaimer

This manuscript is the work product of a large group of researchers collectively representing a diverse array of institutions and a significant number of sponsors; however, the statements, opinions and conclusions expressed herein do not necessarily represent the views or positions of these institutions and sponsors. Conflict of interest statement: None declared

## References

- Forman, D., et al. (2014) World Cancer Report 2014, Cancer Worldwide (Chp 1). In Wild, B.S.a.C.P. (ed.). World Health Organization, Geneva, Switzerland.
- Malhotra, J. (2014) Molecular and genetic epidemiology of cancer in low- and medium-income countries. *Ann. Glob. Health*, 80, 418–425.
- McGuinn, L.A. et al. (2012) Cancer and environment: definitions and misconceptions. *Environ. Res.*, 112, 230–234.



4. Sankpal, U.T. et al. (2012) Environmental factors in causing human cancers: emphasis on tumorigenesis. *Tumour Biol.*, 33, 1265–1274.
5. Trosko, J.E. et al. (2005) The emperor wears no clothes in the field of carcinogen risk assessment: ignored concepts in cancer risk assessment. *Mutagenesis*, 20, 81–92.
6. Christiani, D.C. (2011) Combating environmental causes of cancer. *N. Engl. J. Med.*, 364, 791–793.
7. Clapp, R. (2011) Chemicals policy in the 2008–2009 President's Cancer Panel Report. *New Solut.*, 21, 447–455.
8. Reuben, S.H., et al. (2010) Reducing Environmental Cancer Risk: What We Can Do Now 2008–2009 Annual Report President's Cancer Panel. National Institutes of Health, National Cancer Institute, Bethesda, Maryland
9. Parkin, D.M. et al. (2011) The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. *Br. J. Cancer*, 105(Suppl 2), S77–S81.
10. Mathers, C., et al. (2009) Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. World Health Organization, Geneva.
11. Straif, K. (2008) The burden of occupational cancer. *Occup. Environ. Med.*, 65, 787–788.
12. Vandenberg, L.N. et al. (2012) Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. *Endocr. Rev.*, 33, 378–455.
13. (2009) OECD Guidelines for the Testing of Chemicals, Section 4 Health Effects, Test No. 451: Carcinogenicity Studies. OECD.
14. Wignall, J.A. et al. (2014) Standardizing benchmark dose calculations to improve science-based decisions in human health assessments. *Environ. Health Perspect.*, 122, 499–505.
15. Myers, J.P. et al. (2009) A clash of old and new scientific concepts in toxicity, with important implications for public health. *Environ. Health Perspect.*, 117, 1652–1655.
16. Vandenberg, L.N. et al. (2013) Regulatory decisions on endocrine disrupting chemicals should be based on the principles of endocrinology. *Reprod. Toxicol.*, 38, 1–15.
17. Bergman, A. et al. (2013) Science and policy on endocrine disruptors must not be mixed: a reply to a “common sense” intervention by toxicology journal editors. *Environ. Health*, 12, 69.
18. Ames, B.N. (1979) Identifying environmental chemicals causing mutations and cancer. *Science*, 204, 587–593.
19. Armitage, P. et al. (1954) The age distribution of cancer and a multi-stage theory of carcinogenesis. *Br. J. Cancer*, 8, 1–12.
20. Truhaut, R. (1990) [Recent progress in the evaluation of the dangers of chemical carcinogens]. *J. Pharm. Belg.*, 45, 131–140.
21. Hanahan, D. et al. (2000) The hallmarks of cancer. *Cell*, 100, 57–70.
22. Preston, R.J. (2005) Extrapolations are the Achilles heel of risk assessment. *Mutat. Res.*, 589, 153–157.
23. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. *Cell*, 144, 646–674.
24. Colotta, F. et al. (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis*, 30, 1073–1081.
25. Warburg, O. (ed.) (1930) *The Metabolism of Tumours: Investigations from the Kaiser Wilhelm Institute for Biology, Berlin-Dahlen*. Constable & Company Limited, London.
26. Aisenberg, A.C. (1961) *The Glycolysis and Respiration of Tumors*. Academic Press, New York, NY.
27. Ankley, G.T. et al. (2010) Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. *Environ. Toxicol. Chem.*, 29, 730–741.
28. Groh, K.J. et al. (2015) Development and application of the adverse outcome pathway framework for understanding and predicting chronic toxicity: I. Challenges and research needs in ecotoxicology. *Chemosphere*, 120, 764–777.
29. Kleinstreuer, N.C. et al. (2013) *In vitro* perturbations of targets in cancer hallmark processes predict rodent chemical carcinogenesis. *Toxicol. Sci.*, 131, 40–55.
30. Yates, L.R. et al. (2012) Evolution of the cancer genome. *Nat. Rev. Genet.*, 13, 795–806.
31. (2001) National Toxicology Program's report of the endocrine disruptors low dose peer review. National Institute of Environmental Health Sciences, National Toxicology Program, Research Triangle Park, NC.
32. Melnick, R. et al. (2002) Summary of the National Toxicology Program's report of the endocrine disruptors low-dose peer review. *Environ. Health Perspect.*, 110, 427–431.
33. Welshons, W.V. et al. (2006) Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. *Endocrinology*, 147(Suppl 6), S56–S69.
34. Vandenberg, L.N. et al. (2007) Human exposure to bisphenol A (BPA). *Reprod. Toxicol.*, 24, 139–177.
35. Brucker-Davis, F. et al. (2001) Significant effects of mild endogenous hormonal changes in humans: considerations for low-dose testing. *Environ. Health Perspect.*, 109(Suppl 1), 21–26.
36. EPA, U.S. The U.S. Environmental Protection Agency ToxCast Phase I/II data. <http://www.epa.gov/ncct/toxcast/data.html>. (1 December 2014, date last accessed)
37. Taylor, T.R. et al. (2011) Ziram activates mitogen-activated protein kinases and decreases cytolytic protein levels in human natural killer cells. *Toxicol. Mech. Methods*, 21, 577–584.
38. McMahon, T.A. et al. (2011) The fungicide chlorothalonil is nonlinearly associated with corticosterone levels, immunity, and mortality in amphibians. *Environ. Health Perspect.*, 119, 1098–1103.
39. Goldman, J.M. et al. (2004) Methoxychlor-induced alterations in the histological expression of angiogenic factors in pituitary and uterus. *J. Mol. Histol.*, 35, 363–375.
40. Chapin, R.E. et al. (1997) The effects of perinatal/juvenile methoxychlor exposure on adult rat nervous, immune, and reproductive system function. *Fundam. Appl. Toxicol.*, 40, 138–157.
41. Qian, Y. et al. (2010) Perfluorooctane sulfonate (PFOS) induces reactive oxygen species (ROS) production in human microvascular endothelial cells: role in endothelial permeability. *J. Toxicol. Environ. Health A*, 73, 819–836.
42. Hu, J.X. et al. (2013) Toxic effects of cypermethrin on the male reproductive system: with emphasis on the androgen receptor. *J. Appl. Toxicol.*, 33, 576–585.
43. Jin, M. et al. (2010) Estrogenic activities of two synthetic pyrethroids and their metabolites. *J. Environ. Sci. (China)*, 22, 290–296.
44. Kakko, I. et al. (2004) Oestradiol potentiates the effects of certain pyrethroid compounds in the MCF7 human breast carcinoma cell line. *Altern. Lab. Anim.*, 32, 383–390.
45. Feng, Z. et al. (2006) Acrolein is a major cigarette-related lung cancer agent: preferential binding at p53 mutational hotspots and inhibition of DNA repair. *Proc. Natl Acad. Sci. USA*, 103, 15404–15409.
46. Günther, M. et al. (2008) Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy? *J. Cell. Mol. Med.*, 12(6B), 2704–2716.
47. Luo, C. et al. (2013) A cigarette component acrolein induces accelerated senescence in human diploid fibroblast IMR-90 cells. *Biogerontology*, 14, 503–511.
48. Roy, J. et al. (2010) Acrolein induces apoptosis through the death receptor pathway in A549 lung cells: role of p53. *Can. J. Physiol. Pharmacol.*, 88, 353–368.
49. Tanel, A. et al. (2014) Acrolein activates cell survival and apoptotic death responses involving the endoplasmic reticulum in A549 lung cells. *Biochim. Biophys. Acta*, 1843, 827–835.
50. Tang, M.S. et al. (2011) Acrolein induced DNA damage, mutagenicity and effect on DNA repair. *Mol. Nutr. Food Res.*, 55, 1291–1300.
51. Cabeza-Arvelaiz, Y. et al. (2012) Transcriptome analysis of a rotenone model of parkinsonism reveals complex I-tied and -untied toxicity mechanisms common to neurodegenerative diseases. *PLoS One*, 7, e44700.
52. Deng, Y.T. et al. (2010) Rotenone induces apoptosis in MCF-7 human breast cancer cell-mediated ROS through JNK and p38 signaling. *Mol. Carcinog.*, 49, 141–151.
53. Gonçalves, A.P. et al. (2011) Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone. *Biochim. Biophys. Acta*, 1813, 492–499.
54. Li, Y. et al. (2013) Copper induces cellular senescence in human glioblastoma multiforme cells through downregulation of Bmi-1. *Oncol. Rep.*, 29, 1805–1810.
55. Ostrakhovitch, E.A. et al. (2005) Role of p53 and reactive oxygen species in apoptotic response to copper and zinc in epithelial breast cancer cells. *Apoptosis*, 10, 111–121.

56. Parr-Sturgess, C.A. et al. (2012) Copper modulates zinc metalloproteinase-dependent ectodomain shedding of key signaling and adhesion proteins and promotes the invasion of prostate cancer epithelial cells. *Mol. Cancer Res.*, 10, 1282–1293.
57. Freitas, M. et al. (2013) Nickel induces apoptosis in human neutrophils. *Biometals*, 26, 13–21.
58. Wu, C.H. et al. (2012) Nickel-induced epithelial-mesenchymal transition by reactive oxygen species generation and E-cadherin promoter hypermethylation. *J. Biol. Chem.*, 287, 25292–25302.
59. Aimola, P. et al. (2012) Cadmium induces p53-dependent apoptosis in human prostate epithelial cells. *PLoS One*, 7, e33647.
60. Yuan, D. et al. (2013) Long-term cadmium exposure leads to the enhancement of lymphocyte proliferation via down-regulating p16 by DNA hypermethylation. *Mutat. Res.*, 757, 125–131.
61. Aluigi, M.G. et al. (2010) Apoptosis as a specific biomarker of diazinon toxicity in NTERA2-D1 cells. *Chem. Biol. Interact.*, 187, 299–303.
62. Giordano, G. et al. (2007) Organophosphorus insecticides chlorpyrifos and diazinon and oxidative stress in neuronal cells in a genetic model of glutathione deficiency. *Toxicol. Appl. Pharmacol.*, 219, 181–189.
63. Gilsing, A.M. et al. (2013) Dietary heme iron and the risk of colorectal cancer with specific mutations in KRAS and APC. *Carcinogenesis*, 34, 2757–2766.
64. Pluth, J.M. et al. (1996) Increased frequency of specific genomic deletions resulting from *in vitro* malathion exposure. *Cancer Res.*, 56, 2393–2399.
65. Chen, Z.J. et al. (2014) Bisphenol A modulates colorectal cancer protein profile and promotes the metastasis via induction of epithelial to mesenchymal transitions. *Arch Toxicol.*
66. Zhu, H. et al. (2010) Environmental endocrine disruptors promote invasion and metastasis of SK-N-SH human neuroblastoma cells. *Oncol. Rep.*, 23, 129–139.
67. Pontillo, C.A. et al. (2013) Action of hexachlorobenzene on tumor growth and metastasis in different experimental models. *Toxicol. Appl. Pharmacol.*, 268, 331–342.
68. O'Brien, D.W. et al. (2004) A mechanism of airway injury in an epithelial model of mucociliary clearance. *Respir. Res.*, 5, 10.
69. Ornstein, D.L. et al. (2007) Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells. *Nutr. Cancer*, 58, 115–126.
70. Mao, L. et al. (2012) Circadian gating of epithelial-to-mesenchymal transition in breast cancer cells via melatonin-regulation of GSK3 $\beta$ . *Mol. Endocrinol.*, 26, 1808–1820.
71. Papagerakis, S. et al. (2014) The circadian clock in oral health and diseases. *J. Dent. Res.*, 93, 27–35.
72. Bouskine, A. et al. (2009) Low doses of bisphenol A promote human seminoma cell proliferation by activating PKA and PKG via a membrane G-protein-coupled estrogen receptor. *Environ. Health Perspect.*, 117, 1053–1058.
73. Hernández, L.G. et al. (2013) A mode-of-action approach for the identification of genotoxic carcinogens. *PLoS One*, 8, e64532.
74. Wetherill, Y.B. et al. (2002) The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. *Mol. Cancer Ther.*, 1, 515–524.
75. Park, S.H. et al. (2009) Cell growth of ovarian cancer cells is stimulated by xenoestrogens through an estrogen-dependent pathway, but their stimulation of cell growth appears not to be involved in the activation of the mitogen-activated protein kinases ERK-1 and p38. *J. Reprod. Dev.*, 55, 23–29.
76. Wilkinson, C.F. et al. (1996) A mechanistic interpretation of the oncogenicity of chlorothalonil in rodents and an assessment of human relevance. *Regul. Toxicol. Pharmacol.*, 24(1 Pt 1), 69–84.
77. Vesselinovitch, S.D. et al. (1983) Lindane bioassay studies and human cancer risk assessment. *Toxicol. Pathol.*, 11, 12–22.
78. Wang, Q.L. et al. (2013) Risk assessment of mouse gastric tissue cancer induced by dichlorvos and dimethoate. *Oncol. Lett.*, 5, 1385–1389.
79. Lee, H.R. et al. (2012) Treatment with bisphenol A and methoxychlor results in the growth of human breast cancer cells and alteration of the expression of cell cycle-related genes, cyclin D1 and p21, via an estrogen receptor-dependent signaling pathway. *Int. J. Mol. Med.*, 29, 883–890.
80. Stagg, N.J. et al. (2012) Assessment of possible carcinogenicity of oxyfluorfen to humans using mode of action analysis of rodent liver effects. *Toxicol. Sci.*, 128, 334–345.
81. Doull, J. et al. (1999) A cancer risk assessment of di(2-ethylhexyl) phthalate: application of the new U.S. EPA Risk Assessment Guidelines. *Regul. Toxicol. Pharmacol.*, 29, 327–357.
82. Mazzoleni, G. et al. (1994) Influence of the herbicide Linuron on growth rate and gap-junctional intercellular communication of cultured endothelial cells. *J. Environ. Pathol. Toxicol. Oncol.*, 13, 1–10.
83. Yasaei, H. et al. (2013) Carcinogen-specific mutational and epigenetic alterations in INK4A, INK4B and p53 tumour-suppressor genes drive induced senescence bypass in normal diploid mammalian cells. *Oncogene*, 32, 171–179.
84. Singh, K.P. et al. (2008) Allelic loss and mutations in a new ETRG-1 gene are early events in diethylstilbestrol-induced renal carcinogenesis in Syrian hamsters. *Gene*, 408, 18–26.
85. Tsutsui, T. et al. (1994) Reserpine-induced cell transformation without detectable genetic effects in Syrian hamster embryo cells in culture. *Carcinogenesis*, 15, 11–14.
86. Martens, U. et al. (1996) Low expression of the WAF1/CIP1 gene product, p21, in enzyme-altered foci induced in rat liver by diethylnitrosamine or phenobarbital. *Cancer Lett.*, 104, 21–26.
87. Geter, D.R. et al. (2014) Dose-response modeling of early molecular and cellular key events in the CAR-mediated hepatocarcinogenesis pathway. *Toxicol. Sci.*, 138, 425–445.
88. Bader, A. et al. (2011) Paracetamol treatment increases telomerase activity in rat embryonic liver cells. *Pharmacol. Rep.*, 63, 1435–1441.
89. Tsuruga, Y. et al. (2008) Establishment of immortalized human hepatocytes by introduction of HPV16 E6/E7 and hTERT as cell sources for liver cell-based therapy. *Cell Transplant.*, 17, 1083–1094.
90. Nguyen, T.H. et al. (2005) Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes. *J. Hepatol.*, 43, 1031–1037.
91. Bode-Böger, S.M. et al. (2005) Aspirin reduces endothelial cell senescence. *Biochem. Biophys. Res. Commun.*, 334, 1226–1232.
92. Heinloth, A.N. et al. (2004) Gene expression profiling of rat livers reveals indicators of potential adverse effects. *Toxicol. Sci.*, 80, 193–202.
93. Jacob, T. et al. (2009) The effect of cotinine on telomerase activity in human vascular smooth muscle cells. *J. Cardiovasc. Surg. (Torino)*, 50, 345–349.
94. Brüne, B. et al. (2001) Transcription factors p53 and HIF-1 $\alpha$  as targets of nitric oxide. *Cell. Signal.*, 13, 525–533.
95. Davis, C.D. et al. (2000) Dietary selenium and arsenic affect DNA methylation *in vitro* in Caco-2 cells and *in vivo* in rat liver and colon. *J. Nutr.*, 130, 2903–2909.
96. Arnér, E.S. et al. (2006) The thioredoxin system in cancer. *Semin. Cancer Biol.*, 16, 420–426.
97. vom Saal, F.S. et al. (2007) Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. *Reprod. Toxicol.*, 24, 131–138.
98. Qin, X.Y. et al. (2012) Effects of bisphenol A exposure on the proliferation and senescence of normal human mammary epithelial cells. *Cancer Biol. Ther.*, 13, 296–306.
99. Peluso, M.E. et al. (2014) Bisphenol-A exposures and behavioural aberrations: median and linear spline and meta-regression analyses of 12 toxicity studies in rodents. *Toxicology*, 325, 200–208.
100. Fang, C.C. et al. (2013) Cyprodinil as an activator of aryl hydrocarbon receptor. *Toxicology*, 304, 32–40.
101. Bharadwaj, R. et al. (2004) The spindle checkpoint, aneuploidy, and cancer. *Oncogene*, 23, 2016–2027.
102. Orton, F. et al. (2011) Widely used pesticides with previously unknown endocrine activity revealed as *in vitro* antiandrogens. *Environ. Health Perspect.*, 119, 794–800.
103. Tanaka, T. et al. (2013) Effects of maternal exposure to imazalil on behavioral development in F<sub>1</sub>-generation mice. *Birth Defects Res. B Dev. Reprod. Toxicol.*, 98, 334–342.
104. Ahmad, I. et al. (2008) The involvement of nitric oxide in maneb- and paraquat-induced oxidative stress in rat polymorphonuclear leukocytes. *Free Radic. Res.*, 42, 849–862.

## AQ11

105. (1988) Integrated Risk Information System—Maneb (CASRN 12427-38-2). US Environmental Protection Agency. <http://www.epa.gov/iris> accessed in 2014
106. Miller, K.P. et al. (2006) Methoxychlor metabolites may cause ovarian toxicity through estrogen-regulated pathways. *Toxicol. Sci.*, 93, 180–188.
107. Du, X. et al. (2014) Perinatal exposure to low-dose methoxychlor impairs testicular development in C57BL/6 mice. *PLoS One*, 9, e103016.
108. Palanza, P. et al. (2001) Effects of prenatal exposure to low doses of diethylstilbestrol, o,p'DDT, and methoxychlor on postnatal growth and neurobehavioral development in male and female mice. *Horm. Behav.*, 40, 252–265.
109. Du, G. et al. (2013) Perfluorooctane sulfonate (PFOS) affects hormone receptor activity, steroidogenesis, and expression of endocrine-related genes *in vitro* and *in vivo*. *Environ. Toxicol. Chem.*, 32, 353–360.
110. Kim, H.S. et al. (2011) Induction of apoptosis and CYP4A1 expression in Sprague-Dawley rats exposed to low doses of perfluorooctane sulfonate. *J. Toxicol. Sci.*, 36, 201–210.
111. Eveillard, A. et al. (2009) Di-(2-ethylhexyl)-phthalate (DEHP) activates the constitutive androstane receptor (CAR): a novel signalling pathway sensitive to phthalates. *Biochem. Pharmacol.*, 77, 1735–1746.
112. Nakai, M. et al. (1999) Binding characteristics of dialkyl phthalates for the estrogen receptor. *Biochem. Biophys. Res. Commun.*, 254, 311–314.
113. Grande, S.W. et al. (2006) A dose-response study following *in utero* and lactational exposure to di(2-ethylhexyl)phthalate: effects on female rat reproductive development. *Toxicol. Sci.*, 91, 247–254.
114. Kojima, H. et al. (2011) Comparative study of human and mouse pregnane X receptor agonistic activity in 200 pesticides using *in vitro* reporter gene assays. *Toxicology*, 280, 77–87.
115. (2006) Phosalone Reregistration Eligibility Decision (RED). The United States Environmental Protection Agency Office of Pesticide Programs, Washington, D.C.
116. Li, X. et al. (2013) Structure-dependent activities of hydroxylated polybrominated diphenyl ethers on human estrogen receptor. *Toxicology*, 309, 15–22.
117. Berger, R.G. et al. (2014) Exposure to an environmentally relevant mixture of brominated flame retardants affects fetal development in Sprague-Dawley rats. *Toxicology*, 320, 56–66.
118. Hofmeister, M.V. et al. (2004) Effects of the pesticides prochloraz and methiocarb on human estrogen receptor alpha and beta mRNA levels analyzed by on-line RT-PCR. *Toxicol. In Vitro*, 18, 427–433.
119. Jacobsen, P.R. et al. (2012) Persistent developmental toxicity in rat offspring after low dose exposure to a mixture of endocrine disrupting pesticides. *Reprod. Toxicol.*, 34, 237–250.
120. Kamanga-Sollo, E. et al. (2008) Roles of IGF-I and the estrogen, androgen and IGF-I receptors in estradiol-17beta- and trenbolone acetate-stimulated proliferation of cultured bovine satellite cells. *Domest. Anim. Endocrinol.*, 35, 88–97.
121. Yarrow, J.F. et al. (2010) Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): a potent anabolic steroid with reduced androgenic and estrogenic activity. *Steroids*, 75, 377–389.
122. Yan, H. et al. (2008) Exposure to bisphenol A prenatally or in adulthood promotes T(H)2 cytokine production associated with reduction of CD4CD25 regulatory T cells. *Environ. Health Perspect.*, 116, 514–519.
123. Erden, E.S. et al. (2014) Investigation of Bisphenol A as an endocrine disruptor, total thiol, malondialdehyde, and C-reactive protein levels in chronic obstructive pulmonary disease. *Eur. Rev. Med. Pharmacol. Sci.*, 18, 3477–3483.
124. Kharrazian, D. (2014) The potential roles of bisphenol A (BPA) pathogenesis in autoimmunity. *Autoimmune Dis.*, 2014, 743616.
125. Liu, Y. et al. (2014) Modulation of cytokine expression in human macrophages by endocrine-disrupting chemical Bisphenol-A. *Biochem. Biophys. Res. Commun.*, 451, 592–598.
126. Rogers, J.A. et al. (2013) Review: endocrine disrupting chemicals and immune responses: a focus on bisphenol-A and its potential mechanisms. *Mol. Immunol.*, 53, 421–430.
127. Deutschle, T. et al. (2008) A controlled challenge study on di(2-ethylhexyl) phthalate (DEHP) in house dust and the immune response in human nasal mucosa of allergic subjects. *Environ. Health Perspect.*, 116, 1487–1493.
128. Peltier, M.R. et al. (2012) Polybrominated diphenyl ethers enhance the production of proinflammatory cytokines by the placenta. *Placenta*, 33, 745–749.
129. Park, H.R. et al. (2014) Involvement of reactive oxygen species in brominated diphenyl ether-47-induced inflammatory cytokine release from human extravillous trophoblasts *in vitro*. *Toxicol. Appl. Pharmacol.*, 274, 283–292.
130. Park, H.R. et al. (2014) Protective effect of nuclear factor E2-related factor 2 on inflammatory cytokine response to brominated diphenyl ether-47 in the HTR-8/SVneo human first trimester extravillous trophoblast cell line. *Toxicol. Appl. Pharmacol.*, 281, 67–77.
131. Koike, E. et al. (2014) Penta- and octa-bromodiphenyl ethers promote proinflammatory protein expression in human bronchial epithelial cells *in vitro*. *Toxicol. In Vitro*, 28, 327–333.
132. Zhao, S. et al. (2013) Sub-acute exposure to the herbicide atrazine suppresses cell immune functions in adolescent mice. *Biosci. Trends*, 7, 193–201.
133. Rowe, A.M. et al. (2006) Immunomodulatory effects of maternal atrazine exposure on male Balb/c mice. *Toxicol. Appl. Pharmacol.*, 214, 69–77.
134. Skinner, M.K. et al. (2007) Epigenetic transgenerational actions of vinclozolin on the development of disease and cancer. *Crit. Rev. Oncog.*, 13, 75–82.
135. Anway, M.D. et al. (2008) Transgenerational effects of the endocrine disruptor vinclozolin on the prostate transcriptome and adult onset disease. *Prostate*, 68, 517–529.
136. Cowin, P.A. et al. (2008) Early-onset endocrine disruptor-induced prostatitis in the rat. *Environ. Health Perspect.*, 116, 923–929.
137. Zhou, H.R. et al. (2003) Rapid, sequential activation of mitogen-activated protein kinases and transcription factors precedes proinflammatory cytokine mRNA expression in spleens of mice exposed to the trichothecene vomitoxin. *Toxicol. Sci.*, 72, 130–142.
138. Shin, S.G. et al. (2005) Suppression of inducible nitric oxide synthase and cyclooxygenase-2 expression in RAW 264.7 macrophages by sesquiterpene lactones. *J. Toxicol. Environ. Health A*, 68, 2119–2131.
139. Gollamudi, S. et al. (2012) Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease. *PLoS One*, 7, e36191.
140. Morgan, J.B. et al. (2010) The marine sponge metabolite mycothiazole: a novel prototype mitochondrial complex I inhibitor. *Bioorg. Med. Chem.*, 18, 5988–5994.
141. (1997) Pyridaben (Sanmite) Pesticide Tolerance Petition 3/97, [PF-721; FRL-5592-7]. In Agency, U.E.P. (ed).
142. Barros, S.P. et al. (2010) Triclosan inhibition of acute and chronic inflammatory gene pathways. *J. Clin. Periodontol.*, 37, 412–418.
143. Wallet, M.A. et al. (2013) Triclosan alters antimicrobial and inflammatory responses of epithelial cells. *Oral Dis.*, 19, 296–302.
144. Bhargava, H.N. et al. (1996) Triclosan: applications and safety. *Am. J. Infect. Control*, 24, 209–218.
145. Winithana, T. et al. (2014) Triclosan potentiates epithelial-to-mesenchymal transition in anoikis-resistant human lung cancer cells. *PLoS One*, 9, e110851.
146. Stoker, T.E. et al. (2010) Triclosan exposure modulates estrogen-dependent responses in the female wistar rat. *Toxicol. Sci.*, 117, 45–53.
147. Shioda, T. et al. (2006) Importance of dosage standardization for interpreting transcriptomal signature profiles: evidence from studies of xenoestrogens. *Proc. Natl Acad. Sci. USA*, 103, 12033–12038.
148. Welshons, W.V. et al. (1999) Low-dose bioactivity of xenoestrogens in animals: fetal exposure to low doses of methoxychlor and other xenoestrogens increases adult prostate size in mice. *Toxicol. Ind. Health*, 15, 12–25.
149. Alyea, R.A. et al. (2009) Differential regulation of dopamine transporter function and location by low concentrations of environmental estrogens and 17beta-estradiol. *Environ. Health Perspect.*, 117, 778–783.
150. Wozniak, A.L. et al. (2005) Xenoestrogens at picomolar to nanomolar concentrations trigger membrane estrogen receptor-alpha-mediated Ca<sup>2+</sup> fluxes and prolactin release in GH3/B6 pituitary tumor cells. *Environ. Health Perspect.*, 113, 431–439.
151. Jeng, Y.J. et al. (2011) Combinations of physiologic estrogens with xenoestrogens alter ERK phosphorylation profiles in rat pituitary cells. *Environ. Health Perspect.*, 119, 104–112.

## AQ12



152. Cabaton, N.J. et al. (2011) Perinatal exposure to environmentally relevant levels of bisphenol A decreases fertility and fecundity in CD-1 mice. *Environ. Health Perspect.*, 119, 547–552.
153. Jones, B.A. et al. (2011) Pre- and postnatal bisphenol A treatment results in persistent deficits in the sexual behavior of male rats, but not female rats, in adulthood. *Horm. Behav.*, 59, 246–251.
154. Lemos, M.F. et al. (2010) Protein differential expression induced by endocrine disrupting compounds in a terrestrial isopod. *Chemosphere*, 79, 570–576.
155. Markey, C.M. et al. (2001) The mouse uterotrophic assay: a reevaluation of its validity in assessing the estrogenicity of bisphenol A. *Environ. Health Perspect.*, 109, 55–60.
156. Filipov, N.M. et al. (2005) Manganese potentiates *in vitro* production of proinflammatory cytokines and nitric oxide by microglia through a nuclear factor kappa B-dependent mechanism. *Toxicol. Sci.*, 84, 139–148.
157. Knudsen, T.B. et al. (2011) Disruption of embryonic vascular development in predictive toxicology. *Birth Defects Res. Part C*, 93, 312–323.
158. Qin, R. et al. (2011) Protection by tetrahydroxystilbene glucoside against neurotoxicity induced by MPP<sup>+</sup>: the involvement of PI3K/Akt pathway activation. *Toxicol. Lett.*, 202, 1–7.
159. Manfo, F.P. et al. (2011) Effects of maneb on testosterone release in male rats. *Drug Chem. Toxicol.*, 34, 120–128.
160. Matsushita, T. et al. (1976) Experimental study on contact dermatitis caused by dithiocarbamates maneb, mancozeb, zineb, and their related compounds. *Int. Arch. Occup. Environ. Health*, 37, 169–178.
161. (1991) Maneb. International Labour Organization.
162. Kazantseva, Y.A. et al. (2013) Dichlorodiphenyltrichloroethane technical mixture regulates cell cycle and apoptosis genes through the activation of CAR and ER $\alpha$  in mouse livers. *Toxicol. Appl. Pharmacol.*, 271, 137–143.
163. Lin, Z.X. et al. (1986) Inhibition of gap junctional intercellular communication in human teratocarcinoma cells by organochlorine pesticides. *Toxicol. Appl. Pharmacol.*, 83, 10–19.
164. Ruch, R.J. et al. (1987) Inhibition of intercellular communication between mouse hepatocytes by tumor promoters. *Toxicol. Appl. Pharmacol.*, 87, 111–120.
165. Ventura, C. et al. (2012) Differential mechanisms of action are involved in chlorpyrifos effects in estrogen-dependent or -independent breast cancer cells exposed to low or high concentrations of the pesticide. *Toxicol. Lett.*, 213, 184–193.
166. Mense, S.M. et al. (2006) The common insecticides cyfluthrin and chlorpyrifos alter the expression of a subset of genes with diverse functions in primary human astrocytes. *Toxicol. Sci.*, 93, 125–135.
167. Santucci, M.A. et al. (2003) Cell-cycle deregulation in BALB/c 3T3 cells transformed by 1,2-dibromoethane and folpet pesticides. *Environ. Mol. Mutagen.*, 41, 315–321.
168. Albanito, L. et al. (2008) G-protein-coupled receptor 30 and estrogen receptor- $\alpha$  are involved in the proliferative effects induced by atrazine in ovarian cancer cells. *Environ. Health Perspect.*, 116, 1648–1655.
169. Tsuda, H. et al. (2005) High susceptibility of human c-Ha-ras proto-oncogene transgenic rats to carcinogenesis: a cancer-prone animal model. *Cancer Sci.*, 96, 309–316.
170. Wetzel, L.T. et al. (1994) Chronic effects of atrazine on estrus and mammary tumor formation in female Sprague-Dawley and Fischer 344 rats. *J. Toxicol. Environ. Health*, 43, 169–182.
171. Andersson, H. et al. (2012) Proangiogenic effects of environmentally relevant levels of bisphenol A in human primary endothelial cells. *Arch. Toxicol.*, 86, 465–474.
172. Dairkee, S.H. et al. (2013) Bisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cells. *Carcinogenesis*, 34, 703–712.
173. Betancourt, A.M. et al. (2012) Altered carcinogenesis and proteome in mammary glands of rats after prepubertal exposures to the hormonally active chemicals bisphenol A and genistein. *J. Nutr.*, 142, 1382S–1388S.
174. Andrysk, Z. et al. (2013) Aryl hydrocarbon receptor-mediated disruption of contact inhibition is associated with connexin43 downregulation and inhibition of gap junctional intercellular communication. *Arch. Toxicol.*, 87, 491–503.
175. Haber, L.T. et al. (2000) Hazard identification and dose response of inhaled nickel-soluble salts. *Regul. Toxicol. Pharmacol.*, 31(2 Pt 1), 210–230.
176. LN, V. et al. (2013) Low dose effects of bisphenol A: an integrated review of *in vitro*, laboratory animal and human studies. *Endocrine Disruptors*, 1, e1.1–e1.20.
177. Tryphonas, H. et al. (2004) Oral (gavage), *in utero* and post-natal exposure of Sprague-Dawley rats to low doses of tributyltin chloride. Part II: effects on the immune system. *Food Chem. Toxicol.*, 42, 221–235.
178. Watanabe, J. et al. (2013) Low dose of methylmercury (MeHg) exposure induces caspase mediated-apoptosis in cultured neural progenitor cells. *J. Toxicol. Sci.*, 38, 931–935.
179. Petroni, D. et al. (2012) Low-dose methylmercury-induced oxidative stress, cytotoxicity, and tau-hyperphosphorylation in human neuroblastoma (SH-SY5Y) cells. *Environ. Toxicol.*, 27, 549–555.
180. McCormack, A.L. et al. (2005) Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. *J. Neurochem.*, 93, 1030–1037.
181. Hartwig, A. et al. (2002) Interference by toxic metal ions with DNA repair processes and cell cycle control: molecular mechanisms. *Environ. Health Perspect.*, 110(Suppl 5), 797–799.
182. Asmuss, M. et al. (2000) Differential effects of toxic metal compounds on the activities of Fpg and XPA, two zinc finger proteins involved in DNA repair. *Carcinogenesis*, 21, 2097–2104.
183. McNeill, D.R. et al. (2004) Inhibition of Ape1 nuclease activity by lead, iron, and cadmium. *Environ. Health Perspect.*, 112, 799–804.
184. Pottier, G. et al. (2013) Lead exposure induces telomere instability in human cells. *PLoS One*, 8, e67501.
185. Zhang, X. et al. (2013) Environmental and occupational exposure to chemicals and telomere length in human studies. *Occup. Environ. Med.*, 70, 743–749.
186. Exon, J.H. (2006) A review of the toxicology of acrylamide. *J. Toxicol. Environ. Health B. Crit. Rev.*, 9, 397–412.
187. Sickles, D.W. et al. (2007) Acrylamide effects on kinesin-related proteins of the mitotic/meiotic spindle. *Toxicol. Appl. Pharmacol.*, 222, 111–121.
188. Wang, X. et al. (2013) Epigenotoxicity of environmental pollutants evaluated by a combination of DNA methylation inhibition and capillary electrophoresis-laser-induced fluorescence immunoassay. *Anal. Bioanal. Chem.*, 405, 2435–2442.
189. Arita, A. et al. (2012) Global levels of histone modifications in peripheral blood mononuclear cells of subjects with exposure to nickel. *Environ. Health Perspect.*, 120, 198–203.
190. Cantone, L. et al. (2011) Inhalable metal-rich air particles and histone H3K4 dimethylation and H3K9 acetylation in a cross-sectional study of steel workers. *Environ. Health Perspect.*, 119, 964–969.
191. Chervona, Y. et al. (2012) Carcinogenic metals and the epigenome: understanding the effect of nickel, arsenic, and chromium. *Metalomics*, 4, 619–627.
192. Avissar-Whiting, M. et al. (2010) Bisphenol A exposure leads to specific microRNA alterations in placental cells. *Reprod. Toxicol.*, 29, 401–406.
193. Roedel, E.Q. et al. (2012) Pulmonary toxicity after exposure to military-relevant heavy metal tungsten alloy particles. *Toxicol. Appl. Pharmacol.*, 259, 74–86.
194. Freyre-Fonseca, V. et al. (2011) Titanium dioxide nanoparticles impair lung mitochondrial function. *Toxicol. Lett.*, 202, 111–119.
195. Elhajoui, A. et al. (2011) Potential thresholds for genotoxic effects by micronucleus scoring. *Mutagenesis*, 26, 199–204.
196. Ermler, S. et al. (2013) Seven benzimidazole pesticides combined at sub-threshold levels induce micronuclei *in vitro*. *Mutagenesis*, 28, 417–426.
197. Sargent, L.M. et al. (2012) Single-walled carbon nanotube-induced mitotic disruption. *Mutat. Res.*, 745, 28–37.
198. Muller, J. et al. (2008) Clastogenic and aneugenic effects of multi-wall carbon nanotubes in epithelial cells. *Carcinogenesis*, 29, 427–433.
199. Thomas, D. (2010) Gene-environment-wide association studies: emerging approaches. *Nat. Rev. Genet.*, 11, 259–272.

200. Santella, R.M. et al. (2005) DNA adducts, DNA repair genotype/phenotype and cancer risk. *Mutat. Res.*, 592, 29–35.
201. (2011) Cytogenetic Dosimetry: Applications in Preparedness for and Response to Radiation Emergencies. International Atomic Energy Agency, Vienna.
202. De Lange, T. (2005) Telomere-related genome instability in cancer. *Cold Spring Harb. Symp. Quant. Biol.*, 70, 197–204.
203. Frias, C. et al. (2012) Telomere dysfunction and genome instability. *Front. Biosci. (Landmark Ed)*, 17, 2181–2196.
204. Hollstein, M. et al. (1991) p53 mutations in human cancers. *Science*, 253, 49–53.
205. Jang, J.W. et al. (2006) Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. *Mol. Cell. Biol.*, 26, 8109–8121.
206. Muñoz, D.M. et al. (2013) Loss of p53 cooperates with K-ras activation to induce glioma formation in a region-independent manner. *Glia*, 61, 1862–1872.
207. Pierotti, M.A. et al. (2003) Mechanisms of oncogene activation. In Kufe D.W., Weichselbaum R.R., and et al. (eds) *Holland-Frei Cancer Medicine*. BC Decker, Hamilton (ON).
- AQ13 208. Mazzei, F. et al. (2013) Role of MUTYH in human cancer. *Mutat. Res.*, 743–744, 33–43.
209. Sancar, A. (1995) Excision repair in mammalian cells. *J. Biol. Chem.*, 270, 15915–15918.
210. Vineis, P. et al. (2009) A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. *J. Natl Cancer Inst.*, 101, 24–36.
211. Bohacek, J. et al. (2013) Epigenetic inheritance of disease and disease risk. *Neuropsychopharmacology*, 38, 220–236.
212. Esteller, M. (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. *Nat. Rev. Genet.*, 8, 286–298.
213. Caffarelli, E. et al. (2011) Epigenetic regulation in cancer development. *Front. Biosci. (Landmark Ed)*, 16, 2682–2694.
214. Croce, C.M. (2009) Causes and consequences of microRNA dysregulation in cancer. *Nat. Rev. Genet.*, 10, 704–714.
215. Wang, Y. et al. (2013) MicroRNAs and DNA damage response: implications for cancer therapy. *Cell Cycle*, 12, 32–42.
216. Devalle, S. et al. (2012) Implications of aneuploidy for stem cell biology and brain therapeutics. *Front. Cell. Neurosci.*, 6, 36.
217. Linschooten, J.O. et al. (2013) Paternal lifestyle as a potential source of germline mutations transmitted to offspring. *FASEB J.*, 27, 2873–2879.
- AQ14 218. Leyns, L. et al. (2012) Genomic integrity of mouse embryonic stem cells. In Sato, D.K.-I. (ed), *Embryogenesis*, pp. 333–358.
219. Blessing, H. et al. (2004) Interaction of selenium compounds with zinc finger proteins involved in DNA repair. *Eur. J. Biochem.*, 271, 3190–3199.
220. Zhang, X. et al. (2013) Environmental and occupational exposure to chemicals and telomere length in human studies. *Postgrad. Med. J.*, 89, 722–728.
221. Lombaert, N. et al. (2013) Hard-metal (WC-Co) particles trigger a signaling cascade involving p38 MAPK, HIF-1 $\alpha$ , HMOX1, and p53 activation in human PBMC. *Arch. Toxicol.*, 87, 259–268.
222. Jugan, M.L. et al. (2012) Titanium dioxide nanoparticles exhibit genotoxicity and impair DNA repair activity in A549 cells. *Nanotoxicology*, 6, 501–513.
223. Song, M.F. et al. (2012) Metal nanoparticle-induced micronuclei and oxidative DNA damage in mice. *J. Clin. Biochem. Nutr.*, 50, 211–216.
224. Doshi, T. et al. (2011) Hypermethylation of estrogen receptor promoter region in adult testis of rats exposed neonatally to bisphenol A. *Toxicology*, 289, 74–82.
225. Kundakovic, M. et al. (2013) Sex-specific epigenetic disruption and behavioral changes following low-dose in utero bisphenol A exposure. *Proc. Natl Acad. Sci. USA*, 110, 9956–9961.
- AQ15 226. Pupo, M. et al. (2012) Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. *Environ. Health Perspect.*, 120, 1177–1182.
227. Ribeiro-Varandas, E. et al. (2013) Bisphenol A at concentrations found in human serum induces aneuploidic effects in endothelial cells. *Mutat. Res.*, 751, 27–33.
228. Marshall, H. (2002) Fact sheet: carbendazim. *Pesticides News*, 57, 20–21.
229. Zhao, Y. et al. (2010) Characterization and determination of chloro- and bromo-benzoquinones as new chlorination disinfection byproducts in drinking water. *Anal. Chem.*, 82, 4599–4605.
230. Piao, M.J. et al. (2011) Silver nanoparticles induce oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis. *Toxicol. Lett.*, 201, 92–100.
231. Gong, C. et al. (2012) Methylation of PARP-1 promoter involved in the regulation of nano-SiO<sub>2</sub>-induced decrease of PARP-1 mRNA expression. *Toxicol. Lett.*, 209, 264–269.
232. Choi, A.O. et al. (2008) Quantum dot-induced epigenetic and genotoxic changes in human breast cancer cells. *J. Mol. Med. (Berl)*, 86, 291–302.
233. Balansky, R. et al. (2013) Transplacental clastogenic and epigenetic effects of gold nanoparticles in mice. *Mutat. Res.*, 751–752, 42–48.
234. Liu, Y. et al. (2013) Understanding the toxicity of carbon nanotubes. *Acc. Chem. Res.*, 46, 702–713.
235. Chisholm, H. (1910–1911) 11th Edition of *Encyclopedia Britannica*.
236. Stoker, T.E. et al. (1999) Prepubertal exposure to compounds that increase prolactin secretion in the male rat: effects on the adult prostate. *Biol. Reprod.*, 61, 1636–1643.
237. Ho, S.M. et al. (2006) Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. *Cancer Res.*, 66, 5624–5632.
238. Riu, A. et al. (2011) Characterization of novel ligands of ER $\alpha$ , ER $\beta$ , and PARG $\gamma$ : the case of halogenated bisphenol A and their conjugated metabolites. *Toxicol. Sci.*, 122, 372–82.
239. Riu, A. et al. (2011) Peroxisome proliferator-activated receptor  $\gamma$  is a target for halogenated analogs of bisphenol A. *Environ. Health Perspect.*, 119, 1227–1232.
240. Thuesen, L.E. et al. (2015) *In vitro* exposure to the herbicide atrazine inhibits T cell activation, proliferation, and cytokine production and significantly increases the frequency of Foxp3<sup>+</sup> regulatory T cells. *Toxicol. Sci.*, 143, 418–429.
241. Hooghe, R.J. et al. (2000) Effects of selected herbicides on cytokine production *in vitro*. *Life Sci.*, 66, 2519–2525.
242. Filipov, N.M. et al. (2005) Immunotoxic effects of short-term atrazine exposure in young male C57BL/6 mice. *Toxicol. Sci.*, 86, 324–332.
243. Karrow, N.A. et al. (2005) Oral exposure to atrazine modulates cell-mediated immune function and decreases host resistance to the B16F10 tumor model in female B6C3F1 mice. *Toxicology*, 209, 15–28.
244. Basini, G. et al. (2012) Atrazine disrupts steroidogenesis, VEGF and NO production in swine granulosa cells. *Ecotoxicol. Environ. Saf.*, 85, 59–63.
245. Chen, J.Y. et al. (2013) Immunotoxicity of atrazine in Balb/c mice. *J. Environ. Sci. Health B.*, 48, 637–645.
246. Chen, J. et al. (2015) Effects of atrazine on the proliferation and cytotoxicity of murine lymphocytes with the use of carboxyfluorescein succinimidyl ester-based flow cytometric approaches. *Food Chem. Toxicol.*, 76, 61–69.
247. Danelli, L. et al. (2015) Mast cells boost myeloid-derived suppressor cell activity and contribute to the development of tumor-favoring microenvironment. *Cancer Immunol. Res.*, 3, 85–95.
248. Grimm, E.A. et al. (2013) Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. *Clin. Cancer Res.*, 19, 5557–5563.
249. Costa, A. et al. (2014) The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. *Semin. Cancer Biol.*, 25, 23–32.
250. Lei, Y. et al. (2014) Redox regulation of inflammation: old elements, a new story. *Med. Res. Rev.*
251. Wu, Y. et al. (2014) Molecular mechanisms underlying chronic inflammation-associated cancers. *Cancer Lett.*, 345, 164–173.
252. Zhang, H.Y. et al. (2014) Perinatal exposure to 4-nonylphenol affects adipogenesis in first and second generation rats offspring. *Toxicol. Lett.*, 225, 325–332.



253. Mitchison, J. (1971) The Biology of the Cell Cycle. Cambridge University Press, Cambridge.
254. Keating, M.T. et al. (1988) Autocrine stimulation of intracellular PDGF receptors in v-sis-transformed cells. *Science*, 239, 914–916.
255. Skobe, M. et al. (1998) Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. *Proc. Natl Acad. Sci. USA*, 95, 1050–1055.
256. Lemmon, M.A. (2009) Ligand-induced ErbB receptor dimerization. *Exp. Cell Res.*, 315, 638–648.
257. Kerkhoff, E. et al. (1998) Cell cycle targets of Ras/Raf signalling. *Oncogene*, 17, 1457–1462.
258. Mezquita, B. et al. (2014) Unlocking doors without keys: activation of Src by truncated C-terminal intracellular receptor tyrosine kinases lacking tyrosine kinase activity. *Cells*, 3, 92–111.
259. Grünfeld, H.T. et al. (2004) Effect of *in vitro* estrogenic pesticides on human oestrogen receptor alpha and beta mRNA levels. *Toxicol. Lett.*, 151, 467–480.
260. Symonds, D.A. et al. (2005) Methoxychlor induces proliferation of the mouse ovarian surface epithelium. *Toxicol. Sci.*, 83, 355–362.
261. Muro, E.P. et al. (2004) The effects of the reported active metabolite of methoxychlor, 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane, on testosterone formation by cultured Leydig cells from young adult rats. *Reprod. Toxicol.*, 19, 135–146.
262. Gaido, K.W. et al. (2000) Interaction of methoxychlor and related compounds with estrogen receptor alpha and beta, and androgen receptor: structure-activity studies. *Mol. Pharmacol.*, 58, 852–858.
263. Paulose, T. et al. (2011) Increased sensitivity of estrogen receptor alpha overexpressing antral follicles to methoxychlor and its metabolites. *Toxicol. Sci.*, 120, 447–459.
264. S, W. et al. (2009) Growth factors differentially augment the effects of HPTE on estrogen response element-mediated gene transcription in a dose- and time-dependent manner among human breast cancer cell lines. *Res. J. Med. Med. Sci.*, 4, 171–180.
265. Kojima, H. et al. (2010) Endocrine-disrupting potential of pesticides via nuclear receptors and aryl hydrocarbon receptor. *J. Health Sci.*, 56, 374–386.
266. Noriega, N.C. et al. (2005) Late gestational exposure to the fungicide prochloraz delays the onset of parturition and causes reproductive malformations in male but not female rat offspring. *Biol. Reprod.*, 72, 1324–1335.
267. Cocco, P. (2002) On the rumors about the silent spring. Review of the scientific evidence linking occupational and environmental pesticide exposure to endocrine disruption health effects. *Cad. Saude. Publica.*, 18, 379–402.
268. Kleinstreuer, N.C. et al. (2011) Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics. *Toxicol. Appl. Pharmacol.*, 257, 111–121.
269. Cummings, A.M. et al. (1989) Antifertility effect of methoxychlor in female rats: dose- and time-dependent blockade of pregnancy. *Toxicol. Appl. Pharmacol.*, 97, 454–462.
270. Gray, L.E. Jr et al. (1989) A dose-response analysis of methoxychlor-induced alterations of reproductive development and function in the rat. *Fundam. Appl. Toxicol.*, 12, 92–108.
271. Metcalf, J.L. et al. (1996) Methoxychlor mimics the action of 17 beta-estradiol on induction of uterine epidermal growth factor receptors in immature female rats. *Reprod. Toxicol.*, 10, 393–399.
272. Kuiper, G.G. et al. (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. *Endocrinology*, 139, 4252–4263.
273. Andersen, H.R. et al. (2002) Effects of currently used pesticides in assays for estrogenicity, androgenicity, and aromatase activity *in vitro*. *Toxicol. Appl. Pharmacol.*, 179, 1–12.
274. Vinggaard, A.M. et al. (2006) Prochloraz: an imidazole fungicide with multiple mechanisms of action. *Int. J. Androl.*, 29, 186–192.
275. Liu, C. et al. (2011) Effects of prochloraz or propylthiouracil on the cross-talk between the HPG, HPA, and HPT axes in zebrafish. *Environ. Sci. Technol.*, 45, 769–775.
276. Chorfa, A. et al. (2013) Specific pesticide-dependent increases in  $\alpha$ -synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines. *Toxicol. Sci.*, 133, 289–297.
277. Rencüzoğullari, E. et al. (2004) The genotoxic effect of the new acaricide etoxazole. *Genetika*, 40, 1571–1575.
278. Thrash, B. et al. (2007) Paraquat and maneb induced neurotoxicity. *Proc. West. Pharmacol. Soc.*, 50, 31–42.
279. Singleton, A.B. et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. *Science*, 302, 841.
280. Ahmad, I. et al. (2013) Biochemical and molecular mechanisms of N-acetyl cysteine and silymarin-mediated protection against maneb- and paraquat-induced hepatotoxicity in rats. *Chem. Biol. Interact.*, 201, 9–18.
281. Zhang, W. et al. (2013) Known and emerging factors modulating estrogenic effects of estrogen-disrupting chemicals. *Environ. Rev.*, 21, 1–12.
282. Medjakovic, S. et al. (2014) Effect of nonpersistent pesticides on estrogen receptor, androgen receptor, and aryl hydrocarbon receptor. *Environ. Toxicol.*, 29, 1201–1216.
283. Jenkins, S. et al. (2009) Oral exposure to bisphenol A increases dimethylbenzanthracene-induced mammary cancer in rats. *Environ. Health Perspect.*, 117, 910–915.
284. Matthews, J.B. et al. (2001) *In vitro* and *in vivo* interactions of bisphenol A and its metabolite, bisphenol A glucuronide, with estrogen receptors alpha and beta. *Chem. Res. Toxicol.*, 14, 149–157.
285. Goodson, W.H. III et al. (2011) Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women. *Carcinogenesis*, 32, 1724–1733.
286. Meironyté, D. et al. (1999) Analysis of polybrominated diphenyl ethers in Swedish human milk. A time-related trend study, 1972–1997. *J. Toxicol. Environ. Health A*, 58, 329–341.
287. Brown, D.J. et al. (2004) Analysis of Ah receptor pathway activation by brominated flame retardants. *Chemosphere*, 55, 1509–1518.
288. Hsieh, T.H. et al. (2012) Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway. *FASEB J.*, 26, 778–787.
289. Janjua, N.R. et al. (2007) Systemic uptake of diethyl phthalate, dibutyl phthalate, and butyl paraben following whole-body topical application and reproductive and thyroid hormone levels in humans. *Environ. Sci. Technol.*, 41, 5564–5570.
290. Liu, W.L. et al. (2010) [Distribution characteristics of phthalic acid esters in soils and plants at e-waste recycling sites in Taizhou of Zhejiang, China]. *Ying Yong Sheng Tai Xue Bao*, 21, 489–494.
291. Wormuth, M. et al. (2006) What are the sources of exposure to eight frequently used phthalic acid esters in Europeans? *Risk Anal.*, 26, 803–824.
292. Long, M. et al. (2003) Effects of currently used pesticides in the AhR-CALUX assay: comparison between the human TV101L and the rat H4IIE cell line. *Toxicology*, 194, 77–93.
293. Galbraith, H. (2002) Hormones in international meat production: biological, sociological and consumer issues. *Nutr. Res. Rev.*, 15, 293–314.
294. Boettcher, M. et al. (2011) Low-dose effects and biphasic effect profiles: is trenbolone a genotoxicant? *Mutat. Res.*, 723, 152–157.
295. Kongsuwan, K. et al. (2012) The effect of combination treatment with trenbolone acetate and estradiol-17 $\beta$  on skeletal muscle expression and plasma concentrations of oxytocin in sheep. *Domest. Anim. Endocrinol.*, 43, 67–73.
296. Hotchkiss, A.K. et al. (2007) An environmental androgen, 17beta-trenbolone, affects delayed-type hypersensitivity and reproductive tissues in male mice. *J. Toxicol. Environ. Health A*, 70, 138–140.
297. Zhao, J.X. et al. (2011) Trenbolone enhances myogenic differentiation by enhancing  $\beta$ -catenin signaling in muscle-derived stem cells of cattle. *Domest. Anim. Endocrinol.*, 40, 222–229.
298. Ansari, K.M. et al. (2010) Skin tumor promotion by argemone oil/alkaloid in mice: evidence for enhanced cell proliferation, ornithine decarboxylase, cyclooxygenase-2 and activation of MAPK/NF-kappaB pathway. *Food Chem. Toxicol.*, 48, 132–138.
299. Mishra, V. et al. (2012) Role of ErbB2 mediated AKT and MAPK pathway in gall bladder cell proliferation induced by argemone oil and butter yellow. Argemone oil and butter yellow induced gall bladder cell proliferation. *Cell Biol. Toxicol.*, 28, 149–159.
300. Parker, M. (1991) Nuclear Hormone Receptors: Molecular Mechanisms, Cellular Functions, Clinical Abnormalities. Academic Press, London.

AQ16

AQ17

AQ18

301. Gulliver, L.S.M. (2013) Estradiol synthesis and metabolism and risk of ovarian cancer in older women taking prescribed or plant-derived estrogen supplementation. *J. Steroids Horm. Sci.*, S12.
302. Leroy, B. et al. (2014) TP53 mutations in human cancer: database reassessment and prospects for the next decade. *Hum. Mutat.*, 35, 672–688.
303. De Blasio, A. et al. (2005) Differentiative pathway activated by 3-aminobenzamide, an inhibitor of PARP, in human osteosarcoma MG-63 cells. *FEBS Lett.*, 579, 615–620.
304. Nielsen, G.P. et al. (1998) CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. *Am. J. Pathol.*, 153, 159–163.
305. Pietruszewska, W. et al. (2008) Loss of heterozygosity for Rb locus and pRb immunostaining in laryngeal cancer: a clinicopathologic, molecular and immunohistochemical study. *Folia Histochem. Cytobiol.*, 46, 479–485.
306. Myong, N.H. (2008) Cyclin D1 overexpression, p16 loss, and pRb inactivation play a key role in pulmonary carcinogenesis and have a prognostic implication for the long-term survival in non-small cell lung carcinoma patients. *Cancer Res. Treat.*, 40, 45–52.
307. Ikushima, H. et al. (2010) TGFβ signalling: a complex web in cancer progression. *Nat. Rev. Cancer*, 10, 415–424.
308. Su, V. et al. (2014) Connexins: mechanisms regulating protein levels and intercellular communication. *FEBS Lett.*, 588, 1212–1220.
309. Li, M.W. et al. (2010) Connexin 43 is critical to maintain the homeostasis of the blood-testis barrier via its effects on tight junction reassembly. *Proc. Natl Acad. Sci. USA*, 107, 17998–18003.
310. Campos-Pereira, F.D. et al. (2012) Early cytotoxic and genotoxic effects of atrazine on Wistar rat liver: a morphological, immunohistochemical, biochemical, and molecular study. *Ecotoxicol. Environ. Saf.*, 78, 170–177.
311. Stenner-Liewen, F. et al. (2003) Apoptosis and cancer: basic mechanisms and therapeutic opportunities in the postgenomic era. *Cancer Res.*, 63, 263–268.
312. Thompson, C.B. (1995) Apoptosis in the pathogenesis and treatment of disease. *Science*, 267, 1456–1462.
313. Shortt, J. et al. (2012) Oncogenes in cell survival and cell death. *Cold Spring Harb. Perspect. Biol.*, 4.
314. Alberts, B. et al. (2002) Extracellular control of cell division, cell growth, and apoptosis. In *Molecular Biology of the Cell*. Garland Science, New York, NY.
315. Roos, W.P. et al. (2006) DNA damage-induced cell death by apoptosis. *Trends Mol. Med.*, 12, 440–450.
316. Fridman, J.S. et al. (2003) Control of apoptosis by p53. *Oncogene*, 22, 9030–9040.
317. Adams, J.M. (2003) Ways of dying: multiple pathways to apoptosis. *Genes Dev.*, 17, 2481–2495.
318. Deveraux, Q.L. et al. (1999) IAP family proteins—suppressors of apoptosis. *Genes Dev.*, 13, 239–252.
319. Yang, Y.L. et al. (2000) The IAP family: endogenous caspase inhibitors with multiple biological activities. *Cell Res.*, 10, 169–177.
320. Wu, W. et al. (2013) Metabolic changes in cancer: beyond the Warburg effect. *Acta Biochim. Biophys. Sin. (Shanghai)*, 45, 18–26.
321. Gonzalez, M.J. et al. (2012) The bio-energetic theory of carcinogenesis. *Med. Hypotheses*, 79, 433–439.
322. Ferreira, L.M. et al. (2012) Metabolic reprogramming of the tumor. *Oncogene*, 31, 3999–4011.
323. Yi, C.H. et al. (2011) Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. *Cell*, 146, 607–620.
324. Wu, G.S. (2009) TRAIL as a target in anti-cancer therapy. *Cancer Lett.*, 285, 1–5.
325. Klaunig, J.E. et al. (1990) Gap-junctional intercellular communication and murine hepatic carcinogenesis. *Prog. Clin. Biol. Res.*, 331, 277–291.
326. Carette, D. et al. (2014) Connexin a check-point component of cell apoptosis in normal and physiopathological conditions. *Biochimie*, 101, 1–9.
327. Leung-Toung, R. et al. (2006) Thiol proteases: inhibitors and potential therapeutic targets. *Curr. Med. Chem.*, 13, 547–581.
328. Kim, I.Y. et al. (2004) Phthalates inhibit tamoxifen-induced apoptosis in MCF-7 human breast cancer cells. *J. Toxicol. Environ. Health A*, 67, 2025–2035.
329. Corcelle, E. et al. (2006) Disruption of autophagy at the maturation step by the carcinogen lindane is associated with the sustained mitogen-activated protein kinase/extracellular signal-regulated kinase activity. *Cancer Res.*, 66, 6861–6870.
330. Kim, J.Y. et al. (2014) Methoxychlor and triclosan stimulates ovarian cancer growth by regulating cell cycle- and apoptosis-related genes via an estrogen receptor-dependent pathway. *Environ. Toxicol. Pharmacol.*, 37, 1264–1274.
331. Carnero, A. (2013) Markers of cellular senescence. *Methods Mol. Biol.*, 965, 63–81.
332. Serrano, M. et al. (2001) Putting the stress on senescence. *Curr. Opin. Cell Biol.*, 13, 748–753.
333. Shay, J.W. et al. (2004) Hallmarks of senescence in carcinogenesis and cancer therapy. *Oncogene*, 23, 2919–2933.
334. Ohtani, N. et al. (2004) The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. *J. Med. Invest.*, 51, 146–153.
335. Sherr, C.J. et al. (2002) The RB and p53 pathways in cancer. *Cancer Cell*, 2, 103–112.
336. Vergel, M. et al. (2010) Bypassing cellular senescence by genetic screening tools. *Clin. Transl. Oncol.*, 12, 410–417.
337. Zanella, F. et al. (2010) Understanding FOXO, new views on old transcription factors. *Curr. Cancer Drug Targets*, 10, 135–146.
338. Ruiz, L. et al. (2008) Characterization of the p53 response to oncogene-induced senescence. *PLoS One*, 3, e3230.
339. Newbold, R.F. et al. (1982) Induction of immortality is an early event in malignant transformation of mammalian cells by carcinogens. *Nature*, 299, 633–635.
340. Russo, I. et al. (1998) A telomere-independent senescence mechanism is the sole barrier to Syrian hamster cell immortalization. *Oncogene*, 17, 3417–3426.
341. Newbold, R.F. et al. (1980) Mutagenicity of carcinogenic methylating agents is associated with a specific DNA modification. *Nature*, 283, 596–599.
342. Lehman, T.A. et al. (1993) p53 mutations in human immortalized epithelial cell lines. *Carcinogenesis*, 14, 833–839.
343. Lafarge-Frayssinet, C. et al. (1989) Over expression of proto-oncogenes: ki-ras, fos and myc in rat liver cells treated in vitro by two liver tumor promoters: phenobarbital and biliverdin. *Cancer Lett.*, 44, 191–198.
344. Arita, A. et al. (2009) Epigenetics in metal carcinogenesis: nickel, arsenic, chromium and cadmium. *Metallomics*, 1, 222–228.
345. Trott, D.A. et al. (1995) Mechanisms involved in the immortalization of mammalian cells by ionizing radiation and chemical carcinogens. *Carcinogenesis*, 16, 193–204.
346. Rivedal, E. et al. (2000) Morphological transformation and effect on gap junction intercellular communication in Syrian hamster embryo cells as screening tests for carcinogens devoid of mutagenic activity. *Toxicol. In Vitro*, 14, 185–192.
347. Zhou, X. et al. (2009) Effects of nickel, chromate, and arsenite on histone 3 lysine methylation. *Toxicol. Appl. Pharmacol.*, 236, 78–84.
348. Creton, S. et al. (2010) Acute toxicity testing of chemicals—Opportunities to avoid redundant testing and use alternative approaches. *Crit. Rev. Toxicol.*, 40, 50–83.
349. Dickens, F. et al. (1933) The metabolism of normal and tumour tissue: The effects of lactate, pyruvate and deprivation of substrate. *Biochem. J.*, 27, 1134–1140.
350. MEDES, G. et al. (1953) Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. *Cancer Res.*, 13, 27–29.
351. Menendez, J.A. et al. (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nat. Rev. Cancer*, 7, 763–777.
352. Deberardinis, R.J. et al. (2008) Brick by brick: metabolism and tumor cell growth. *Curr. Opin. Genet. Dev.*, 18, 54–61.
353. Vander Heiden, M.G. et al. (2011) Metabolic pathway alterations that support cell proliferation. *Cold Spring Harb. Symp. Quant. Biol.*, 76, 325–334.
354. Currie, E. et al. (2013) Cellular fatty acid metabolism and cancer. *Cell Metab.*, 18, 153–161.
355. Kamphorst, J.J. et al. (2013) Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. *Proc. Natl Acad. Sci. USA*, 110, 8882–8887.

356. Lazebnik, Y. (2010) What are the hallmarks of cancer? *Nat. Rev. Cancer*, 10, 232–233.
357. Berridge, M.V. et al. (2010) Metabolic flexibility and cell hierarchy in metastatic cancer. *Mitochondrion*, 10, 584–588.
358. Floor, S.L. et al. (2012) Hallmarks of cancer: of all cancer cells, all the time? *Trends Mol. Med.*, 18, 509–515.
359. Newsholme, E.A. et al. (1973) *Regulation in Metabolism*. Wiley, London, New York.
360. Shim, H. et al. (1997) c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. *Proc. Natl Acad. Sci. USA*, 94, 6658–6663.
361. Fantin, V.R. et al. (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. *Cancer Cell*, 9, 425–434.
362. Stanton, R.C. (2012) Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. *IUBMB Life*, 64, 362–369.
363. Raimundo, N. et al. (2011) Revisiting the TCA cycle: signaling to tumor formation. *Trends Mol. Med.*, 17, 641–649.
364. Mullen, A.R. et al. (2012) Genetically-defined metabolic reprogramming in cancer. *Trends Endocrinol. Metab.*, 23, 552–559.
365. Wallace, D.C. (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. *Annu. Rev. Genet.*, 39, 359–407.
366. Santidrian, A.F. et al. (2013) Mitochondrial complex I activity and NAD<sup>+</sup>/NADH balance regulate breast cancer progression. *J. Clin. Invest.*, 123, 1068–1081.
367. Lapuente-Brun, E. et al. (2013) Supercomplex assembly determines electron flux in the mitochondrial electron transport chain. *Science*, 340, 1567–1570.
368. Zaidi, N. et al. (2013) Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. *Prog. Lipid Res.*
369. Weidberg, H. et al. (2009) Lipophagy: selective catabolism designed for lipids. *Dev. Cell*, 16, 628–630.
370. Liu, K. et al. (2013) Regulation of lipid stores and metabolism by lipophagy. *Cell Death Differ.*, 20, 3–11.
371. Newsholme, E.A. et al. (1991) Application of metabolic-control logic to fuel utilization and its significance in tumor cells. *Adv. Enzyme Regul.*, 31, 225–246.
372. Kalhan, S.C. et al. (2012) Resurgence of serine: an often neglected but indispensable amino acid. *J. Biol. Chem.*, 287, 19786–19791.
373. Locasale, J.W. (2013) Serine, glycine and one-carbon units: cancer metabolism in full circle. *Nat. Rev. Cancer*, 13, 572–583.
374. Cho, H.M. et al. (2000) Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene. *Gene*, 245, 193–201.
375. Owen, O.E. et al. (2002) The key role of anaplerosis and cataplerosis for citric acid cycle function. *J. Biol. Chem.*, 277, 30409–30412.
376. Meyerhof, O. (1951) Mechanisms of glycolysis and fermentation. *Can. J. Med. Sci.*, 29, 63–77.
377. Lowry, O.H. et al. (1964) The relationships between substrates and enzymes of glycolysis in brain. *J. Biol. Chem.*, 239, 31–42.
378. Warburg, O. et al. (1958) [Partial anaerobiosis and radiation-sensitivity of cancer cells]. *Arch. Biochem. Biophys.*, 78, 573–586.
379. Robey, R.B. (2011) On dogma and the metabolic gestalt of tumor cells. *Science*.
380. Copley, S.D. (2003) Enzymes with extra talents: moonlighting functions and catalytic promiscuity. *Curr. Opin. Chem. Biol.*, 7, 265–272.
381. Luo, W. et al. (2012) Emerging roles of PKM2 in cell metabolism and cancer progression. *Trends Endocrinol. Metab.*, 23, 560–566.
382. Gao, X. et al. (2012) Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. *Mol. Cell*, 45, 598–609.
383. Robey, R.B. et al. (2006) Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. *Oncogene*, 25, 4683–4696.
384. Hu, J. et al. (2013) Heterogeneity of tumor-induced gene expression changes in the human metabolic network. *Nat. Biotechnol.*, 31, 522–529.
385. Kacser, H. et al. (1973) The control of flux. *Symp. Soc. Exp. Biol.*, 27, 65–104.
386. Agarwal, A.R. et al. (2013) Metabolic shift in lung alveolar cell mitochondria following acrolein exposure. *Am. J. Physiol. Lung Cell. Mol. Physiol.*, 305, L764–L773.
387. Ishida, S. et al. (2013) Bioavailable copper modulates oxidative phosphorylation and growth of tumors. *Proc. Natl Acad. Sci. USA*, 110, 19507–19512.
388. George, J. et al. (2011) Cypermethrin exposure leads to regulation of proteins expression involved in neoplastic transformation in mouse skin. *Proteomics*, 11, 4411–4421.
389. Tsitsimpikou, C. et al. (2013) Histopathological lesions, oxidative stress and genotoxic effects in liver and kidneys following long term exposure of rabbits to diazinon and propoxur. *Toxicology*, 307, 109–114.
390. Abdollahi, M. et al. (2004) Pesticides and oxidative stress: a review. *Med. Sci. Monit.*, 10, RA141–RA147.
391. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat. Med.*, 1, 27–31.
392. Carmeliet, P. (2005) Angiogenesis in life, disease and medicine. *Nature*, 438, 932–936.
393. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. *N. Engl. J. Med.*, 285, 1182–1186.
394. Carmeliet, P. et al. (2011) Molecular mechanisms and clinical applications of angiogenesis. *Nature*, 473, 298–307.
395. Ferrara, N. et al. (2005) Angiogenesis as a therapeutic target. *Nature*, 438, 967–974.
396. Folkman, J. (2003) Fundamental concepts of the angiogenic process. *Curr. Mol. Med.*, 3, 643–651.
397. Folkman, J. (2003) Angiogenesis inhibitors: a new class of drugs. *Cancer Biol. Ther.*, 2, S127–S133.
398. Siemann, D.W. et al. (2005) Differentiation and definition of vascular-targeted therapies. *Clin. Cancer Res.*, 11(2 Pt 1), 416–420.
399. Thorpe, P.E. (2004) Vascular targeting agents as cancer therapeutics. *Clin. Cancer Res.*, 10, 415–427.
400. Patterson, D.M. et al. (2007) Vascular damaging agents. *Clin. Oncol. (R. Coll. Radiol.)*, 19, 443–456.
401. Hu, Z. et al. (1999) Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. *Proc. Natl Acad. Sci. USA*, 96, 8161–8166.
402. Hu, Z. et al. (2000) Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. *Proc. Natl Acad. Sci. USA*, 97, 9221–9225.
403. Hu, Z. et al. (2001) Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. *Proc. Natl Acad. Sci. USA*, 98, 12180–12185.
404. Hu, Z. et al. (2010) Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer. *BMC Immunol.*, 11, 49.
405. Konigsberg, W.H. et al. (1988) Molecular cloning of the cDNA for human tissue factor. *Cell*, 52, 639–640.
406. Contrino, J. et al. (1996) In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. *Nat. Med.*, 2, 209–215.
407. Hu, Z. (2011) Factor VII-Targeted Photodynamic Therapy for Breast Cancer and Its Therapeutic Potential for Other Solid Cancers and Leukemia, Breast Cancer—Current and Alternative Therapeutic Modalities. In Esra Gunduz and Mehmet Gunduz (eds), InTech. <http://www.intechopen.com/articles/show/title/factor-vii-targeted-photodynamic-therapy-for-breast-cancer-and-its-therapeutic-potential-for-other-s>. ISBN: 978-953-307-776-5.
408. Hu, Z. et al. (2010) Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice. *BMC Cancer*, 10, 235.
409. Duanmu, J. et al. (2011) Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy. *Br. J. Cancer*, 104, 1401–1409.
410. Hu, Z. et al. (2011) Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer. *Breast Cancer Res. Treat.*, 126, 589–600.
411. Jessen-Eller, K.K.J. et al. (2002) A new invertebrate member of the p53 gene family is developmentally expressed and responds to polychlorinated biphenyls. *Environ. Health Perspect.*, 110, 9.



412. Taylor, T.R. et al. (2011) Ziram activates mitogen-activated protein kinases and decreases cytolytic protein levels in human natural killer cells. *Toxicol. Mech. Methods*, 21, 8.
413. Berx, G. et al. (2009) Involvement of members of the cadherin superfamily in cancer. *Cold Spring Harb. Perspect. Biol.*, 1, a003129.
414. Klymkowsky, M.W. et al. (2009) Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. *Am. J. Pathol.*, 174, 1588–1593.
415. Micalizzi, D.S. et al. (2010) Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. *J. Mammary Gland Biol. Neoplasia*, 15, 117–134.
416. Yang, J. et al. (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. *Dev. Cell*, 14, 818–829.
417. Kawata, M. et al. (2012) TGF- $\beta$ -induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells. *J. Biochem.*, 151, 205–216.
418. Nagase, H. et al. (2006) Structure and function of matrix metalloproteinases and TIMPs. *Cardiovasc. Res.*, 69, 562–573.
419. Chen, H.C. et al. (1998) Tyrosine phosphorylation of focal adhesion kinase stimulated by hepatocyte growth factor leads to mitogen-activated protein kinase activation. *J. Biol. Chem.*, 273, 25777–25782.
420. Al-Mehdi, A.B. et al. (2000) Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. *Nat. Med.*, 6, 100–102.
421. Chang, C.C. et al. (2013) Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells. *Cancer Res.*, 73, 4147–4157.
422. McCormick, J.M. et al. (2010) Embryonic exposure to tetrabromobisphenol A and its metabolites, bisphenol A and tetrabromobisphenol A dimethyl ether disrupts normal zebrafish (*Danio rerio*) development and matrix metalloproteinase expression. *Aquat. Toxicol.*, 100, 255–262.
423. Ding, S.Z. et al. (2013) Epithelial-mesenchymal transition during oncogenic transformation induced by hexavalent chromium involves reactive oxygen species-dependent mechanism in lung epithelial cells. *Toxicol. Appl. Pharmacol.*, 269, 61–71.
424. Hsiang, C.Y. et al. (2007) Acetaldehyde induces matrix metalloproteinase-9 gene expression via nuclear factor-kappaB and activator protein 1 signaling pathways in human hepatocellular carcinoma cells: association with the invasive potential. *Toxicol. Lett.*, 171, 78–86.
425. Seo, J.H. et al. (2004) *Helicobacter pylori* in a Korean isolate activates mitogen-activated protein kinases, AP-1, and NF-kappaB and induces chemokine expression in gastric epithelial AGS cells. *Lab. Invest.*, 84, 49–62.
426. Olumi, A.F. et al. (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. *Cancer Res.*, 59, 5002–5011.
427. Le Bitoux, M.A. et al. (2008) Tumor-host interactions: the role of inflammation. *Histochem. Cell Biol.*, 130, 1079–1090.
428. Maffini, M.V. et al. (2005) Stromal regulation of neoplastic development: age-dependent normalization of neoplastic mammary cells by mammary stroma. *Am. J. Pathol.*, 167, 1405–1410.
429. Weaver, V.M. et al. (2004) Watch thy neighbor: cancer is a communal affair. *J. Cell Sci.*, 117, 1287–1290.
430. Maguer-Satta, V. (2011) The stem cell niche: the black master of cancer. *Cancer Stem Cells Theories and Practices*, ISBN 978-953-307-225-8.
431. Laconi, S. et al. (2001) A growth-constrained environment drives tumor progression *in vivo*. *Proc. Natl Acad. Sci. USA*, 98, 7806–7811.
432. Ding, J. et al. (2009) TNF- $\alpha$  induction by nickel compounds is specific through ERKs/AP-1-dependent pathway in human bronchial epithelial cells. *Curr. Cancer Drug Targets*, 9, 81–90.
433. Li, J. et al. (2004) Nickel compounds act through phosphatidylinositol-3-kinase/Akt-dependent, p70(S6k)-independent pathway to induce hypoxia inducible factor transactivation and Cap43 expression in mouse epidermal Cl41 cells. *Cancer Res.*, 64, 94–101.
434. Ding, J. et al. (2006) Nickel compounds render anti-apoptotic effect to human bronchial epithelial Beas-2B cells by induction of cyclooxygenase-2 through an IKK $\beta$ /p65-dependent and IKK $\alpha$ - and p50-independent pathway. *J. Biol. Chem.*, 281, 39022–39032.
435. Zhang, J. et al. (2013) The alteration of miR-222 and its target genes in nickel-induced tumor. *Biol. Trace Elem. Res.*, 152, 267–274.
436. Allard, P. et al. (2010) Bisphenol A impairs the double-strand break repair machinery in the germline and causes chromosome abnormalities. *Proc. Natl Acad. Sci. USA*, 107, 20405–20410.
437. Hassan, Z.K. et al. (2012) Bisphenol A induces hepatotoxicity through oxidative stress in rat model. *Oxid. Med. Cell. Longev.*, 2012, 194829.
438. Takahashi, A. et al. (2004) Bisphenol A from dental polycarbonate crown upregulates the expression of hTERT. *J. Biomed. Mater. Res. B. Appl. Biomater.*, 71, 214–221.
439. Hurt, K. et al. (2013) Tributyltin and dibutyltin alter secretion of tumor necrosis factor alpha from human natural killer cells and a mixture of T cells and natural killer cells. *J. Appl. Toxicol.*, 33, 503–510.
440. Patel, E. et al. (2013) Methylmercury impairs motor function in early development and induces oxidative stress in cerebellar granule cells. *Toxicol. Lett.*, 222, 265–272.
441. Sherwani, S.I. et al. (2013) Eicosanoid signaling and vascular dysfunction: methylmercury-induced phospholipase D activation in vascular endothelial cells. *Cell Biochem. Biophys.*, 67, 317–329.
442. Black, A.T. et al. (2008) Increased oxidative stress and antioxidant expression in mouse keratinocytes following exposure to paraquat. *Toxicol. Appl. Pharmacol.*, 231, 384–392.
443. Chang, X. et al. (2013) Paraquat inhibits cell viability via enhanced oxidative stress and apoptosis in human neural progenitor cells. *Chem. Biol. Interact.*, 206, 248–255.
444. Khatami, M. (2014) Chronic inflammation: synergistic interactions of recruiting macrophages (TAMs) and eosinophils (Eos) with host mast cells (MCs) and tumorigenesis in CALTs. M-CSF, suitable biomarker for cancer diagnosis! *Cancers (Basel)*, 6, 297–322.
445. Whiteside, T.L. (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. *Seminars in Cancer Biology*. Vol. 16. Elsevier, pp. 3–15.
446. Whiteside, T.L. (2002) Tumor-induced death of immune cells: its mechanisms and consequences. *Seminars in Cancer Biology*. Vol. 12. Elsevier, pp. 43–50.
447. Yang, L. et al. (2010) TGF- $\beta$  and immune cells: an important regulatory axis in the tumor microenvironment and progression. *Trends Immunol.*, 31, 220–227.
448. Mocellin, S. et al. (2004) The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. *Cytokine Growth Factor Rev.*, 15, 61–76.
449. Zou, W. (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. *Nat. Rev. Cancer*, 5, 263–274.
450. IARC (2013) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Agents classified by the IARC Monographs. International Agency for Research and Cancer.
451. IARC (1982) Monograph on the Evaluation of Carcinogenic Risk to Humans. Some Industrial Chemicals and Dyestuffs. Di(2-ethylhexyl) Phthalate. International Agency for Research and Cancer.
452. IARC (2000) Monograph on the Evaluation of Carcinogenic Risk to Humans. Some Industrial Chemicals. Di(2-ethylhexyl) Phthalate. International Agency for Research and Cancer, pp. 41–148.
453. Odermatt, A. et al. (2008) Disruption of glucocorticoid and mineralocorticoid receptor-mediated responses by environmental chemicals. *CHIMIA Int. J. Chem.*, 62, 335–339.
454. Santos, P.M. et al. (2009) Insights into yeast adaptive response to the agricultural fungicide mancozeb: a toxicoproteomics approach. *Proteomics*, 9, 657–670.
455. Kuster, M. et al. (2009) Liquid chromatography-tandem mass spectrometric analysis and regulatory issues of polar pesticides in natural and treated waters. *J. Chromatogr. A*, 1216, 520–529.
456. Kim, J.H. et al. (2013) Synergism of antifungal activity between mitochondrial respiration inhibitors and kojic acid. *Molecules*, 18, 1564–1581.
457. Çayır, A. et al. (2012) Micronuclei, nucleoplasmic bridges, and nuclear buds induced in human lymphocytes by the fungicide signum and its active ingredients (boscalid and pyraclostrobin). *Environ. Toxicol.*
458. Judson, R.S. et al. (2010) *In vitro* screening of environmental chemicals for targeted testing prioritization: the ToxCast project. *Environ. Health Persp. (Online)*, 118, 485.

459. Pereboeva, L. et al. (2013) DNA damage responses and oxidative stress in dyskeratosis congenita. *PLoS One*, 8, e76473.
460. Pinchuk, L.M. et al. (2007) *In vitro* atrazine exposure affects the phenotypic and functional maturation of dendritic cells. *Toxicol. Appl. Pharmacol.*, 223, 206–217.
461. Kavlock, R. et al. (2012) Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management. *Chem. Res. Toxicol.*, 25, 1287–1302.
462. Martin, M.T. et al. (2011) Predictive model of rat reproductive toxicity from ToxCast high throughput screening. *Biol. Reprod.*, 85, 327–339.
463. Metzler, M. et al. (2001) Chemistry of natural and anthropogenic endocrine active compounds. In *Endocrine Disruptors—Part I*. Springer, pp. 63–80.
464. Gatidou, G. et al. (2007) Simultaneous determination of the endocrine disrupting compounds nonylphenol, nonylphenol ethoxylates, triclosan and bisphenol A in wastewater and sewage sludge by gas chromatography–mass spectrometry. *J. Chromatogr. A*, 1138, 32–41.
465. Foran, C. et al. (2000) Developmental evaluation of a potential non-steroidal estrogen: triclosan. *Mar. Environ. Res.*, 50, 153–156.
466. Ishibashi, H. et al. (2004) Effects of triclosan on the early life stages and reproduction of medaka *Oryzias latipes* and induction of hepatic vitellogenin. *Aquat. Toxicol.*, 67, 167–179.
467. Boyd, G.R. et al. (2003) Pharmaceuticals and personal care products (PPCPs) in surface and treated waters of Louisiana, USA and Ontario, Canada. *Sci. Total Environ.*, 311, 135–149.
468. Kolpin, D.W. et al. (2002) Pharmaceuticals, hormones, and other organic wastewater contaminants in US streams, 1999–2000: a national reconnaissance. *Environ. Sci. Technol.*, 36, 1202–1211.
469. Vandhana, S. et al. (2013) Biochemical changes accompanying apoptotic cell death in retinoblastoma cancer cells treated with lipogenic enzyme inhibitors. *Biochim. Biophys. Acta (BBA)—Molecular and Cell Biology of Lipids*, 1831, 1458–1466.
470. Zuckerbraun, H.L. et al. (1998) Triclosan, cytotoxicity, mode of action, and induction of apoptosis in human gingival cells *in vitro*. *Eur. J. Oral Sci.*, 106, 628–636.
471. Terasaka, H. et al. (2005) Cytotoxicity and apoptosis-inducing activity of bisphenol A and hydroquinone in HL-60 cells. *Anticancer Res.*, 25, 2241–2247.
472. NICNAS (2006) Diethylhexyl Phthalate (DEHP) Factsheet. CAS: 117-81-7. In Scheme, N.I.C.N.a.a. (ed) NICNAS.
473. Jobling, S. et al. (1995) A variety of environmentally persistent chemicals, including some phthalate plasticizers, are weakly estrogenic. *Environ. Health Persp.*, 103, 582.
474. Hao, C. et al. (2012) Perinatal exposure to diethyl-hexyl-phthalate induces obesity in mice. *Front. Biosci. (Elite edition)*, 5, 725–733.
475. Moushumi Priya, A. et al. (2012) Induction of Apoptosis and cell cycle arrest by Bis (2-ethylhexyl) phthalate produced by Marine *Bacillus pumilus* MB 40. *Chem. Biol. Interact.*, 195, 133–143.
476. Park, M.A. et al. (2012) Cell growth of BG-1 ovarian cancer cells is promoted by di-n-butyl phthalate and hexabromocyclododecane via upregulation of the cyclin D and cyclin-dependent kinase-4 genes. *Mol. Med. Rep.*, 5, 761–766.
477. Kinoshita, Y. et al. (2003) Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha. *Cancer Res.*, 63, 3546–3555.
478. Prins, G.S. (2008) Endocrine disruptors and prostate cancer risk. *Endocr. Relat. Cancer*, 15, 649–656.
479. Laville, N. et al. (2006) Modulation of aromatase activity and mRNA by various selected pesticides in the human choriocarcinoma JEG-3 cell line. *Toxicology*, 228, 98–108.
480. Bulun, S.E. et al. (2007) Aromatase excess in cancers of breast, endometrium and ovary. *J. Steroid Biochem. Mol. Biol.*, 106, 81–96.
481. (2012) A Review of Human Carcinogens—Pharmaceuticals IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Vol. 100, World Health Organization IARC, Geneva, Switzerland.
482. Paul, A. et al. (2014) The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. *Front. Biosci. (Landmark Ed)*, 19, 605–618.
483. (2000) Supplementary Guidance for Conducting Health Risk Assessment of Chemical Mixtures. In *Forum*, U.S.E.P.A.R.A. (ed).
484. Dellarco, V. et al. (2012) Mode of action: moving toward a more relevant and efficient assessment paradigm. *J. Nutr.*, 142, 2192S–2198S.
485. Meek, M.E. et al. (2003) A framework for human relevance analysis of information on carcinogenic modes of action. *Crit. Rev. Toxicol.*, 33, 591–653.
486. Boobis, A.R. et al. (2006) IPCS framework for analyzing the relevance of a cancer mode of action for humans. *Crit. Rev. Toxicol.*, 36, 781–792.
487. (2012) OECD Guidance Document 116 On The Conduct And Design Of Chronic Toxicity And Carcinogenicity Studies, Supporting Test Guidelines 451, 452 And 453, 2nd Edition, Series on Testing and Assessment, ENV/JM/MONO(2011)47. OECD Environment Directorate Joint Meeting of the Chemicals Committee and the Working Party on Chemicals, Pesticides and Biotechnology.
488. U.S.E.P.A. (2002) Guidance on Cumulative Risk Assessment of Pesticide Chemicals That Have a Common Mechanism of Toxicity. In *Office of Pesticide Programs*, Washington, D.C. 20460.
489. EFSA PPR Panel (EFSA Panel on Plant Protection Products and their Residues) (2013). Scientific opinion on the relevance of dissimilar mode of action and its appropriate application for cumulative risk assessment of pesticides residues in food. *EFSA J.*, 11, 40.
490. Driedger, A.A. et al. (1971) Demonstration of two types of DNA repair in X-irradiated *Micrococcus radiodurans*. *Can. J. Microbiol.*, 17, 495–499.
491. Mason, P.A. et al. (2003) Mismatch repair activity in mammalian mitochondria. *Nucleic Acids Res.*, 31, 1052–1058.
492. Heindorff, K. et al. (1983) Genetic toxicology of ethylenediaminetetraacetic acid (EDTA). *Mutat. Res.*, 115, 149–173.
493. (2008) Phthalates Cumulative Risk Assessment—The Tasks Ahead. In *National Research Council, N.A.o.S., Board on Environmental Science and Technology, Committee on Phthalates Health Risks*. National Academy Press, Washington, DC, p. 208.
494. Bucala, R. (1996) MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. *FASEB J.*, 10, 1607–1613.
495. Bucala, R. et al. (2007) Macrophage migration inhibitory factor: a probable link between inflammation and cancer. *Immunity*, 26, 281–285.
496. Grieb, G. et al. (2010) Macrophage migration inhibitory factor (MIF): a promising biomarker. *Drug News Perspect.*, 23, 257–264.
497. Landesmann, B. et al. (2013) Adverse outcome pathway-based screening strategies for an animal-free safety assessment of chemicals. *Altern. Lab. Anim.*, 41, 461–471.
498. Malhotra, J. et al. (2015) Effect of occupational exposures on lung cancer susceptibility: a study of gene-environment interaction analysis. *Cancer Epidemiol. Biomarkers Prev.*, 24, 570–579.
499. Singh, S. et al. (2012) Epigenetic effects of environmental chemicals bisphenol a and phthalates. *Int. J. Mol. Sci.*, 13, 10143–10153.
500. Vineis, P. et al. (2010) Models of carcinogenesis: an overview. *Carcinogenesis*, 31, 1703–1709.
501. Brash, D. et al. (2009) The mysterious steps in carcinogenesis. *Br. J. Cancer*, 101, 379–380.
502. Brash, D. et al. (2009) The mysterious steps in carcinogenesis: addendum. *Br. J. Cancer*, 101, 1490.
503. Rappaport, S.M. et al. (2010) Epidemiology. Environment and disease risks. *Science*, 330, 460–461.
504. Bisson, W.H. (2012) Editorial: computational chemogenomics in drug design and discovery. *Curr. Top. Med. Chem.*, 12, 1867–1868.
505. Tomasetti, C. et al. (2015) Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. *Science*, 347, 78–81.
506. Weinberg, R.A. (2014) Coming full circle—from endless complexity to simplicity and back again. *Cell*, 157, 267–271.
507. Koutsogiannouli, E. et al. (2013) Complexity in cancer biology: is systems biology the answer? *Cancer Med.*, 2, 164–177.
508. Alberghina, L. et al. (2004) Systems biology and the molecular circuits of cancer. *ChemBiochem*, 5, 1322–1333.
509. Carvalho, R.N. et al. (2014) Mixtures of chemical pollutants at European legislation safety concentrations: how safe are they? *Toxicol. Sci.*

AQ23

AQ24

AQ21

AQ22



510. Porter, W.P. et al. (1999) Endocrine, immune, and behavioral effects of aldicarb (carbamate), atrazine (triazine) and nitrate (fertilizer) mixtures at groundwater concentrations. *Toxicol. Ind. Health*, 15, 133–150.
511. Tarone, R.E. et al. (2011) Combating environmental causes of cancer. *N. Engl. J. Med.*, 364, 2266–2267.
512. Willett, W.C. et al. (2011) Combating environmental causes of cancer. *N. Engl. J. Med.*, 364, 2266.
513. Richter, E.D. et al. (2004) The precautionary principle, epidemiology and the ethics of delay. *Int. J. Occup. Med. Environ. Health*, 17, 9–16.
514. Pohl, H.R. et al. (2010) Chemical risk assessment and uncertainty associated with extrapolation across exposure duration. *Regul. Toxicol. Pharmacol.*, 57, 18–23.
515. Tice, R.R. et al. (2013) Improving the human hazard characterization of chemicals: a Tox21 update. *Environ. Health Perspect.*, 121, 756–765.

## Appendix

### The Halifax Project Environmental Mixtures Taskforce

**Project Design:** Leroy Lowe<sup>1,2</sup> and Michael Gilbertson<sup>3</sup>

**Project Management:** Leroy Lowe<sup>1,2</sup>

**NIEHS Funding:** Arranged by David O.Carpenter<sup>4</sup>

**Core Writing Team:** William H.Goodson III<sup>5\*</sup>, Leroy Lowe<sup>1,2</sup>, Michael Gilbertson<sup>3</sup> and David O.Carpenter<sup>4</sup>

**Angiogenesis:** *Team Leader:* Zhiwei Hu<sup>6</sup>, *Team Members:* Chia-Wen Hsu<sup>7</sup>, Hsue-Yin Hsu<sup>8</sup>, Liang-Tzung Lin<sup>9</sup>, Menghang Xia<sup>7</sup>, Nicole Kleinstreuer<sup>10</sup>, Samira A.Brooks<sup>11</sup>, Thierry Massfelder<sup>12</sup>, Valérian Dormoy<sup>12,13</sup> and W.Kimryn Rathmell<sup>11</sup>

**Deregulated Metabolism:** *Team Leader:* R.Brooks Robey<sup>14,15</sup>, *Team Members:* Anna C.Salzberg<sup>16</sup>, Arthur Berg<sup>17</sup>, Elizabeth P.Ryan<sup>18</sup>, Dustin G.Brown<sup>18</sup>, Ferdinando Chiaradonna<sup>19,20</sup>, Francis L.Martin<sup>2</sup>, Graeme Williams<sup>21</sup>, Judith Weisz<sup>22</sup>, Nancy B.Kuemmerle<sup>14,15</sup> and Roberta Palorini<sup>19,20</sup>

**Evasion of Anti-Growth Signalling:** *Team Leader:* Rita Nahta<sup>23</sup>, *Team Members:* Ahmed Lasfar<sup>24</sup>, Christian C.Naus<sup>25</sup>, Dale W.Laird<sup>26</sup>, Debasish Roy<sup>27</sup>, Gary S.Goldberg<sup>28</sup>, Gloria M.Calaf<sup>29,30</sup>, Harini Krishnan<sup>31</sup>, Jan Vondráček<sup>32</sup>, Karine A.Cohen-Solal<sup>33</sup>, Mark Wade<sup>34</sup>, Nichola Cruickshanks<sup>35</sup>, Paola A.Marignani<sup>36</sup>, Paul Dent<sup>35</sup>, Rafaela Andrade-Vieira<sup>36</sup>, Renza Vento<sup>37,38</sup>, Riccardo Di Fiore<sup>37</sup>, Richard Ponce-Cusi<sup>39</sup>, Robert C.Castellino<sup>40,41</sup> and Sarah N.Bay<sup>42</sup>

**Genetic Instability:** *Team Leader:* Sabine A.S.Langie<sup>43</sup>, *Team Members:* Adela Lopez de Cerain Salsamendi<sup>44</sup>, Amaya Azqueta<sup>44</sup>, Amelia K.Charles<sup>45</sup>, Andrew R.Collins<sup>46</sup>, Ann-Karin Olsen<sup>47</sup>, Emilio Rojas<sup>48</sup>, Firouz Darroudi<sup>49</sup>, Frederik J.Van Schooten<sup>50</sup>, Gudrun Koppen<sup>43</sup>, Gunnar Brunborg<sup>47</sup>, Laetitia Gonzalez<sup>51</sup>, Luc Leyns<sup>51</sup>, Luoping Zhang<sup>52</sup>, Mahara Valverde<sup>48</sup>, Micheline Kirsch-Volders<sup>51</sup>, Nik van Larebeke<sup>53</sup>, Patricia Ostrosky-Wegman<sup>48</sup>, Sofia Pavanello<sup>54</sup> and Tao Chen<sup>55</sup>

**Immune System Evasion:** *Team Leader:* H.Kim Lysterly<sup>56</sup>, *Team Members:* Emanuela Corsini<sup>57</sup>, Julia Kravchenko<sup>56</sup>, Marc A.Williams<sup>58</sup>, Masoud H.Manjili<sup>59</sup>, Takemi Otsuki<sup>60</sup> and William K.Decker<sup>61</sup>,

**Replicative Immortality:** *Team Leader:* Amancio Carnero<sup>62</sup>, *Team Members:* Carmen Blanco-Aparicio<sup>63</sup>, Hemad Yasaei<sup>64,145</sup>, Hiroshi Kondoh<sup>65</sup>, John Pierce Wise Sr., Juan Fernando Martinez-Leal<sup>67</sup>, Matilde E.Lleonart<sup>68</sup> and Sandra S.Wise<sup>66</sup>

**Resistance to Cell Death:** *Team Leader:* Hyun Ho Park<sup>69</sup>, *Team Members:* Abdul Manaf Ali<sup>70</sup>, Barry J.Barclay<sup>71</sup>, Clement Yedjou<sup>72</sup>, Edward Ratovitski<sup>73</sup>, Kannan Badri

Narayanan, Leandro S. D'Abronzio<sup>75</sup>, Lin Li<sup>76</sup>, Maria Fiammetta Romano<sup>77</sup>, Michael J. Gonzalez<sup>78</sup>, Paramita M. Ghosh<sup>75</sup>, Po Sing Leung<sup>76</sup>, Qiang Cheng<sup>79</sup>, Ranjeet Kumar Sinha<sup>80</sup>, Rita Dornetshuber-Fleiss<sup>81,82</sup>, Simona Romano<sup>77</sup>, Sudjit Luanpitpong<sup>145</sup>, Tae-Jin Lee and Yon Rojanasakul<sup>83</sup>

**Sustained Proliferative Signalling:** Team Leader: Wilhelm Engström<sup>84</sup>, Team Members: Andrew Ward<sup>85</sup>, Gerard Wagemaker<sup>86</sup>, Hideko Sone<sup>87</sup>, James E. Klaunig<sup>88</sup>, Jayadev Raju<sup>89</sup>, Kim Moorwood<sup>85</sup>, Linda Gulliver<sup>90</sup>, Michalis V. Karamouzis<sup>91</sup>, Pankaj Vadgama<sup>92</sup>, Philippa Darbre<sup>93</sup>, Rekha Mehta<sup>89</sup>, Staffan Eriksson<sup>94</sup>, Thomas Sanderson<sup>95</sup> and Tove Hultman<sup>84</sup>

**Tissue Invasion and Metastasis:** Team Leader: Josiah Ochieng<sup>96</sup>, Team Members: Binhua P. Zhou<sup>97</sup>, Chenfang Dong<sup>97</sup>, Gladys Nangami<sup>96</sup>, Gregory T. Wolf<sup>98</sup>, Igor Koturbash<sup>99</sup>, Isabelle R. Miousse<sup>99</sup>, Lisa J. McCawley<sup>100</sup>, Nuzhat Ahmed<sup>101</sup>, Olugbemiga Ogunkua<sup>96</sup>, Pratima Nangia-Makker<sup>102</sup>, Sakina Eltom<sup>96</sup>, Silvana Papagerakis<sup>98</sup>, Valerie Odero-Marah<sup>103</sup>, Yunus Luqmani<sup>104</sup> and Zhenbang Chen<sup>96</sup>

**Tumor Microenvironment:** Team Leader: Dean W. Felsher<sup>105</sup>, Team Members: Colleen S. Curran<sup>106</sup>, Daniel C. Koch<sup>107</sup>, Ezio Laconi<sup>108</sup>, Fabio Marongiu<sup>108</sup>, Jesse Roman<sup>109,110</sup>, Joseph A. Christopher<sup>111</sup>, Jonathan R. Whitfield<sup>112</sup>, Laura Soucek<sup>112,113</sup>, Louis Vermeulen<sup>114</sup>, Marion Chapellier<sup>115</sup>, P.K. Krishnakumar<sup>116</sup>, Petr Heneberg<sup>117</sup>, Sandra Ryeom<sup>118</sup>, Stephanie C. Casey<sup>107</sup> and Veronique Maguer-Satta<sup>115</sup>

**Tumor Promoting Inflammation:** Team Leader: Patricia Thompson<sup>119</sup>, Team Members: Carolyn J. Baglole<sup>120</sup>, Eun-Yi Moon<sup>121</sup>, Jun Sun<sup>122</sup>, Le Jian<sup>123</sup>, Mahin Khatami<sup>125</sup>, Shelley Harris<sup>126,127</sup>, Tiziana Guarnieri<sup>128,129,130</sup> and Venkata Sabbiseti<sup>131</sup>

**Cross-validation:** Team Leader: William H. Bisson<sup>132</sup>, Team Members: Amedeo Amedei<sup>133</sup>, A. Ivana Scovassi<sup>134</sup>, Annamaria Colacci<sup>135</sup>, Chiara Mondello<sup>134</sup>, Dustin G. Brown<sup>18</sup>, Elizabeth P. Ryan<sup>18</sup>, Fahd Al-Mulla<sup>136</sup>, Hasiah Ab Hamid<sup>137</sup>, Hosni K. Salem<sup>138</sup>, Jayadev Raju<sup>89</sup>, Jordan Woodrick<sup>139</sup>, Kalan R. Prudhomme<sup>140</sup>, Lorenzo Memeo<sup>141</sup>, Monica Vaccari<sup>135</sup>, Neetu Singh<sup>142</sup>, Rabeah Al-Temaimi<sup>143</sup>, Rabindra Roy<sup>139</sup>, Roslida Abd Hamid<sup>137</sup> and Stefano Forte<sup>141</sup>

**NIEHS Priorities:** Danielle J. Carlin<sup>144</sup>

**Low-Dose Characterizations:** Nicole Kleinstreuer<sup>10</sup>, Annamaria Colacci<sup>135</sup> and Rekha Mehta<sup>89</sup>

<sup>1</sup>Getting to Know Cancer, 36 Arthur St, Truro, Nova Scotia, Canada, <sup>2</sup>Lancaster Environment Centre, Lancaster University, Bailrigg, Lancaster, UK, <sup>3</sup>Getting to Know Cancer, Guelph, Canada, <sup>4</sup>Institute for Health and the Environment, University at Albany, 5 University Pl., Rensselaer, NY 12144, USA, <sup>5</sup>California Pacific Medical Center Research Institute, 2100 Webster St #401, San Francisco, CA 94115, USA, <sup>6</sup>The Ohio State University College of Medicine, Department of Surgery, The James Comprehensive Cancer Center, Columbus, OH 43210, USA, <sup>7</sup>National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892-3375, USA, <sup>8</sup>Department of Life Sciences, Tzu-Chi University, Hualien 970, Taiwan, <sup>9</sup>Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan, <sup>10</sup>Integrated Laboratory Systems, Inc., in support of the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, RTP, NC 27709, USA, <sup>11</sup>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, USA, <sup>12</sup>INSERM U1113, Team 3 "Cell Signalling and Communication in Kidney and Prostate Cancer", University of Strasbourg, Faculté de Médecine, 67085 Strasbourg, France, <sup>13</sup>Department of Cell and Developmental Biology, University of California, Irvine, CA 92697, USA, <sup>14</sup>White River Junction Veterans Affairs Medical Center, White River Junction, VT 05009, USA, <sup>15</sup>Geisel School of Medicine at Dartmouth, Hanover, NH, USA, <sup>16</sup>Department of Public Health Sciences, Penn State, Hershey, PA 17033, USA, <sup>17</sup>Department of

Public Health Sciences, Penn State, USA, <sup>18</sup>Department of Environmental and Radiological Health Sciences, Colorado State University, Colorado School of Public Health, Fort Collins, CO 80523–1680, USA, <sup>19</sup>Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan 20126, Italy, <sup>20</sup>SYSBIO Centre of Systems Biology, Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan 20126, Italy, <sup>21</sup>Department of Molecular Medicine and Clinical Endocrinology, University of Reading, UK, <sup>22</sup>Departments of Obstetrics and Gynecology and Pathology, Pennsylvania State University College of Medicine, Hershey PA 17033, USA, <sup>23</sup>Departments of Pharmacology and Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA, <sup>24</sup>Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers, State University of New Jersey, Piscataway, NJ, USA, <sup>25</sup> Department of Cellular and Physiological Sciences, Life Sciences Institute, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada, <sup>26</sup> Department of Anatomy and Cell Biology, University of Western Ontario, London, Ontario, Canada, <sup>27</sup> Department of Natural Science, The City University of New York at Hostos Campus, Bronx, New York, USA, <sup>28</sup>Department of Molecular Biology, School of Osteopathic Medicine, Rowan University, Stratford, NJ, USA, <sup>29</sup>Center for Radiological Research, Columbia University Medical Center, New York, NY, USA, <sup>30</sup>Instituto de Alta Investigacion, Universidad de Tarapaca, Arica, Chile, <sup>31</sup>Department of Molecular Biology, School of Osteopathic Medicine, Rowan University, Stratford, NJ, USA, <sup>32</sup>Department of Cytokinetics, Institute of Biophysics AS CR, Brno, CZ-61265, Czech Republic, <sup>33</sup>Department of Medicine/Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08903 USA, <sup>34</sup>Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia, Via Adamello 16, 20139, Milano, Italy, <sup>35</sup>Departments of Neurosurgery and Biochemistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA, <sup>36</sup>Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada, <sup>37</sup>Department of Biological, Chemical, and Pharmaceutical Sciences and Technologies, University of Palermo, Italy, <sup>38</sup>Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA, <sup>39</sup>Instituto de Alta Investigación, Universidad de Tarapacá, Arica, Chile, <sup>40</sup>Division of Hematology and Oncology, Department of Pediatrics, Children's Healthcare of Atlanta, GA, USA, <sup>41</sup>Emory University, Atlanta, GA, USA, <sup>42</sup>Program in Genetics and Molecular Biology, Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA, USA, <sup>43</sup>Environmental Risk and Health Unit, Flemish Institute for Technological Research, Mol, Belgium, <sup>44</sup>Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Navarra, Pamplona, Spain, <sup>45</sup>Former work address: Hopkins Building, School of Biological Sciences, University of Reading, Reading, Berkshire, UK, <sup>46</sup>Department of Nutrition, University of Oslo, Oslo 0316, Norway, <sup>47</sup>Department of Chemicals and Radiation, Division of Environmental Medicine, Norwegian Institute of Public Health, Oslo, Norway, <sup>48</sup>Universidad Nacional Autonoma de México. México, <sup>49</sup>Human Safety and Environmental Research, Department of Health Sciences, College of North Atlantic, Doha, State of Qatar, <sup>50</sup>Department of Toxicology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University, Maastricht, The Netherlands, <sup>51</sup>Laboratory for Cell Genetics, Vrije Universiteit Brussel, 1050 Brussels, Belgium, <sup>52</sup>Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA, USA, <sup>53</sup>Analytische, Milieu en Geochemie, Vrije Universiteit Brussel, Brussel B1050, Belgium, <sup>54</sup>Department of Cardiac, Thoracic and Vascular Sciences, Unit of Occupational Medicine, University of Padova, 35128, Italy, <sup>55</sup>Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA, <sup>56</sup>Department of Surgery, Duke University Medical Center, USA, <sup>57</sup>Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, Italy, <sup>58</sup>Medical Command U.S. Army Institute of Public Health, Toxicology Portfolio - Health Effects Research Program, Aberdeen Proving Ground, Edgewood, MD, USA, <sup>59</sup>Department of Microbiology and Immunology, Virginia Commonwealth University, Massey Cancer Center, Richmond, VA 23298, USA, <sup>60</sup>Kawasaki Medical School, Japan, <sup>61</sup>Baylor College of Medicine, USA, <sup>62</sup>Instituto de Biomedicina de Sevilla, Consejo Superior de Investigaciones Científicas, Hospital Universitario Virgen del Rocío, Univ. de Sevilla. Avda Manuel Siurot sn, 41013 Sevilla, Spain, <sup>63</sup>Department of Experimental Therapeutics, Spanish National Cancer Research Centre (CNIO), Melchor Fernandez Almagro, 3, 28029 Madrid, Spain, <sup>64</sup>Department of Life Sciences, College of Health and Life Sciences, Brunel University London, Kingston Lane, Uxbridge, UB8 3PH, UK, <sup>65</sup> Department of Geriatric Medicine, Kyoto University Hospital 54 Kawaharacho, Shogoin, Sakyo-ku Kyoto, 606–8507, Japan, <sup>66</sup>Department of Applied Medical Sciences, University of Southern Maine, 96 Falmouth St., Portland, ME 04104, USA, <sup>67</sup>Cell Biology Department, Pharmamar-SAU, Avda. De los Reyes, 1. 28770-Colmenar Viejo, Madrid, Spain, <sup>68</sup>Institut De Recerca Hospital Vall D'Hebron, Passeig Vall d'Hebron, 119–129, 08035 Barcelona, Spain, <sup>69</sup>School of Biotechnology, Yeungnam University, South Korea, <sup>70</sup>School of Biotechnology, Faculty of Agriculture Biotechnology and Food Sciences, Sultan Zainal Abidin University, Tembilala Campus, 22200 Besut, Terengganu, Malaysia, <sup>71</sup>Planet Biotechnologies Inc, St Albert, Canada, <sup>72</sup>Department of Biology, Jackson State University, Jackson, MS 39217, USA, <sup>73</sup>Department of Head and Neck Surgery/Head and Neck Cancer Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA, <sup>74</sup>Department of Anatomy, College of Medicine, Yeungnam University, Daegu, 705–717, South Korea, <sup>75</sup>Department of Urology, University of California Davis, Sacramento, CA, USA, <sup>76</sup>School of Biomedical Sciences, The Chinese University of Hong Kong, China, <sup>77</sup>Department of Molecular Medicine and Medical Biotechnology, Federico II University of Naples, Naples, 80131, Italy, <sup>78</sup>University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico, <sup>79</sup>Computer Science Department, Southern Illinois University, Carbondale, IL 62901, USA, <sup>80</sup>Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA, <sup>81</sup>Department of Pharmacology and Toxicology, University of Vienna, Austria, <sup>82</sup>Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Austria, <sup>83</sup>Department of Pharmaceutical Sciences and Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV 26506, USA, <sup>84</sup>Department of Biosciences and Veterinary Public Health, Faculty of Veterinary Medicine, Swedish University of Agricultural Sciences, PO Box 7028, 75007 Uppsala, Sweden, <sup>85</sup>Department of



Biochemistry and Biology, University of Bath, Claverton Down, Bath, BA2 7AY, UK, <sup>86</sup>Hacettepe University, Center for Stem Cell Research and Development, Ankara, Turkey, <sup>87</sup>National Institute for Environmental Studies, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan, <sup>88</sup>Department of Environmental Health, Indiana University, School of Public Health, Bloomington, IN 47405, USA, <sup>89</sup>Toxicology Research Division Bureau of Chemical Safety Food Directorate, HPFB Health Canada Ottawa, Ontario, K1A0K9, Canada, <sup>90</sup>Faculty of Medicine, University of Otago, P.O. Box 913, Dunedin 9050, New Zealand, <sup>91</sup>Department of Biological Chemistry, Medical School, University of Athens, Institute of Molecular Medicine and Biomedical Research, 10676 Athens, Greece, <sup>92</sup>IRC in Biomedical Materials, School of Engineering and Materials Science, Queen Mary University of London, Mile End Road, London, E1 4NS, UK, <sup>93</sup>School of Biological Sciences, The University of Reading, Whiteknights, Reading RG6 6UB, England, <sup>94</sup>Department of Anatomy, Physiology and Biochemistry, The Swedish University of Agricultural Sciences, PO Box 7011, VHC, Almas Allé 4, SE-756 51, Uppsala, Sweden, <sup>95</sup>INRS-Institut Armand-Frappier, 531 Boulevard des Prairies, Laval, QC, H7V 1B7, Canada, <sup>96</sup>Department of Biochemistry and Cancer Biology, Meharry Medical College, Nashville, TN, USA, <sup>97</sup>Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, USA, <sup>98</sup>Department of Otolaryngology - Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI, USA, <sup>99</sup>Department of Environmental and Occupational Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA, <sup>100</sup>Department of Biomedical Engineering and Cancer Biology, Vanderbilt University, Nashville, TN, USA, <sup>101</sup>Department of Obstetrics and Gynecology, University of Melbourne, Victoria 3052, Australia, <sup>102</sup>Department of Pathology, Wayne State University, Detroit, MI, USA, <sup>103</sup>Department of Biology/Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA, USA, <sup>104</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, PO Box 24923, Safat 13110, Kuwait, <sup>105</sup>Stanford University Department of Medicine, Departments of Oncology and Pathology, Stanford, CA 94305, USA, <sup>106</sup>Department of Molecular and Environmental Toxicology, University of Wisconsin-Madison, Madison, WI 53706, USA, <sup>107</sup>Stanford University Department of Medicine, Division of Oncology, Stanford, CA 94305, USA, <sup>108</sup>Department of Biomedical Sciences, University of Cagliari, Italy, <sup>109</sup>Department of Medicine, University of Louisville, Louisville, KY 40202, USA, <sup>110</sup>Robley Rex VA Medical Center, Louisville, KY 40202, USA, <sup>111</sup>Cancer Research UK, Cambridge Institute, University of Cambridge, Robinson Way, CB2 0RE Cambridge, UK, <sup>112</sup>Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain, <sup>113</sup>Catalan Institution for Research and Advanced Studies (ICREA), Barcelona 08010, Spain, <sup>114</sup>Center for Experimental Molecular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands, <sup>115</sup>Centre De Recherche En Cancerologie De Lyon U1052-UMR5286, France, <sup>116</sup>Center for Environment and Water, Research Institute, King Fahd University of Petroleum and Minerals, Dhahran 3126, Saudi Arabia, <sup>117</sup>Charles University in Prague, Third Faculty of Medicine, Czech Republic, <sup>118</sup>Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA, <sup>119</sup>The University of Arizona Cancer Center, USA, <sup>120</sup>Department of Medicine, McGill University, Montreal, Quebec H4A 3J1, Canada, <sup>121</sup>Department of Bioscience and Biotechnology, Sejong University, Seoul 143-747, Korea, <sup>122</sup>Department of Biochemistry, Rush University, Chicago, IL 60612, USA, <sup>123</sup>School of Public Health, Curtin University, Australia, <sup>124</sup>Public Health and Clinical Services Division, Department of Health, Government of Western Australia, <sup>125</sup>Inflammation and Cancer Research, National Cancer Institute (NCI) (Retired), NIH, USA, <sup>126</sup>Research, Prevention and Cancer Control, Cancer Care Ontario, Toronto, ON, M5G 2L7, Canada, <sup>127</sup>Dalla Lana School of Public Health, Division of Epidemiology and Division of Occupational and Environmental Health, University of Toronto, Toronto, Ontario, M5T 3M7, Canada, <sup>128</sup>Department of Biology, Geology and Environmental Sciences, Alma Mater Studiorum Università di Bologna, 40126 Bologna, Italy, <sup>129</sup>Center for Applied Biomedical Research (CRBA), S. Orsola-Malpighi University Hospital, Via Massarenti, 9, 40126 Bologna, Italy, <sup>130</sup>National Institute of Biostructures and Biosystems (INBB), Viale Medaglie d' Oro, 305, 00136 Roma, Italy, <sup>131</sup>Harvard Medical School/Brigham and Women's Hospital, USA, <sup>132</sup>Environmental and Molecular Toxicology, Environmental Health Sciences Center, Oregon State University, Corvallis, OR 97331, USA, <sup>133</sup>Department of Experimental and Clinical Medicine, University of Firenze, Firenze 50134, Italy, <sup>134</sup>Institute of Molecular Genetics, National Research Council, Pavia, 27100, Italy, <sup>135</sup>Center for Environmental Carcinogenesis and Risk Assessment, Environmental Protection and Health Prevention Agency, Bologna, 40126, Italy, <sup>136</sup>Department of Pathology, Kuwait University, Safat 13110, Kuwait, <sup>137</sup>Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor 43400 Malaysia, <sup>138</sup>Urology Department, Kasr Al-Ainy School of Medicine, Cairo University, El Manial, Cairo 12515, Egypt, <sup>139</sup>Molecular Oncology Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA, <sup>140</sup>Environmental and Molecular Toxicology, Environmental Health Science Center, Oregon State University, Corvallis, OR, USA, <sup>141</sup>Department of Experimental Oncology, Mediterranean Institute of Oncology, Via Penninazzo 7, Viagrande (CT) 95029, Italy, <sup>142</sup>Advanced Molecular Science Research Centre (Centre for Advanced Research), King George's Medical University, Lucknow, Uttar Pradesh 226 003, India, <sup>143</sup>Human Genetics Unit, Department of Pathology, Faculty of Medicine, Kuwait University, Jabriya, Kuwait, <sup>144</sup>Superfund Research Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27560, USA, <sup>145</sup>Health and Environment Theme, Institute of Environment, Health and Societies, Brunel University London, Kingston Lane, Uxbridge UB8 3PH, UK and <sup>146</sup>Siriraj Center of Excellence for Stem Cell Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

## **Chat on cancer immunotherapies**

*Immunotherapy for cancer* was the subject of a Twitter Chat hosted by the National Cancer Institute in April following the national airing of the PBS documentary *Cancer: The Emperor of All Maladies*. VCU Massey Cancer Center's Masoud Manjili, D.V.M., Ph.D., member of the Cancer Cell Signaling research program at Massey, and associate professor in the Department of Microbiology and Immunology at the VCU School of Medicine, provided expert commentary as the moderator posed a series of questions and discussion topics.

Below is a recap of the chat. Responses have been slightly modified to provide context that could not fit into the original 140-character tweets. Be sure to follow @VCUMassey on Twitter to keep up with the latest groundbreaking research and clinical trials at Massey, to learn about patient and caregiver resources and discover volunteer and philanthropic opportunities while connecting with others who share similar interests and life experiences.

### **What is precision medicine?**

Precision medicine is the area in which we can deliver individualized cancer therapies. Individual genetic variations can impact the similarities or variations of individuals and cells within the tumor, known as tumor heterogeneity.

### **What are immunotherapies?**

Immunotherapies are treatments designed to reprogram the patient's immune system to fight cancer. Because cancer cells are mutated from normal healthy cells, the immune system does not always recognize them as harmless. Immunotherapies reprogram the immune system to identify and take action against the tumor.

### **What role does the immune system play in fighting cancer?**

The immune system reduces the incidence of cancer in a person and edits cancer cells, which is called "tumor immunoediting and escape." The



interplay of cancer and the immune system is really dynamic in that cancer cells can give off substances that suppress an anti-tumor immune response, and the immune system could keep tumor cells in a dormant state. Dormant tumor cells are generally resistant to conventional cancer therapies, but are the best target for immunotherapy.

### **Are there different types of cancer immunotherapies?**

Yes, there is passive immunotherapy, active specific immunotherapy (vaccine) and adoptive immunotherapy. There is also therapy called a “checkpoint blockade” that is complimentary to tumor-specific immunotherapy and is effective against immunogenic tumors. Immunogenic tumors are those tumors that promote an immune system response.

### **Are some types of cancer more likely to respond to immunotherapies than others?**

Immunogenic tumors, such as melanoma, are more likely to respond to immunotherapy. Weakly-immunogenic tumors could be reprogrammed by epigenetic modulators that alter the cancer cells’ epigenetic structure to make the tumor strongly immunogenic and respond to immunotherapy. Decitabine is one such drug that can **potentially** induce the expression of highly immunogenic cancer-testis Ag (CTA), making tumors highly responsive to immunotherapy.

### **What are some challenges in developing these treatments?**

One challenge is working with tumors when they secrete proteins that support particular cells that can inhibit the anti-tumor function of the immunotherapy. Another challenge is that tumors escape by **engaging immune checkpoint pathways and/or** losing the tumor-associated antigens and hide under immune pressure. Dormant tumor cells, however, cannot divide; thus they cannot escape during immunotherapy. Dormant tumors, or minimal residual disease, respond best to immunotherapy while being resistant to conventional cancer therapies.

### **Are more of these agents being tested in clinical trials?**

Immune checkpoint blockade pathways, such as PD-1 and CTLA-4, are being tested in clinical trials for immunotherapy of cancer. Anti-PD-1 therapy is poised to take the next step in the treatment of melanoma.

**Where can I learn more about these treatments?**

You can learn more about Massey's clinical trials, including immunotherapy for cancer, at our website ([massey.vcu.edu](http://massey.vcu.edu)).